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ABSTRACT 
Recent observations on the reduced susceptibility of HIV-1 cell-to-cell 
infection to inhibition by Reverse Transcriptase Inhibitors (RTIs) have raised 
questions on the bearing this mode of spread may have on the successful 
treatment of HIV-1, the maintenance of viral reservoirs and viral pathogenesis. 
This thesis presents a detailed assessment of the individual drug classes, which 
constitute first-line and second-line antiretroviral therapy, with regard to their 
ability to inhibit HIV-1 cell-to-cell infection in comparison to cell-free infection. 
Special emphases is given to the study of Protease Inhibitors (PIs), which have 
a mechanism of action different from RTIs, present a higher barrier to the 
selection of drug-resistant viruses, are highly potent and very important in 
both first-line and second-line treatment of HIV-1 infection.  Also, PIs have not 
been studied before in the context of cell-to-cell spread of HIV-1. The results 
obtained show that different classes of antiretroviral drugs have different 
potencies against cell-to-cell spread of HIV-1. While PIs are equally effective 
at inhibiting cell-to-cell and cell-free spread of HIV-1, RTIs especially those of 
the Nucleoside Reverse Transcriptase Inhibitor (NRTI) class are ineffective 
inhibitors of cell-to-cell spread of the virus. This thesis also assesses the impact 
of combination antiretroviral therapy on these two modes of viral infection, 
using drug synergy analysis by the median effect principle. We show that 
combination antiretroviral therapy is effective against both cell-to-cell and 
cell-free HIV-1 infection. However in the context of antiretroviral drug 
resistance, cell-to-cell spread may contribute to a reduced efficiency of 
combination antiretroviral therapy in blocking the spread of infection. Overall, 
the study provides a better understanding of the impact of antiretroviral 
therapy on cell-to-cell spread of HIV-1 and within reason, bearing in mind the 
limitations of in vitro models, gives some insight on the possible clinical 
implications of these observations for current HIV-1 therapy. 
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CDC – Centers for Disease Control 
cDNA – complementary deoxyribonucleic acid  
CFAR – Centre for AIDS research 
Cpz - chimpanzee 
CT – cytoplasmic tail 
CTS – Central termination signal 
CXCR4 – Chemokine (C-X-C motif) receptor 4 
DC – Dendritic cell 
DHHS – Department of Health and Human Services 
DLV – Delaviridine 
DMEM - Dulbecco’s Modified Eagle Medium 
DMSO - Dimethyl sulphoxide 
DNA- Deoxy ribonucleic acid 
dNTP- deoxyribonucleotidetriphosphate 
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DRV- Darunavir 
EDTA – Ethylene diaminetetracetic acid 
ELISA – Enzyme linked immunoabsorbent assay 
Env - Envelope 
ESCRT – Endosomal Sorting Complex Required for Transport 
ETV - Etravirine 
FACS – Fluorecence activated cell sorting 
FCS – Fetal calf serum 
FDA – Food and drug administration 
Gag – Group-specific antigen 
Gor – Gorilla 
HAART – Highly active antiretroviral therapy 
HB – Helix bundle 
HEK – Human embryonic kidney 
HIV – Human Immunodeficiency Virus  
HRP – Horseradish peroxidase 
HTLV – Human T Lymphocyte Virus 
ICAM – Intercellular cell adhesion 
Ig - Immbunoglobulin 
IL - Interleukin 
InSTI – Integrase strand transfer inhibitor 
IS – Immunologic Synapse 
LB – Luria Bertani 
LEDGF- Lens epithelium derived growth factor 
LFA-1- Lymphocyte function Antigen 
LPV- Lopinavir 
LTR- Long terminal repeat 
MA – Matrix 
MACS – Magnetic activated cell sorting 
Mg – Magnesium 
MHC – Major Histocompatibility Complex 
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Min -minutes 
MLV – Murine Leukemia Virus 
MOI – Multiplicity of Infection 
MTOC – Microtubule organizing centre 
MVC – Maraviroc 
Nef – Negative factor 
NIBSC – National Institute of Biological Standards and Control 
NIH – National Institutes for Health 
NNRTI – Non nucleoside reverse transcrptase inhibitor 
NRTI- Nucleos(t)ide reverse transcriptase inhibitors 
NUP – Nucleoporin 
NVP- Nevirapine 
P-TEFb – Positive transcription elongation factor b 
PBMC – Peripheral blood mononuclear cells 
PBS- Phosphate buffered saline 
PCR- Polymerase Chain Reaction 
PEP – Post exposure prophylaxes 
PHA- Pytohemgglutinin 
PI – Protease Inhibitor 
PIC – Pre-integration complex 
Pol - Polymerase 
PPT – Polypurune tract 
PreP – Pre-exposure prophylaxes 
RAL- Raltegravir 
Rpm – revolutions per minute 
RPMI – Roswell Park Memorial Institute 
RPV - Rilpivirine 
RT-PCR – Real-time polymerase chain reaction 
RTI - Reverse transcriptase 
RTV – Ritonavir 
SAMHD1 – Sam domain and HD domain containing protein 1 
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SAQ – Saquinavir 
SDM – Site directed mutagenesis 
SIV – Simian Immunodeficiency virus 
Sp  - Spacer 
T-20 – Enfurvitide 
TAE – Tris acetate EDTA 
Tat - Transactivator 
TBS- Tris buffered saline 
TCR – T cell receptor 
TFV - Tenofovir 
TRIM5α – Tripartite motif 5 alpha 
Vif- viral infectivity factor 
Vpr – viral protein R 
Vpu- viral protein U 
VS – Virological synapse 
WHO – World Health Organisation 
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1 Introduction and Background 
1.1 Introduction 
The Human Immunodeficiency Virus (HIV) was first identified as the 
causative agent of the Acquired Immunodefiency Syndrome (AIDS) at 
the Pasteur Institute in Paris in 1983 (Barré-Sinoussi et al., 1983). Two 
related human retroviruses can cause AIDS in humans; HIV type-1 (HIV-
1) (Barré-Sinoussi et al., 1983) has a worldwide distribution and is 
responsible for the global pandemic while HIV type-2 (HIV-2) (Clavel et 
al., 1986) which is primarily confined to West Africa, is responsible for a 
much smaller proportion of infections (Schim van der Loeff and Aaby, 
1999). The discussions in this thesis will focus on HIV-1.  
 
In the three decades that have followed its discovery, HIV/AIDS has 
caused over 36 million deaths and an estimated 65 million people 
have become infected with the virus worldwide (UNAIDS, 2013). In 2013 
there were an estimated 35.3 million people living with HIV-1 infection 
globally (UNAIDS, 2013).  These elements make HIV/AIDS one of the 
biggest epidemics of the last century and have spurred intense 
scientific research towards finding effective treatments for HIV/AIDS. 
There has been significant progress in the treatment of HIV/AIDS and 
the therapeutic options currently available have transformed what was 
once a death sentence for those infected, into a chronic and 
manageable condition. The current arsenal of antiretroviral agents 
allows infected individuals receiving treatment to live normal lives and 
have the same life expectancy as healthy uninfected individuals. With 
more people receiving life-saving antiretroviral therapy (ART) and 
widespread public health campaigns aimed at reducing transmission, 
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there has been a steady decline in the number of new infections from 
3.4 million in 2011 to 2.3 million in 2013 (UNAIDS, 2013). 
 
Despite the success of existing ART in controlling viral replication, 
treatment is not curative and remains a life-long commitment for 
infected individuals. HIV-1 also has the ability to persist in reservoirs 
within the body and to re-emerge if there are therapeutic lapses. This 
feature and the development of drug-resistant variants, continue to 
frustrate the efforts directed towards finding a definitive cure and an 
effective vaccine.  
 
Furthermore, the roll out of antiretroviral therapy has not been without 
its challenges. In 2013, under the current WHO treatment guidelines, 
coverage of antiretroviral treatment remained low with only 34% of the 
28.6 million people eligible for treatment having access to therapy 
(UNAIDS, 2013). Also, rising drug resistance to the available antiretroviral 
drugs poses a serious challenge for clinicians and patients (Gupta et 
al., 2012, WHO, July 2012) especially in resource poor settings where 
second and third-line treatment options are often limited or non-
existent. Patients receiving ART do not necessarily always achieve full 
immune recovery and remain at a high risk of developing HIV-related 
malignancies as well as exhibiting increased levels of immune 
activation and persistent inflammation (Long et al., 2008, Hasse et al., 
2011). A small subset of treated patients, termed CD4+ immunologic 
non-responders, have suppression of viral replication but their CD4+ T 
cell levels fail to rebound to normal on ART (Aiuti and Mezzaroma, 2006, 
Lewden et al., 2007, Gazzola et al., 2009, Valdez et al., 2002). In 
addition to the emergence of drug resistance and the ability of the 
virus to persist in reservoirs within the body, recent studies suggest that 
cell-to-cell spread of HIV-1 across a virological synapse (VS) may serve 
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as an additional mechanism of antiretroviral escape for the virus (Sigal 
et al., 2011).  
 
Cell-to-cell spread is a very efficient mode of retroviral dissemination, 
which allows for directed virus transfer across a virological synapse, 
obviating the need for prolonged fluid-phase diffusion (Jolly and 
Sattentau, 2004, Jolly et al., 2004, Igakura et al., 2003, Sattentau, 2008, 
Sattentau, 2010, Martin et al., 2010). This mode of viral spread is more 
efficient than the classical mode of cell-free diffusion (Mazurov et al., 
2010, Dimitrov et al., 1993, Johnson and Huber, 2002, Jolly et al., 2007, 
Sourisseau et al., 2007, Martin et al., 2010) and may be less sensitive to 
neutralisation by antibodies (Abela et al., 2012, Sourisseau et al., 2007, 
Sattentau, 2008, Sattentau, 2010, Piguet and Sattentau, 2004, Malbec 
et al., 2013). Cell-to-cell spread confers a replicative advantage for the 
virus. This is mediated by direct physical interaction between effector 
cells and target cells, and may be especially important in lymphoid 
tissues where densely packed CD4+ T lymphocytes increase the 
likelihood of frequent contacts. This could potentially contribute to the 
maintenance of the virus reservoir (Sewald et al., 2012, Sigal and 
Baltimore, 2012).  
 
Indeed, BLT (bone-marrow, liver and thymus) humanised mice based 
studies using the technique of intravital imaging have recently 
validated the concept of the virological synapse in vivo, highlighting its 
putative relevance in the spread of retroviruses (Sewald et al., 2012, 
Murooka et al., 2012). Sigal et al. were the first group to suggest that 
cell-to-cell virus transfer may be a mechanism by which HIV-1 evades 
the effects of antiretroviral drugs and thus continues to replicate at low 
levels in treated patients (Sigal et al., 2011). In their study, they 
proposed that the large number of viral particles that are transmitted 
to an uninfected target cell during cell-to-cell transfer, increases the 
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probability that at least one virus particle will stochastically escape 
inhibition by drugs and proceed to infect the cell (Sigal et al., 2011). 
They tested this hypothesis by assessing the effects of Reverse 
Transcriptase Inhibitors (RTIs) on virus dissemination in an in vitro 
experimental model and found that cell-to-cell spread was less 
sensitive to inhibition by RTIs than cell-free transmission (Sigal et al., 
2011). While interesting, these findings raise significant questions 
regarding the impact of other antiretroviral drug classes that constitute 
conventional cART, notably Protease Inhibitors (PIs) and Integrase 
Inhibitors (INIs), on HIV-1 cell-to-cell infection. Also the relevance of this 
observation in the context of cART has been brought to debate, given 
that triple therapy as currently prescribed is generally effective in 
patients treated for HIV-1 infection. In this thesis, in vitro co-culture 
systems are used to study the impact of antiretroviral drugs on HIV-1 
cell-to-cell spread, with the aim of better defining the role and possible 
implications of cell-to-cell spread of HIV-1 in the context of antiretroviral 
therapy. 
 
The data presented in this thesis provide a detailed assessment of the 
impact of the different components of ART on HIV-1 cell-to-cell spread 
in comparison to cell-free spread, with a focus on PIs and INIs, which 
have not been previously studied in the published literature. It also 
explores the effects of clinically relevant drug combinations on cell-to-
cell spread of HIV-1 and provides an assessment of antiretroviral drug 
interactions in the context of cell-to-cell infection with wild type and 
drug-resistant variants of HIV-1. The HIV/AIDS pandemic is now thirty 
years old and there is a growing realisation that we may not be able to 
treat ourselves out of this pandemic. The untenable cost of lifelong 
therapy has shifted the focus towards a push for HIV-1 eradication. An 
understanding of the mechanisms of viral persistence and the 
establishment of viral reservoirs is crucial for developing novel 
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eradication strategies. In the present study, in vitro cell-to-cell assay 
systems are employed to address these specific questions in relation to 
antiretroviral therapy, cell-to-cell spread and antiretroviral drug 
resistance. 
 
1.2 The origins, diversity and global 
distribution of HIV-1 
Studies of primate lentiviruses using phylogenetic tools have enabled 
the origins of HIV-1 to be unravelled in recent years. Lentiviruses have 
been detected in more that 30 non-human primate species found in 
sub-saharan Africa (Sharp et al., 1995, Sharp and Hahn, 2011). These 
Simian Immunodeficiency Viruses (SIVs) appear to be for the most part 
non-pathogenic in their natural hosts (Sharp and Hahn, 2011). It is now 
generally accepted that the 4 distinct groups of HIV-1 that have so far 
been identified, came about as a result of at least four separate cross-
species transmission events of SIVs from primates to humans (Sharp and 
Hahn, 2011). Pandemic HIV-1 group M is most closely related to SIVcpz, 
whose primary host is the chimpanzee (Pan troglodytes). Group M 
(Main), was the first to be identified and is responsible for almost the 
entire human pandemic of HIV-1. It is responsible for millions of 
infections worldwide and has been identified in virtually every location 
across the globe (Sharp and Hahn, 2011). Group N (New), has only be 
isolated from 13 individuals (Simon et al., 1998), all from Cameroon and 
like group M HIV-1 is most closely related to SIVcpz from chimpanzees. 
Group O (Outlier) is less prevalent, representing <1% of infections 
worldwide and is mainly restricted to small pockets in some central 
African countries like Cameroon and Gabon (De Leys et al., 1990, 
Gurtler et al., 1994, Peeters et al., 1997). Very recently the origin of HIV-1 
group O has been traced to SIVgor, a SIV found in western low land 
gorillas in Cameroon (D'Arc, 2014). Group P HIV-1 is also closely related 
to SIVgor from gorillas. It is very rare and only two cases have so far 
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been reported in patients from Cameroon (Plantier et al., 2009, Vallari 
et al., 2011). A lot of what is known about HIV-1 with regard to 
transmission, pathogenesis, and treatment is based on studies of group 
M viruses. This group can be further sub-divided into 9 subtypes or 
clades (A-D, F-H, J, K) as well as over 40 circulating recombinant forms, 
which arise when infection of the same population by multiple sub-
types occurs (Sharp and Hahn, 2011). The distribution of group M 
clades is illustrated in Figure 1.1. Subtype C is predominant in southern 
and eastern Africa, India, Nepal and China (Wainberg, 2004). A and 
A/G recombinants are mainly found in West and Central Africa 
(Wainberg, 2004). Clade B viruses are predominant in North America, 
Western Europe and Australia and most studies on drugs and resistance 
studies have been based on this subtype (Wainberg, 2004). The 
subtype classification is centred on the alignment of env sequences 
where 20-50% differences are seen between subtypes. More recent 
classifications also take into consideration protease and reverse 
transcriptase sequences, which show 10-12% variation at the 
nucleotide level or 5-6% variation at the amino acid level (Wainberg, 
2004).  
 
Some studies have suggested that the different sub-types of HIV-1 may 
possess unique biological properties and these could have implications 
for the rates of transmission, pathogenesis, disease progression and 
response to treatment. For example, infections with subtype D viruses 
have been associated with greater pathogenicity and more rapid 
disease progression in some east African studies (Kiwanuka et al., 2010). 
One study from Thailand suggested that subtype E viruses might be 
better transmitted through heterosexual contact than sub-type B 
viruses, explaining the predominance of sub-type E infections in this 
region (Kunanusont et al., 1995). Sub-type C viruses have spread very 
rapidly throughout southern Africa and the Indian sub-continent and 
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are now responsible for 50% of HIV-1 infections worldwide (Taylor and 
Hammer, 2008). This suggests that sub-type C viruses are inherently 
more transmissible in heterosexual populations than other subtypes. In 
a Kenyan study, the genital tract viral loads were found to be higher for 
women infected with subtype C viruses when compared to women 
infected with subtype A or D viruses, supporting the hypothesis of the 
better transmissibility of subtype C viruses (John-Stewart et al., 2005). 
Also in another study, Tanzanian mothers infected with sub-type A and 
C viruses where found to have an increased risk for mother-child 
transmission in comparison to mothers infected with subtype D virus 
(Renjifo et al., 2001, Renjifo et al., 2004). Another study found no 
differences in the mother-to-child transmissibility of the different sub-
types of group M viruses, highlighting the controversy that still exists in 
the studies in this area (Eshleman et al., 2005).  
 
Concerning antiretroviral therapy, several studies suggest that the 
response to antiretroviral therapy is similar among patients infected 
with different clades of group M virus (Alexander et al., 2002, Pillay et 
al., 2002, Bannister et al., 2006, Gatell, 2011, Scherrer et al., 2011). Some 
studies however have shown that differences exist in the frequency 
and pathways leading to the selection of drug-resistant variants in non-
B clade viruses. Subtype D viruses appear to possess a natural 
resistance to non-nucleoside reverse transcriptase inhibitors, based on 
a single nucleotide substitution (Gao et al., 2004) and non-subtype B 
viruses appear to more frequently select for minor drug resistance 
mutations in protease (Pieniazek et al., 2000). The specific effects of 
subtype variability in relation to cell-to-cell spread of HIV-1 have not 
been investigated. Given the afore mentioned observations and the 
putative relevance of HIV-1 cell-to-cell spread for treatment and 
vaccine development, it would be interesting to find out whether all 
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HIV-1 subtypes exhibit comparable efficiencies in their ability to form 
virological synapses and spread efficiently from cell-to-cell.  
 
Figure 1-1: Current Global distribution of HIV-1 subtypes and recombinant forms (Taylor and 
Hammer, 2008) 
 
1.3 HIV-1: Structure, Function and Replication 
1.3.1 HIV-1 Structure and function 
HIV-1 is a virus that belongs to the family of Retroviridae, the subfamily 
lentivirinae and the genus lentiviridae. The HIV-1 virion is spherical in 
shape and has an average diameter of 110nm. The viral genome 
consists of two copies of single stranded positive sense ribonucleic acid 
(RNA) in complex with viral enzymes, surrounded by a lipid-based 
envelope that is derived from the host cell membrane. The surface 
glycoprotein envelope (Env) of HIV-1 is initially synthesised as a 
precursor polypeptide gp160. This precursor polypeptide is 
subsequently cleaved by the cellular protease furin to generate the 
receptor glycoprotein or “spike” gp120 and the transmembrane and 
fusion-peptide containing component gp41 that remain non-
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covalently associated (Freed, 2003, Sundquist and Krausslich, 2012). 
Gp120 projects from the surface of the viral envelope and mediates 
the attachment to target cell receptors (CD4) and co-receptors (CCR5 
and CXCR4). The transmembrane glycoprotein gp41 facilitates fusion 
of the viral envelope with the target cell membrane and also contains 
essential trafficking determinants within its cytoplasmic tail (Checkley et 
al., 2011). The viral lipid envelope surrounds an internal protein layer 
called the matrix (p17), which is derived from the Gag polyprotein 
(p55) following proteolytic processing and is anchored to the internal 
surface of the virus envelope. The HIV-1 genome is approximately 9.7 
kilobases and encodes major structural and non-structural proteins 
common to all replication competent retroviruses. The viral genome 
and proteins are held in a cone-shaped protein core/capsid Gag 
(p24) that is also the result of Gag p55 processing. 
 
Figure 1-2: HIV-1 Structure (http://upload.wikimedia.org/wikipedia/commons/3/31/800px-
HIV_Viron_es.png) 
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From the 5’- 3’ ends, the HIV-1 genome is made up of 9 genes that 
code for 15 viral proteins. The three main virus genes are gag (group-
specific antigen), pol (polymerase), and env (envelope). In addition to 
these, are 4 accessory genes; vif, vpr, vpu, and nef that generally 
modulate host responses to the virus and two regulatory genes tat and 
rev, which regulate steps in the replication cycle of the virus. 
 
Gag - Encodes the polyprotein precursor Pr55Gag that is cleaved by 
the viral protease to mature structural proteins; matrix (p17), capsid 
(p24), nucleocapsid (NC or p7), p6 as well as the two spacer proteins 
p2 and p1 (Freed, 2003, Wiegers et al., 1998). 
 
Pol - Codes for the polyprotein precursor Pr160GagPol that is processed 
by the viral protease into individual virus enzymes Protease (PR), 
Reverse Transcriptase (RT) and Integrase (IN)(Freed, 2003). 
 
Env - Codes for a polyprotein precursor gp160 that is processed by host 
cell proteases during the trafficking of the virus envelope to the surface 
of the cell. Gp160 is cleaved into the surface glycoprotein gp120 and 
the transmembrane glycoprotein gp41. These two surface 
glycoproteins remain non-covalently associated and are collectively 
referred to as Env (Freed, 2003, Sundquist and Krausslich, 2012). 
 
Vif - Codes for the virion infectivity factor (Vif). Vif plays a role in 
suppressing the viral restriction factors APOBEC3G and APOBEC3F by 
binding and targeting these proteins for degradation via an ubiquitin 
pathway (Schrofelbauer et al., 2004, Sheehy AM, 2002). 
 
Vpr - Codes for viral protein R, which is a moderate enhancer of virus 
infectivity and through its interaction with host cellular proteins has 
been implicated in post-entry nuclear import and cell cycle arrest.  The 
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precise role of Vpr in the viral life cycle remains to be clearly defined 
(Kogan and Rappaport, 2011, Popov et al., 1998a, Popov et al., 1998b, 
Strebel, 2013). 
Rev- Codes for the regulator of expression of viral proteins (Rev). Rev 
binds to a Rev responsive element (RRE) and plays an essential role in 
the nuclear export of unspliced viral mRNAs from the nucleus to the 
cytoplasm (Freed, 2003, Karn and Stoltzfus, 2012). 
 
Vpu - Encodes for viral protein U (vpu).  Vpu downregulates the 
expression of CD4 and MHC on the surface of infected host cells. It also 
counteracts the restriction factor tetherin by targeting it for 
degradation and by so doing induces virion release from the host cell 
surface (Dube et al., 2010, Neil et al., 2008a, Guo and Liang, 2012). 
 
Nef - Codes for negative factor (Nef). Nef downregulates CD4 and 
MHC expression on the surface of infected host cells. It also modulates 
virus infectivity, blocks apoptosis and plays a role in determining 
pathogenicity of the virus (Foster and Garcia, 2007, Strebel, 2013). 
 
Tat - Encodes for the transactivator of transcription (Tat) protein. Tat 
binds to the transacting response element (TAR) and acts as a potent 
activator of viral gene expression (Freed, 2003, Karn and Stoltzfus, 2012, 
Romani et al., 2010, Debaisieux et al., 2012, Van Lint et al., 2013). 
 
Two untranslated repeat regions flank the HIV-1 RNA genome. At the 5’ 
end of the repeat region internally is a unique 5’ region (U5) and at the 
3’ end internally is a unique 3’ region (U3) (Freed, 2003). At the end of 
reverse transcription of the viral RNA into proviral DNA, longer repeat 
regions are generated and the proviral DNA is flanked by 2 identical 
long terminal repeats (LTRs) containing the U3, R and U5 regions. The 
HIV-1 LTR is 630-640bp long and plays a vital role in initiating the 
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transcription of viral genes (Starcich et al., 1985, Karn and Stoltzfus, 
2012). The U3 region contains the viral promoter and enhancer 
sequences, while the R regions contain the polyadenylation signal and 
the transactivation response element (TAR), to which the viral Tat 
protein binds (Starcich et al., 1985, Karn and Stoltzfus, 2012). 
 
Figure 1-3: Organisation of the HIV-1 genome (Suzuki, 2011) 
 
Targeting viral proteins and enzymes important for HIV-1 replication is 
the main strategy that has been adopted for the development of 
antiretroviral therapies currently used to treat HIV-1 infection. The steps 
in the replication cycle of HIV-1 are briefly described below. 
 
1.3.2 HIV-1 Replication 
1.3.2.1  Cell binding and entry 
HIV-1 typically infects immune cells carrying the CD4 cell surface 
receptor and one or both of the co-receptors CCR5 and CXCR4. These 
cells include mainly helper T cells (CD4+ T cells) and macrophages, as 
well as some subsets of dendritic cells and langerhans cells. The viral 
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Env is a heavily glycosylated trimer of gp120 and gp41 heterodimers. 
The infection of a cell with HIV-1 begins when the virus surface 
glycoprotein gp120 binds to the CD4 receptor on the surface of the 
host cell. Gp120 has five relatively conserved domains (C1-C5) and five 
variable loops (V1-V5)(Wilen et al., 2012, Kwong et al., 1998). The 
variable loops are located predominantly on the surface of gp120 and 
are important for immune evasion and co-receptor binding. When 
gp120 binds to CD4 this triggers a reorganisation of the V1/V2 and 
subsequently V3 loops and also induces the formation of a bridging 
sheet facilitating co-receptor engagement (Wilen et al., 2012, Kwong 
et al., 1998). Engagement of the co-receptor triggers the exposure of 
the hydrophobic fusion peptide of gp41, which inserts into the host cell 
membrane and tethers the virus and host cell membranes (Chan et al., 
1997, Weissenhorn et al., 1997, Wilen et al., 2012). The fusion peptide of 
each gp41 in the trimer folds at a hinge region, and this folding brings 
an amino terminal helical region and a carboxy terminal region from 
each gp41 subunit together to form a six-helix bundle (6HB) (Wilen et 
al., 2012, Chan et al., 1997, Weissenhorn et al., 1997). The formation of 
the 6HB drives the formation of the fusion pore and enables the fusion 
of the virus and host cell membrane. Membrane fusion is central to the 
infection process as it enables the introduction of the virus core into the 
cytoplasm of the host cell (Freed, 2003, Wilen et al., 2012). 
 
1.3.2.2 Reverse transcription 
Following fusion, the core, which contains the genomic RNA, is 
released into the cytoplasm. The viral core uncoats and is converted to 
a reverse transcription complex (RTC) and then to a pre-integration 
complex (PIC). Reverse transcription of the viral RNA into double 
stranded DNA is performed by the viral reverse transcriptase protein 
(RT) in the RTC and is one of the defining steps in the life cycle of all 
retroviruses. The precise location and timing of uncoating remains a 
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matter of debate, and whether uncoating occurs before or during the 
process of RT remains unclear. Retroviruses generally use host cell tRNAs 
as primers to initiate the process of reverse transcription (Hu and 
Hughes, 2012). The 3’ end of the tRNALys3 in host cells is base paired to a 
complementary sequence at the 5’ end of the HIV-1 RNA called the 
primer-binding site (pbs) and serves as the primer for initiating reverse 
transcription of the HIV-1 genome (Freed, 2003, Hu and Hughes, 2012). 
The pbs is 180 nucleotides from the 5’ end of the viral genomic RNA. 
After binding of the tRNALys3 primer to the pbs, RT synthesises a 
DNA/RNA hybrid and the RNA portion is degraded by RNaseH which is 
an inherent part of the RT holoenzyme, generating a fragment of DNA 
known as the minus strand strong stop. The ends of the viral RNA 
contain the R regions which serve as a bridge allowing the newly 
synthesised minus-strand DNA to be transferred or “jump” from the 5’ to 
the 3’ end of the genome in a process referred to as first-strand 
transfer. The 3’ end of the strong stop DNA serves as a primer for the 
continuing synthesis of the minus strand. A purine–rich sequence (ppt) 
of RNA, resistant to RNaseH digestion at the 3’ terminus (3’ppt) and the 
center of (central-ppt), remaining from minus strand synthesis, primes 
the synthesis of the plus strand (Hu and Hughes, 2012). The synthesis of 
the plus strand continues until the tRNA has been copied, allowing its 
removal by RNaseH and the second strand transfer to occur. Extension 
of the minus and plus strands completes the synthesis of the double-
stranded linear viral DNA. The newly synthesised viral DNA remains 
associated with viral and cellular proteins in a large complex called the 
pre-integration complex (PIC) (Hu and Hughes, 2012).  HIV-1 RT lacks 
the proofreading ability of cellular DNA polymerases and as such is 
highly error prone introducing an estimated 3.4×105 errors per base pair 
per cycle (Hu and Hughes, 2012). Also, the RT binds to its template with 
a very low affinity and is able to jump between the two strands of 
genomic RNA, potentially adding to RT-mediated sequence diversity 
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(Hu and Hughes, 2012). These characteristics of RT account for the 
sequence variability that is seen among HIV-1 isolates and the 
existence of a pool of viruses or quasi-species within an infected host. 
 
1.3.2.3 Nuclear import and Integration 
The PIC enters the nucleus through nuclear pore complexes (NPCs). 
The NPCs are specialised nuclear membrane channels, that are 
comprised of proteins called nucleoporins (Matreyek and Engelman, 
2013). The precise mechanism by which the PIC is imported into the 
nucleus has been intensely studied but remains highly controversial.  
Based on recently reported findings, a popular model suggests that the 
PIC docks at the NPC by engaging the nucleoporin NUP358 through 
interactions with remaining CA proteins (Matreyek and Engelman, 
2013, Schaller et al., 2011). Once docked, the PIC further engages with 
the cellular protein cleavage and polyadenylation specificity factor 
subunit 6 (CPSF6) and NUP153, an essential step in facilitating nuclear 
import of the PIC (Matreyek and Engelman, 2013). Transportin 3 
(TNPO3) is a nuclear transport protein that also plays an important role 
in the nuclear import of the PIC and possibly nuclear trafficking and 
integration(Brass et al., 2008, Matreyek and Engelman, 2013, Diaz-
Griffero, 2012). TPNO3 is required for proper nuclear localisation of 
CPSF6 and depletion of TPNO3 in human cells leads to a dramatic 
reduction in HIV-1 infection. Several viral factors associated with the 
PIC are also important for nuclear import, these include; MA, IN and 
Vpr, which all possess nuclear localisation signals (Popov et al., 1998b, 
Haffar et al., 2000, Bouyac-Bertoia et al., 2001, Matreyek and 
Engelman, 2013). These factors recruit nuclear transport proteins 
facilitating nuclear import of the PIC. The reverse transcribed genome 
also contains an important determinant of PIC nuclear import, a triple 
stranded DNA flap element generated through the action of the 
central polypurine tract (cPPT) and central termination signal 
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(CTS)(Matreyek and Engelman, 2013, Ao et al., 2004, Riviere et al., 
2010). This DNA flap enhances the efficiency of both viral replication 
and nuclear import (Ao et al., 2004, Riviere et al., 2010). The process of 
integration mediated by the viral integrase is initiated in the PIC in the 
cytoplasm. Integrase binds to specific sequences in the LTR regions of 
the viral cDNA and is part of the PIC. Integrase cleaves the viral DNA at 
the 3’ ends in a process known as 3’ processing leading to the 
exposure of conserved CA dinucleotides at the 3’ ends of the viral DNA 
(Craigie and Bushman, 2012). 
 
Once the PIC is imported into the nucleus, the integration process 
proceeds by a strand transfer reaction in which the viral DNA is ligated 
to the host chromosomal DNA completing the process of integration. 
The viral DNA also undergoes several circularisation reactions leading 
to the generation of forms, which are unable to support replication 
and represent dead ends for the virus (Craigie and Bushman, 2012). 2 
LTR circles are formed by ligation of the two ends of the viral DNA to 
each other (Craigie and Bushman, 2012). 1 LTR circles are also 
detected. HIV-1 exploits host cellular factors to enhance integration 
and integration site selection. The viral cDNA preferentially integrates 
into sites of active transcription within the host genome (Craigie and 
Bushman, 2012). LEDGF/p75 (Lens epithelium derived growth factor) is 
an important host derived co-factor required for integration of the viral 
DNA (Cherepanov et al., 2003). It tethers HIV-1 integrase and 
chromatin at the sites of active transcription, targeting integration to 
these locations (Cherepanov et al., 2003, Craigie and Bushman, 2012). 
The interaction between integrase and LEDGF/p75 is a promising target 
for the therapeutic inhibition of HIV-1 replication. Small molecules 
called LEDGINs, which are potent inhibitors of the LEDGF/p75-IN 
protein-protein interaction and allosteric inhibitors of the catalytic 
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function of integrase, are currently in the early stages of drug 
development (Christ and Debyser, 2013).  
 
1.3.2.4 Transcription and post-transcriptional regulation of 
HIV-1 gene expression 
Once integrated into the host genome, the proviral DNA can remain 
silent or be transcribed by the cellular machinery if the infected CD4+ T 
cell is activated. Although the mechanisms by which HIV-1 establishes 
latency are not fully understood, the widely held view is that a small 
fraction of activated CD4+ T cells which are infected with the virus 
survive long enough to revert to a resting memory state in which 
transcription of viral genes is silent (Shan and Siliciano, 2013). It is also 
possible that HIV-1 is capable of directly infecting resting CD4+ T cells 
despite the very low efficiency of reverse transcription and integration 
in these cells (Agosto et al., 2007, Vatakis et al., 2009, Pace et al., 2012). 
These infected resting CD4+ T cells are believed to constitute an 
important component of the viral reservoir and can resume active 
production of infectious virions once they become re-activated. The 
integrated proviral DNA serves as a template for the synthesis of viral 
mRNAs that are translated into viral structural, regulatory and 
accessory proteins. 
 
Transcription of the proviral DNA is initiated at the HIV-1 LTR and is 
greatly enhanced by the binding of Tat to the transactivation response 
element (TAR) (Romani et al., 2010, Karn and Stoltzfus, 2012). The HIV-1 
promoter is located in the 5’ LTR and bears important regulatory 
components needed for transcription. Transcription is initiated from the 
U3/R junction and is mediated by the cellular RNA polymerase II (Van 
Lint et al., 2013). Upstream of the promoter is a TATA box and binding 
sites for additional host transcriptional factors such as Sp1, NFkB and 
others (Van Lint et al., 2013). The viral genes, which encode for Tat, Rev 
and Nef are the first to be transcribed. Prior to the generation of Tat, 
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cellular transcription factors are solely responsible for activating the LTR. 
Once present, Tat strongly increases the activation of transcription and 
elongation via a positive feedback loop (Romani et al., 2010, Karn and 
Stoltzfus, 2012). When Tat binds to TAR, it recruits the cellular co-factor 
positive transcription elongation factor b (P-TEFb) complex to the 
promoter (Karn and Stoltzfus, 2012). The P-TEFb complex in turn 
phosphorylates the C-terminal domain of the RNA polymerase II and by 
so doing enhances its processivity and elongation function. 
Transcription produces a large number of viral RNAs; unspliced RNAs 
which are the mRNA for Gag and Gag-Pol precursor polyproteins 
(about 9kb), partially spliced mRNAs coding for Env, Vif, Vpu and Vpr 
proteins (about 4kb) and multiply spliced mRNAs which are translated 
into Rev, Tat and Nef proteins (about 2kb). Unspliced and partially 
spliced viral mRNAs are transported out of the nucleus with the help of 
the Rev protein.  Rev binds to a Rev responsive element (RRE) to form a 
complex capable of interacting with the nuclear export machinery of 
the cell (Romani et al., 2010, Karn and Stoltzfus, 2012). This complex 
enables the transport of the unspliced and partially spliced mRNAs 
from the nucleus into the cytoplasm for translation, and because Rev 
possesses a nuclear localisation signal it is able to shuttle between the 
nucleus and the cytoplasm (Karn and Stoltzfus, 2012). Following the 
nuclear export of HIV-1 mRNAs, Gag and Gag-Pro-Pol polyproteins and 
most viral accessory proteins are translated in the cytosolic polysomes. 
The two viral membrane proteins Env and Vpu are encoded for by the 
same mRNA and are translated on the rough ER. Newly synthesised 
viral proteins are trafficked from their site of synthesis in the cytoplasm 
to the plasma membrane for assembly. 
 
1.3.2.5 Assembly, binding and release 
All the necessary viral components needed for infectivity are 
packaged during assembly. These include two copies of the virus 
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genomic RNA, cellular tRNALys3 required to prime cDNA synthesis during 
reverse transcription of the virus RNA, the viral envelope protein (Env) 
and the three viral enzymes RT, Protease and Integrase (Sundquist and 
Krausslich, 2012). Assembly of virions occurs at the plasma membrane 
and is coordinated by the HIV-1 Gag (and Gag-Pro-Pol) polyproteins. 
Gag domains play specific roles in the assembly process. Its amino 
terminal MA functions to bind the plasma membrane and possibly 
recruit the viral envelope protein, although the precise mechanism of 
Env incorporation and its interactions with Gag during virus assembly 
remain unresolved. Gag is targeted to the plasma membrane by a 
combination of viral and cellular factors, including the basic patch in 
MA, Gag myristoylation and also a plasma membrane specific lipid 
known as phosphatidylinositol (4,5) bisphosphate (PI (4,5) P2) that are 
collectively essential for targeting Gag to the plasma membrane. 
When MA binds to PI(4,5)P2 this causes the exposure of the amino 
terminal myristoyl group (myristoyl switch) enabling Gag to be stably 
anchored to the inner leaflet of the plasma membrane (Saad et al., 
2006, Sundquist and Krausslich, 2012). The central domain of Gag 
known as CA is responsible for protein-protein interactions required for 
the assembly of immature virions and creates the core of the mature 
virus called the capsid. The nucleocapsid domain captures the viral 
RNA genome during assembly and is also believed to play a role in 
plasma membrane targeting. The carboxy terminal of Gag known as 
the p6 region possesses binding sites for the viral accessory protein Vpr 
and for cellular proteins involved in the ESCRT (endosomal cell sorting 
complex required for transport) pathway (Sundquist and Krausslich, 
2012) that help mediate the process of budding.  The spacer peptides 
in Gag Sp1 and Sp2 regulate conformational changes that are 
induced by the maturation process. Assembled virions acquire their 
lipid envelope and envelope proteins during the budding process. The 
virus envelope, an integral membrane protein, is inserted co-
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translationally into the endoplasmic reticulum and goes through 
secretory pathways in the cell where it is glycosylated, assembled into 
trimeric complexes and processed into the transmembrane (gp41) and 
surface (gp120) subunits by the cellular protease furin (Sundquist and 
Krausslich, 2012). Gp120 and gp41 remain non-covalently linked and 
are delivered to the plasma membrane by the vesicular transport 
pathway. Although the viral Gag protein coordinates the packaging of 
co-factors and virus assembly, the virus hijacks the host cell ESCRT 
pathway for the final stages of budding and membrane pinching to 
release viral particles from the plasma membrane. Virus maturation 
occurs simultaneously during budding or immediately after budding. 
The viral protease is responsible for cleaving Gag and Gag-Pro-Pol 
polyproteins into fully functional sub-units MA, CA, NC, p6, PR, RT and 
IN. During the process of maturation the cleaved proteins are 
rearranged to produce the infectious virion, which is characterised by 
its cone-shaped core and electron dense morphology under the 
electron microscope. MA remains closely associated to the inner 
surface of the viral membrane and capsid surrounds the nucleocapsid. 
These mature virions are now fully capable of replicating in new target 
cells. 
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Figure 1-4: HIV-1 life-Cycle (Suzuki, 2011) 
1.4  The course of HIV-1 infection 
Once an effective person-to-person transmission event has occurred, 
HIV-1 infection follows a well-described course in infected individuals 
who are not treated.  
 
Eclipse phase: The 7-21 days following a transmission event are known 
as the eclipse phase (Cohen et al., 2011, Keele et al., 2008, Lee et al., 
2009). During this phase the virus freely replicates and spreads from the 
initial site of infection to other tissues. During this asymptomatic phase, 
HIV-1 RNA levels in the plasma are undetectable. Studies using plasma 
samples obtained from acutely infected donors collected before 
infection; at peak viraemia and during sero-conversion suggest that an 
early innate immune response occurs during this eclipse phase. This 
response is characterised by increase production of pro-inflammatory 
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cytokines and acute phase proteins (McMichael et al., 2010, Stacey et 
al., 2009). A recent study of SIV infection in macaques provides 
evidence that the viral reservoir is probably seeded during this eclipse 
phase of infection, before detectable viraemia (Whitney et al., 2014, 
Deng and Siliciano, 2014), a proposition which has important 
implications for virus eradication strategies (Deng and Siliciano, 2014, 
Whitney et al., 2014),  
 
Acute phase: Occurring 2-4 weeks after infection, the phase of acute 
or primary infection is characterised by high levels of viral replication 
and HIV-1 RNA levels of up 107 copies/ml of blood (Coffin and 
Swanstrom, 2013, Lee et al., 2009). Some individuals experience “flu-
like” symptoms, fever and lymph node enlargement during this phase 
that is attributed to the inflammatory response in early HIV-1 infection 
also commonly referred to as a “cytokine storm”. Around the time 
viraemia peaks, adaptive immune responses begin to appear. 
Antibodies against viral envelope proteins can be detected as well as 
cytotoxic CD8+ T cell responses targeting HIV-1 antigens. These HIV-1 
antigens are coupled with MHC class I molecules and presented on 
the surface of infected CD4+ T cells which are then destroyed by 
cytotoxic CD8+ T cells. The initial antibody response is non-neutralising 
and doesn’t lead to the selection of escape mutants (McMichael et 
al., 2010, Cohen et al., 2011). Antibodies capable of neutralising 
autologous virus only develop slowly about 12 weeks or more after the 
initial transmission event. 20% of patients are capable of generating 
broadly neutralising antibodies after several years of infection 
(McMichael et al., 2010). By the end of the acute phase of infection, 
the viral set point is established (Cohen et al., 2011). This set point 
represents a relatively steady plasma viral load turnover in a given 
patient. Infected individuals with a higher viral set point, progress more 
rapidly to AIDS and death. There is strong evidence to support that very 
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early treatment lowers this viral set point and reduces the size of the 
viral reservoir, slowing progression from clinical latency to full-blown 
disease (AIDS) (Mellors et al., 1997, Hogan et al., 2012, Fidler et al., 2013, 
Persaud et al., 2013, Strain et al., 2005, Whitney et al., 2014). 
 
Latent phase: A phase of clinical latency follows the acute infection 
phase. During this phase patients remain asymptomatic and largely 
unaware of their infection. The duration of this clinical latency is 
variable from one individual to another but current estimates suggest 
that the average time from infection to the development of clinical 
symptoms is 8 -12 years (Bacchetti and Moss, 1989, Coffin and 
Swanstrom, 2013). The term “latency” to describe this phase of HIV-1 
infection is misleading because there is strong evidence that virus 
replication and progressive decline of CD4+ T cells continues 
throughout this phase leading to progressive destruction of the immune 
system (Coffin and Swanstrom, 2013).  In a small subset of individuals 
known as long-term non-progressors, CD4+ T cell decline is not 
observed and viral replication seems to be controlled by a range of 
genetic, virologic and immunologic mechanisms (Lambotte et al., 
2005, Madec et al., 2005). In children infected at birth the latent phase 
may be shorter or entirely absent with progression to AIDS occurring 
very rapidly (De Rossi et al., 1996). 
 
AIDS: After years of continuous CD4+ T cell decline, the level of these 
cells eventually falls below a tipping point <500 cells/µl of plasma 
(normal range: 600-1200cells/µl). Below this point, the first clinical signs 
of immune compromise begin to appear. The patient becomes more 
susceptible to opportunistic infections and malignancies. The control of 
infection is lost and the viral load rises (Coffin and Swanstrom, 2013). 
The viral set point established at the end of the acute phase of 
infection is an important determinant of the rate of progression to AIDS 
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(Cohen et al., 2011). The decline of CD4+ T cells typically continues until 
virtually all of these cells are lost. Severe immune compromise and the 
inability to fight common infections, as well an increased susceptibility 
to AIDS-related malignancies, eventually culminates in death of the 
patient. 
 
Figure 1-5: Time-course of typical HIV-1 Infection (Pantaleo et al., 1993) 
1.5 Modes of HIV-1 transmission and spread 
between and within the host 
1.5.1 HIV-1 Transmission 
HIV-1 transmission from person-to-person occurs through the exchange 
of bodily fluids containing infectious virus particles via three main 
routes. These include: unprotected sexual intercourse, parenteral 
transmission (infected blood and tissue products and intravenous drug 
use) or mother-to-child transmission during pregnancy, delivery or 
breastfeeding. Transmission occurring across mucosal surfaces 
(vaginally or rectally) is the predominant mode of transmission and 
represents 80% of all adult infections while percutaneous and 
intravenous routes represent 20% of infections (UNAIDS, 2013). In order 
to gain a foothold within the host and establish infection, cell-free or 
cell-associated infectious virus particles must disseminate within the 
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host and infect target cells. Substantial evidence suggests that 
activated CD4+ T cells and Langerhans’ cells are the initial target cells 
for HIV-1 during mucosal transmission (Cohen et al., 2011). Other 
dendritic cells play an important accessory role in facilitating spread of 
the virus from the site of initial entry, while macrophages can support 
productive infection and may serve as important long-lived reservoirs 
of the virus. 
 
1.5.2 Modes of virus spread within the host 
 Three mechanisms of dissemination have been described for HIV-1 
within the host (Piguet and Sattentau, 2004): In the “classical” mode of 
spread by diffusion of cell-free virions in bodily fluids, virions bind to CD4 
receptors and coreceptors on permissive host cells  and trigger the 
steps leading to viral entry and replication (Pierson and Doms, 2003, 
Piguet and Sattentau, 2004). In the second mode of spread, cells such 
as dendritic cells capture virus particles using cellular receptors notably 
DC-SIGN, without necessarily themselves becoming infected, and re-
present the infectious virus particles to permissive target cells, in a 
mode of infection known as  in trans (Geijtenbeek et al., 2000, Hu et al., 
2004, Piguet and Sattentau, 2004, Cameron et al., 1992, Pope et al., 
1994). The third mechanism of virus spread is through direct cell-to-cell 
transmission in which an HIV-1 infected cell is able to directly infect a 
target cell without the requirement for prolonged fluid-phase diffusion 
of cell-free virus in the extracellular milieu. It is important to highlight 
that in this mode of transmission, virus budding from an infected 
effector cell is polarised towards the target cell at the synaptic cleft 
and this does not involve fusion of donor and target cells. Rather the 
released virions have a short distance to travel before they can 
engage receptors on the target cell that is involved in the cell-to-cell 
contact (Jolly and Sattentau, 2004, Jolly et al., 2004, Sattentau, 2008, 
Piguet and Sattentau, 2004). 
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1.5.2.1 Cell-free spread of HIV-1 
 The classical paradigm of HIV-1 dissemination by diffusion of cell-free 
virions probably represents the best means of long distance 
dissemination for the virus. Following fluid phase diffusion, the virus 
particle attaches to the target cell bearing the required cellular 
receptors. The engagement of the CD4 receptor and co-receptors 
(CXCR4 and CCR5) by the virus drives the fusion of the virus envelope 
with the cellular membrane, leading to entry of the virion into the 
cytoplasm and its subsequent replication within the cell. HIV-1 can be 
found both in cell-free and cell-associated forms in semen (Van Voorhis 
et al., 1991, Miller et al., 1992, Quayle et al., 1997, Xu et al., 1997, Tachet 
et al., 1999, Ghosn et al., 2004, Anderson et al., 2010) and in breast milk 
(Koulinska et al., 2006, Ndirangu et al., 2012). A few studies have looked 
into the relative contributions of cell-free and cell-associated virus to 
transmission but so far no clear consensus has been reached as to 
which form of virus is predominantly responsible for person to person 
transmission (Sodora et al., 1998, Weiler et al., 2008, Salle et al., 2010). 
Cell-free spread allows for transmission of the virus from one host to 
another where the virus needs to exit the infected host and remain 
viable for a sufficient period of time to allow it to infect a new host. It 
also may enable long distance spread of the virus from the point of 
initial entry to distant tissues through diffusion in the bloodstream, 
although as discussed latterly, virus captured or infected migrating cells 
may also contribute to viral dissemination from the initial infection site. 
Despite these advantages, cell-free spread imposes a penalty to the 
virus by increasing its exposure to physical, kinetic and immunological 
barriers. HIV-1 has a fragile envelope and is prone to the decay of its 
infectivity over time, making it more challenging for the virus to remain 
infectious in the time required to cross mucosal membranes during 
sexual transmission. Also random diffusion in the blood stream increases 
the time it takes for the virus to encounter a target cell with the right 
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receptors (CD4, CCR5, CXCR4). These disadvantages highlight the 
benefits for a virus to have the ability to use alternative methods for 
dissemination in order to overcome these obstacles and effectively 
spread within the host. 
 
Figure 1-6: Cell-free spread of HIV-1 from T cell-to-T cell. 
1.5.2.2 The virological synapse and T cell-to-T cell spread 
of HIV-1 
Direct virus spread from cell-to-cell was first demonstrated for the 
herpes virus varicella zoster (Weller, 1953). Since then several other virus 
families including rhabdoviruses, poxviruses, paramyxoviruses and 
retroviruses have been shown to use this mechanism of propagation 
(Sattentau, 2010, Sattentau, 2008). HIV-1 is an enveloped retrovirus, 
which is fragile and extremely prone to infectivity decay when located 
outside its host cell. This singular fragility is largely due to the fact that its 
envelope glycoprotein spike is non-covalently assembled and highly 
prone to degeneration over time (McKeating et al., 1991, Layne et al., 
1992). It is therefore primordial for its survival that the virus quickly finds 
and infects new host cells. About 10 years ago, seminal papers 
describing direct transfer of HIV-1 and HTLV-1 across a supramolecular 
structure termed a virological synapse, provided a mechanism for a 
highly efficient and rapid mode of retroviral dissemination through 
direct spread from T cell-to-T cell (Igakura et al., 2003, Jolly et al., 2004, 
Jolly and Sattentau, 2004), these findings were subsequently confirmed 
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by other groups (Sourisseau et al., 2007, Chen et al., 2007, Hubner et al., 
2009). 
 
A synapse has been defined as “a stable adhesive junction across 
which information is relayed by directed secretion” (Dustin and 
Colman, 2002). In vivo, HIV-1 predominantly infects and replicates in 
CD4+ T cells. T cells do not normally form stable contacts with other T 
cells and when these do occur, they are typically transient lasting less 
than 10 minutes (Sabatos et al., 2008). However during direct spread of 
HIV-1 from T cell-to-T cell, an HIV-1 infected T cell (effector cell) is 
capable of forming a stable intercellular junction with an uninfected 
cell (target) (Jolly and Sattentau, 2004). These stable junctions, which 
form when T cells are infected with HIV-1 are longer lasting, persisting 
for about 60 minutes before the cells come apart, (Jolly et al., 2004, 
Chen et al., 2007, Hubner et al., 2009, Martin and Sattentau, 2009) 
however some conjugates can last for several hours . At the point of 
contact, polarised virus assembly and budding occurs towards the 
engaged target cell (Jolly et al., 2004, Chen et al., 2007, Hubner et al., 
2009, Rudnicka et al., 2009). 
 
The virological synapse can be defined by the co-polarisation of HIV-1 
Env and Gag on the infected cell and HIV-1 entry receptors (CD4 and 
co-receptor) on the target cell (Jolly et al., 2004). The initial event that 
leads to the formation of the virological synapse between an infected 
T cell and an uninfected T cell is the binding of the virus gp120 to the 
CD4 receptor. This interaction between the virus envelope proteins on 
the surface of the effector cell and the CD4 receptor and co-receptor 
(CXCR4 or CCR5) on the surface of the target cell is therefore an 
important factor that drives the co-polarisation of the viral Env and 
cellular receptors (Jolly et al., 2004). Drug inhibitors and antibodies, 
which disrupt the interaction between the CD4 receptor and Env, 
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impede formation of the virological synapse and this is substantiated 
by reduced clustering of Env, Gag, CD4 and co-receptors in the 
presence of these agents (Abela et al., 2012, Schiffner et al., 2013, 
Massanella et al., 2009, Sattentau, 2010, Durham et al., 2012, Su et al., 
2012, Malbec et al., 2013). The stability of the synaptic junction is likely 
enhanced by the interaction between integrins such as lymphocyte 
function associated antigen-1 (LFA-1) and its cognate ligands 
intercellular adhesion molecules-1 and 3 (ICAM-1 and ICAM-3)(Jolly et 
al., 2007, Jolly et al., 2004) although this role of cellular adhesion 
molecules is not unanimously accepted (Puigdomenech et al., 2008, 
Rudnicka et al., 2009). However, when antibodies, inhibitory peptides or 
using T cells with mutated conformations of LFA-1, perturb LFA-1-ICAM 
binding the stability of the VS is reduced as well as cell-to-cell spread of 
HIV-1 (Jolly et al., 2007, Rudnicka et al., 2009).  Moreover, both LFA-1 
and ICAM are enriched at the VS (Jolly et al., 2004, Jolly et al., 2007) 
providing further evidence for their contribution to VS formation. The 
interaction between Env and CD4 triggers the recruitment of actin, 
more CD4, HIV-1 co-receptors (CXCR4 or CCR5) and adhesion 
molecules to the synaptic zone (Jolly et al., 2004, Jolly et al., 2007). The 
polarisation of HIV-1 proteins and cellular receptors at the synaptic 
junction creates a focal point for directed assembly and release of 
newly formed virus particles allowing the efficient infection of the 
engaged target cells. Thus the kinetic advantage offered by cell-to-
cell spread can be explained by a combination of factors including 
1)the localised recruitment of viral proteins and polarised budding, 
2)the increased concentration of HIV-1 entry receptors at the contact 
zone and 3) the polarised release of virions that can rapidly engage 
the target cell that is in close physical contact. 
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Figure 1-7: The virological (T cell) synapse. This schematic is based on the HIV-1 and HTLV-1 T 
cell virological synapses. 
The microtubule organising centre (MTOC), mitochondria and other 
components of the cellular secretory apparatus are also polarised 
towards the virological synapse (Jolly and Sattentau, 2007, Jolly et al., 
2011, Sol-Foulon et al., 2007) and it is likely that the recruitment of these 
organelles plays some role in VS formation and subsequent cell-to-cell 
spread. Besides cell-to-cell spread across VS, HIV-1 has also been 
observed to travel along long-tubular structures connecting infected T 
cells to uninfected cells (Rudnicka et al., 2009, Sowinski et al., 2008), 
these membrane nanotubes and filopodia however seem to be less 
frequently observed than virolological synapses. Simultaneous 
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transmission of HIV-1 from effector cells to multiple targets via 
polysynapses has also been observed in vitro (Rudnicka et al., 2009). 
Murine leukemia virus (MLV) a retrovirus that predominantly infects non-
immune cells, notably fibroblasts has been shown to spread between 
cells by surfing on projections arising on the surface of infected cells 
termed filopodia (Sherer et al., 2007, Sherer et al., 2010). Similarly HIV-1 
can move across filopodial bridges towards CD4/CXCR4-expressing 
cells (Sherer et al., 2007). It has now been unequivocally shown that 
HIV-1 spreads from cell-to-cell and recent studies applying intravital 
microscopy to humanised mouse models have allowed visualisation of 
the VS in vivo (Murooka et al., 2012, Sewald et al., 2012). Although the 
relative individual contribution of cell-to-cell spread at VS, via 
membrane nanotubes and through cell-free spread is difficult to 
quantify, cell-to-cell spread has been established as the predominant 
mode of HIV-1 dissemination in in vitro cell cultures (Sourisseau et al., 
2007). 
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Figure 1-8: Cell-to-cell spread between T cell also occurs via membrane nanotubes (A) and 
filopodial bridges (B). 
Cell-to-cell spread provides many advantages to HIV-1 over the 
classical mode of cell-free spread (Sattentau, 2010, Sattentau, 2008). It 
has been shown to be up to three orders of magnitude quicker and 
more efficient than cell-free spread (Dimitrov et al., 1993, Johnson and 
Huber, 2002, Mazurov et al., 2010, Jolly et al., 2007, Sourisseau et al., 
2007, Chen et al., 2007, Martin et al., 2010); it obviates the need for the 
rate limiting step of virus diffusion prior to attachment, and reduces the 
exposure of the virus to the neutralising effects of antibodies and 
complement, an observation that has been confirmed by several 
investigators (Sattentau, 2008, Sattentau, 2010, Sourisseau et al., 2007, 
Abela et al., 2012, Malbec et al., 2013, Martin et al., 2010). More 
recently it has been shown that cell-to-cell spread is less sensitive to 
inhibition by some reverse transcriptase inhibitors and as such may 
serve as a mechanism for antiretroviral escape for HIV-1 in the context 
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of ongoing antiretroviral therapy (Sigal et al., 2011). The impact of 
antiretroviral therapy on cell-to-cell spread of HIV-1 is of particular 
interest because of the possible implications for viral pathogenesis, the 
evolution of drug resistance and maintenance of viral reservoirs in the 
context of therapy.  
 
1.5.2.3 Macrophages and cell-to-cell spread of HIV-1 
Macrophages are a terminally differentiated, non-dividing subset of 
immune cells, which play an important role in the pathogenesis of HIV-
1 infection (Waki and Freed, 2010). Unlike T cells, macrophages 
infected with HIV-1 survive for a long period post infection and the 
ability of these cells to traverse the blood-brain barrier enables the 
spread of HIV-1 infection into the central nervous system (Sharova et 
al., 2005, Gartner et al., 1986). Their inherent ability to resist virus-
induced cytopathic effects also allows them to serve as long-term 
reservoirs of infection. Macrophages infected with HIV-1, like T cells and 
DCs are also capable of forming virological synapses to efficiently 
transfer HIV-1 to uninfected macrophages and T cells (Gousset et al., 
2008, Groot et al., 2008). In comparison to the T cell and DC VS, cell-to-
cell transfer across the VS in macrophages is less well described. Studies 
however suggest that the much of what has been elucidated on the 
VS in T cells and DCs will apply at least to a certain extent to 
macrophage induced VS. Cell-to-cell spread of HIV-1 from 
macrophages-to-T cells have also been shown to be less sensitive to 
inhibition by antiretroviral drugs in much the same way as T cell-to-T cell 
spread of HIV-1 (Duncan et.al, 2013). 
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Figure 1-9: Macrophage to T cell spread of HIV-1 
1.5.2.4 Dendritic cells to T cell HIV-1 trans-infection 
Dendritic cells are a diverse family of cells, which play an important role 
in coordinating innate and adaptive immune responses. These cells 
bind, internalise and degrade antigens picked up from the peripheral 
tissues and subsequently present these antigens in complex with HLA 
class II molecules to CD4+ T cells, triggering an adaptive immune 
response to the specific antigen (Banchereau et al., 2000). When a 
CD4+ T cell encounters a dendritic cell, cellular adhesion molecules like 
LFA-1 and ICAM arrest the movement of the T cell allowing it to probe 
the surface of the dendritic cell (Monks et al., 1998, Grakoui et al., 
1999). If the correct Ag peptide/MHC-II complexes are presented to 
the T cell, it responds by concentrating T cell CD4 receptors and 
signalling molecules to the point of interaction, inducing the formation 
of an immunological synapse (Grakoui et al., 1999). HIV-1 is capable of 
exploiting the dendritic cell mediated immune function to allow for 
effective trans-infection of the virus through dendritic cells to T cells 
(McDonald, 2010). Dendritic cells are thought to be one of the first cell 
types that encounter HIV-1 following sexual transmission, due to their 
abundance in sub-mucosal tissue (McDonald, 2010). DCs were first 
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implicated in the pathogenesis of HIV-1 when it was observed that DCs 
exposed to HIV-1 could greatly amplify infection of T cells without 
themselves becoming infected (Cameron et al., 1992, Pope et al., 
1994).  The identification of DC-specific ICAM-3 grabbing non-integrin 
CD209 (DC-SIGN), a C-type lectin capable of binding the HIV-1 Env 
glycoprotein gp120, was pivotal in elucidating the mechanism of this 
trans-infection (Geijtenbeek et al., 2000, McDonald, 2010). DC-SIGN is 
an adhesion receptor with an important role in DC trafficking and in 
the formation of the immunological synapse (McDonald, 2010, 
Geijtenbeek et al., 2000). Interestingly, it was observed that when HIV-1 
bound to DC-SIGN, it remained infectious and could be transferred to 
target cells without prior replication in the DC (Geijtenbeek et al., 
2000). McDonald et.al confirmed this “Trojan horse” hypothesis by 
directly visualising trans-infection of GFP-tagged HIV-1 from DC to T 
cells (McDonald et al., 2003). They showed that DCs trans-infected T 
cells with HIV-1 by binding and concentrating the intact virus at the 
cellular interface and at the same time inducing the recruitment of 
HIV-1 receptors CD4, CCR5 and CXCR4 on the T cell, forming a 
structure similar to the immunological synapse, called the infectious 
synapse (McDonald et al., 2003, McDonald, 2010). The important 
distinction between the DC-T cell synapse (infectious synapse) and the 
T cell to T cell synapse (virological synapse) previously described is that 
formation of the latter requires interaction between the HIV-1 Env 
gp120 on the effector cell surface with CD4 on the target cell whereas 
the former relies on adhesion molecules employed during natural 
immune exchanges (McDonald, 2010).  
 
There is no doubt that DCs play an important role in the establishment 
of HIV-1 infection and research efforts are currently aimed at 
developing therapeutic strategies which specifically target the 
interactions leading to trans-infection. Such agents will have the 
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potential to be used as topical treatments at the mucosa to block the 
initial DC mediated HIV-1 transmission events. The impact of currently 
existing antiretroviral drugs on specifically blocking trans-infection from 
DC to T cells has not been assessed. However a recent study, which 
aimed to determine whether the activity of antiretroviral drugs was 
limited by the mode of HIV-1 spread and the type of immune cell 
involved in transmission or was independent of these two variables, 
found that the high multiplicity characteristic of cell-to-cell transmission 
limited the efficacy of ARVs in HIV-1 cell-to-cell transmission from 
macrophages to T cells (Duncan et.al, 2013). It is reasonable to suggest 
that this may also apply to trans-infection from DC-T cells given that the 
reduced sensitivity to ARVs appears to be independent of the type of 
cell involved in cell-to-cell spread. 
 
Figure 1-10: Dendritic cell to T cell spread of HIV-1 
1.5.3 Inhibiting cell-to-cell spread of HIV-1 
The ability of neutralising antibodies and drug inhibitors to block HIV-1 
dissemination has typically been assessed by assays using cell-free virus 
infection systems. With increasing evidence that cell-to-cell infection of 
HIV-1 probably plays an important role in viral pathogenesis in vivo, 
several studies have assessed the role of neutralising antibodies, 
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interferon induced restriction factors and antiretroviral drugs on their 
ability to block infection mediated by this mechanism of virus 
transmission.  
 
1.5.3.1 Cell-to-cell infection and neutralising antibodies 
The effects of neutralising antibodies on cell-to-cell spread of HIV-1 
have been extensively studied with results that sometimes appear 
paradoxical. These differences are likely due to the diverse 
experimental methods used (Schiffner et al., 2013). About 20% of HIV-1 
infected individuals produce broadly neutralising antibodies (bNAbs) 2-
4 years after infection (Kwong and Mascola, 2012). These naturally 
acquired bNAbs are insufficient to control or eliminate established 
infection. They have however been reproducibly shown to protect 
macaques against SIV and SHIV challenge (Moldt et al., 2012, Burton et 
al., 2011, Hessell et al., 2009, Parren et al., 2001) and to delay virologic 
rebound when infused in patients who have undergone a structured 
interruption of their antiretroviral treatment (Trkola et al., 2005). This 
makes them attractive targets for the development of prophylactic 
HIV-1 vaccines and immune based treatment strategies. Several 
factors are implicated in the inability of bNAbs to clear HIV-1 infection. 
These include: the high rates of escape mutations in Env allowing 
escape from the effects of antibodies (Wu et al., 2012, Bar et al., 2012), 
the existence of a latent virus reservoir established very early in 
infection (Eisele and Siliciano, 2012) and immune evasion mechanisms 
linked to the conformational flexibility of the viral Env  and the masking 
effects of the glycan protein shield (Kwong and Mascola, 2012). 
Several studies have suggested that cell-to-cell HIV-1 infection serves as 
an additional explanation for the inability of bNAbs to clear HIV-1 
infection in the host. This hypothesis was initially proposed by an early 
study which demonstrated that patient derived sera which effectively 
neutralised cell-free virus infection was ineffective in neutralising 
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infection in co-cultures of patient and donor peripheral blood 
mononuclear cells (PBMCs), over multiple rounds of infection (Gupta et 
al., 1989). With a better understanding of the mechanisms by which 
synaptic HIV-1 infection occurs, recent studies bearing in mind the 
differences in methodological approach, have convincingly shown 
that bNAbs are indeed able to inhibit infection by cell-to-cell spread 
albeit with a reduced efficiency in comparison to cell-free infection 
(Massanella et al., 2009, Durham et al., 2012, Abela et al., 2012, Su et 
al., 2012, Sagar et al., 2012, Malbec et al., 2013)(McCoy, 2014). This 
observation could have a significant bearing on the efficacy of 
prophylactic vaccines, underlining the need to assess the efficacy of 
vaccine candidates on their ability to effectively inhibit both cell-to-cell 
and cell-free modes of infection. There are several possible 
explanations for the relatively reduced sensitivity of synaptic infection 
to inhibition by bNAbs. These include the high multiplicity of infection 
and kinetic advantages characteristic of cell-to-cell infection, the steric 
barriers associated with cell-to-cell viral infection and the 
conformational changes in Env occurring during this mode of infection 
(Schiffner et al., 2013). 
 
The increased multiplicity of infection of target cells, which 
characterises infection across the VS and the kinetic advantage of 
cell-to-cell infection, which is the result of clustering of receptors (CD4 
and co-receptors) and viral Env proteins and Gag at the synapse 
(McDonald et al., 2003, Jolly et al., 2004, Schiffner et al., 2013), have 
been proposed to be at least partly responsible for the reduced in vitro 
efficiency of some bNAbs on cell-to-cell infection. The large number of 
virons which are transmitted during this mode of infection and the 
limited time of exposure to neutralising antibodies before virus 
attachment and infection of target cells, may limit the ability of bNAbs 
to fully inhibit HIV-1 cell-to-cell infections (Schiffner et al., 2013, Martin 
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and Sattentau, 2009, Massanella et al., 2009, Abela et al., 2012, 
Durham et al., 2012, Sagar et al., 2012, Malbec et al., 2013). This 
proposition however has been challenged by one study in which the 
effect of bNAbs were assessed for a DC-T cell mediated infection, and 
showed that even after equalising the infectivity of the virus for both 
cell-free and cell-to-cell modes of infection, some bNAbs directed 
against gp120 still displayed a reduced ability to neutralise cell-to-cell 
infection (Sagar et al., 2012). 
 
In order to exert their neutralising effects NAbs must have access to the 
synapse or the compartment in which virions are held prior to synaptic 
release (in the case of DCs and macrophages).  Steric hindrance is 
therefore a possible mechanism accounting for the reduced 
neutralisation efficiency observed with cell-to-cell HIV-1 infection. A 
study of the DC-T cell synapse using the 3D ion abrasion electron 
microscopy technique has provided a structural basis for steric 
hindrance (Felts et al., 2010). This study shows that T cells are enveloped 
by sheet-like membrane extensions from mature dendritic cells 
providing a shielded region for the formation of the VS. This 
compartment may be less accessible to some bNAbs, explaining their 
reduced efficiency (Felts et al., 2010). In contrast to this, a 3D 
reconstruction of the T cell-to-T cell VS reveals a more open structure, 
which remains accessible to NAbs that bind CD4 e.g. b12. This supports 
why such antibodies remain effective inhibitors of HIV-1 T cell-to-T cell 
infection . 
 
 Durham et.al showed that donor cells acutely transduced with HIV-1 
appeared to transfer virions that expressed Env in conformations that 
were less susceptible to neutralisation by gp120 and gp41 antibodies. 
They also further demonstrated that truncating the cytoplasmic tail of 
gp41 significantly enhanced neutralisation of synaptic infection with 
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little or no effect on cell-free infection depending on the antibody 
assessed (Durham et al., 2012). Based on these results, they proposed 
that the cytoplasmic tail of gp41 regulates the exposure of key 
epitopes required for effective neutralisation during cell-to-cell spread 
and therefore plays an important role in the mechanism of immune 
evasion observed with this mode of infection (Durham et al., 2012). 
Seemingly contradicting these observations, synaptic infection 
mediated by chronically infected donor cells is equally sensitive to 
inhibition by gp120 and gp41 antibodies as cell-free infection. This 
dissimilarity may be attributed to observed differences in where viral 
fusion occurs depending on whether the effector cells are acutely 
transduced or chronically infected with HIV-1 (Schiffner et al., 2013). 
Some groups have suggested that infection with acutely transduced 
donor cells may involve endocytosis of immature virions following virus 
transfer and delayed CD4-dependent fusion from within endosomal 
compartments (Dale et al., 2011), while chronically infected cells  
produce mature viral particles which can immediately fuse following 
interaction with cell surface receptors on the target cell. However viral 
entry by endocytosis as an explanation for the reduced susceptibility to 
some NAbs is highly unlikely as this is now largely disproved. A recent 
study shows that viral fusion and entry occur predominantly at the 
plasma membrane during infection of T cell lines and CD4+ primary T 
cells (Herold et al., 2014).  
 
1.5.3.2 Cell-to-cell infection and interferon inducible 
restriction factors 
Several interferon inducible host factors capable of inhibiting HIV-1 
replication have been identified in recent years. These restriction 
factors constitute part of the innate immune response to virus 
challenge and present an interesting potential usefulness for immune 
modulation and gene therapy strategies, targeting HIV-1. Although the 
ability of restriction factors to inhibit cell-free infection has been 
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extensively studied, their role in inhibiting cell-to-cell spread of HIV-1 
across the VS is less well defined. Studies are however emerging 
specifically addressing this question and so far the roles of some of 
these factors including: Tetherin, Trim5α (tripartite motif-containing 
protein 5α), APOBEC3G (Apolipoprotein B mRNA editing enzyme 
catalytic polypeptide-like 3) proteins, and SAMHD1 (sterile alpha motif 
and HD domain-containing protein-1) in inhibiting cell-to-cell infections 
have been considered. 
 
TRIM5α (Tripartite motif-containing protein 5α): Although human TRIM5α 
does not restrict HIV-1 infection, rhesus TRIM5α (rhTRIM5α) the Old World 
monkey orthologue of human TRIM5α, is a potent restriction factor of 
HIV-1 infection (Neil et al., 2008b, Stremlau et al., 2004, Malim and 
Bieniasz, 2012).  There is interest in exploiting this property of rhTRIM5α in 
gene therapies by genetically modifying human cells to express 
rhTRIM5α as a strategy for treating HIV-1 infection (Malim and Bieniasz, 
2012, Pertel et al., 2011). The mechanisms of HIV-1 restriction by 
rhTRIM5α are not fully understood but it is thought to affect several post 
entry steps in the viral replication cycle (Malim and Bieniasz, 2012). 
These include effects on the rate of capsid disassembly, disruption of 
the reverse transcription and integration steps (Malim and Bieniasz, 
2012, Pertel et al., 2011). Richardson et.al studied the impact of 
rhTRIM5α on cell-to-cell spread of HIV-1 and found that cell associated 
infections were less susceptible to restriction than cell-free infection 
(Richardson et al., 2008). Given that the inhibitory effects of rhTRIM5α 
occur post-entry, it is possible that the high multiplicity in cell-to-cell 
infection increases the pool of incoming virus capsids capable of 
binding and saturating the intracellular rhTRIM5α and as such results in a 
reduced sensitivity of this mode of spread to rhTRIM5α mediated 
restriction (Richardson et al., 2008, Jolly, 2011). In fact this saturation of 
rhTRIM5α has been demonstrated for cell-free virus challenge in cell-
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culture systems engineered to express rhTRIM5α (Stremlau et al., 2004, 
Anderson and Akkina, 2005).  
 
Tetherin: The story is less clear-cut when the impact of tetherin on cell-
to-cell spread of HIV-1 is considered. The studies that have addressed 
this question so far have generated conflicting results that seem at 
least in part, to be the result of the different experimental approaches 
used. Tetherin is a membrane protein which when expressed in the 
absence of the viral protein Vpu traps mature virions to the surface of 
the infected cells from which they are derived, thus preventing virus 
release. Kuhl et al. and Casartelli et al. suggested in their studies that 
tetherin was able to restrict HIV-1 cell-to-cell infection (Kuhl et al., 2010, 
Casartelli et al., 2010) while Jolly et al. showed a reduced susceptibility 
of cell-to-cell infections to the inhibitory effects of tetherin (Jolly et al., 
2010). In the latter study Δvpu HIV-1 was also found to spread faster in T 
cell co-cultures in comparison to wild type HIV-1, under conditions in 
which tetherin inhibited cell-free virus spread (Klimkait et al., 1990, Yao 
et al., 1993, Schubert et al., 1995, Jolly et al., 2010). This finding bolsters 
the evidence supporting the putative importance of Vpu and cell-to-
cell spread of HIV-1 in vivo. Vpu is highly conserved in transmitted 
founder viruses (Salazar-Gonzalez et al., 2009); and it has been 
demonstrated that tetherin can act as an innate immune sensor and 
thus may be important for Vpu conservation regardless of the mode of 
virus spread (Galao et al., 2012). The fact that cell-to-cell spread of HIV-
1 remains efficient in the presence of tetherin may also be an 
indication that this mode of spread may be capable of bypassing the 
effects of an interferon induced virus restriction factor as has also been 
suggested for TRIM5α discussed above. All three studies on the effect 
of tetherin on cell-to-cell spread of HIV-1 though with different 
conclusions, demonstrated the presence of tetherin at the T cell 
virological synapse and showed that tetherin did not disrupt its 
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formation when expressed on the effector cells (Jolly et al., 2010, 
Casartelli et al., 2010, Kuhl et al., 2010). The apparent differences in 
results may be explained by; the different cell types used, the 
chronicity of infection of the effector cells and also the varying levels of 
tetherin expression in the cells, depending on the experimental 
approach. Future studies aiming to clarify the role of tetherin in cell-to-
cell spread are needed and would have to consider potential 
confounding factors in the choice of experimental method. 
 
APOBECs: APOBEC3G proteins are incorporated into newly assembled 
virions and restrict HIV-1 infection by their cytidine deaminase activity. 
They mediate post-synthetic editing of cytidine residues to uridine, 
causing a G to A hypermutation in the newly synthesised viral cDNA, 
thereby inhibiting reverse transcription and integration. They also 
appear to block the tRNALys3 priming that is required for initiating 
reverse transcription. The viral infectivity protein (Vif) specifically 
counteracts the effect of APOBECs by binding and targeting these 
proteins for degradation and preventing their incorporation into newly 
formed virions. A recent study by Mohanram et al. has shown that using 
interferon-α to induce the expression of APOBEC3G, F, and A in 
immature dendritic cells limits the spread of HIV-1 to CD4+ T cells 
(Mohanram et al., 2013). Although this has not been specifically 
investigated for T cell-to-T cell infection, it is possible this cell-to-cell 
spread mechanism could also be sensitive to APOBEC restriction of viral 
replication like DC-to-T cell and cell-free infections. 
 
SAMHD1 is a restriction factor that is expressed in DCs and other cells. It 
has a phosphohydrolase activity, which allows it to convert nucleotide 
triphosphates to a nucleoside and a triphosphate, and by so doing 
depletes the pool of intracellular dNTPs, thus preventing viral replication 
and infection in non-cycling cells (Laguette et al., 2011, Hrecka et al., 
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2011, Lahouassa et al., 2012). The viral protein Vpx, an accessory 
protein encoded by HIV-2 and some SIVs, counteracts the effects of 
SAMHD1 by specifically binding to and targeting this protein for 
proteosomal degradation. Puigdomenech et al. have recently 
investigated the ability of SAMHD1 to inhibit cell-to-cell transmission 
from infected T cells to immature DCs and found that SAMHD1 
significantly inhibits the productive cell-to-cell infection of target DCs 
(Puigdomenech et al., 2013). They also showed that through its ability 
to modulate the susceptibility of DCs to HIV-1 infection, SAMHD1 
impacts on the ability of DCs to sense the virus and trigger an effective 
innate immune response. Although it is possible to hypothesise that 
during cell-to-cell infection dNTPs could be carried over from effector 
cells to target cells and as such counter the effects of SAMHD1 through 
a saturation mechanism, this study indicates that this is not the case at 
least for T cell to DC HIV-1 infection. It is therefore highly likely that 
SAMHD1 remains operative during HIV-1 intercellular spread and its 
activity in restricting virus replication is probably not saturable. 
 
1.5.3.3 Cell-to-cell infection and antiretroviral therapy 
Clinically available drug inhibitors have also been assessed for their 
ability to efficiently inhibit cell-to-cell spread of HIV-1. The fusion inhibitor 
Enfurvitide (T-20) and the attachment inhibitor Maraviroc (MVC) are 
equally efficient in blocking both cell-free and cell-to-cell infections 
(Abela et al., 2012, Agosto et al., 2014). Their efficiency is likely 
accounted for by their ability to block the functional interactions 
between Env and entry receptors during HIV-1 infection that is 
common to both cell-free and cell-to-cell spread. However, why these 
inhibitors that target attachment and entry should not show reduced 
efficacy during cell-to-cell spread, whereas NAbs that also target 
attachment and entry have been reported to do so remains unclear at 
present. Reverse transcriptase inhibitors have recently been shown to 
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have a reduced efficiency in inhibiting both T cell-to-T cell and 
macrophage-to-T cell mediated infection (Duncan et.al, 2013, Sigal et 
al., 2011, Sigal and Baltimore, 2012). The high multiplicity of infection 
that defines cell-to-cell infection has been proposed as the mechanism 
explaining this reduced sensitivity to RTIs. Sigal et al. proposed in a 
mathematical model confirmed using an in vitro system of T cell-to-T 
cell infection, that the high multiplicity in cell-to-cell infection 
stochastically increases the chance of a single virion escaping the 
effect of RTIs within the cell and going on to infect the cell (Sigal et al., 
2011) .This has been confirmed for macrophage -to- T cell spread in the 
presence of RTIs (Duncan et.al, 2013). Permanyer et al. reported 
conflicting findings, stating that RTIs were equally effective against both 
cell-to-cell and cell-to-cell infection (Permanyer et al., 2012a). They 
explained their findings by proposing that the reporter gene assays 
used by Sigal et al. may have led to an overestimation of the level of 
target cell infection occurring during cell-to-cell spread in the presence 
of RTIs (Permanyer et al., 2012a). These discrepancies raise questions on 
the true effect of RTIs on cell-to-cell HIV-1 infections. Notably the effects 
of PIs, which are an important component of triple combination 
therapy and INIs, have not been considered for this mode of spread. 
These questions are specifically investigated in this thesis. 
 
1.6 Antiretroviral therapy and drug resistance 
In 1985-1986 3’-azido-2’,3-dideoxythymidine, Zidouvidine (AZT), a 
nucleoside reverse transcriptase inhibitor, was the first molecule proven 
to effectively inhibit HIV-1 replication in cell culture (Furman et al., 
1986). Over the course of the last 25 years several drugs have been 
developed for the treatment of HIV-1. In current clinical practice, 
physicians now have access to over 30 antiretroviral agents formulated 
either as single drugs or combinations to treat patients infected with 
HIV-1(Arts and Hazuda, 2012). These drugs target steps in the life-cycle 
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of the virus including; binding and entry of the virus into a target cell, 
reverse transcription of the viral RNA to form proviral DNA, integration 
of viral DNA into the host cell DNA and maturation of newly formed 
virions into fully formed infectious virus particles. Antiretroviral agents 
when administered in combination dramatically suppress the 
replication of the virus and reduce the HIV-1 viral load level in the 
plasma below the limits of detection by highly sensitive clinical assays. 
This leads to a significant recovery of the immune system as evidenced 
by an increase in CD4+ T cells with improved clinical outcomes and 
increased life expectancy for treated HIV-1 infected patients (Autran 
et al., 1997, Komanduri et al., 1998, Lederman et al., 1998). Since 2010, 
the HIV-1 treatment guidelines in the United States and the European 
Union recommend that antiretroviral therapy be initiated with three 
antiretroviral agents from at least two different drug classes (combined 
antiretroviral therapy = cART) when the peripheral CD4+ T cell counts 
fall to 350/mm3 (DHHS, 2014). Despite the many successes attributed to 
the introduction and widespread use of cART, these drugs are not 
capable of eliminating the HIV-1 infection and require strict adherence 
to a life-long treatment regimen for continued viral suppression (Arts 
and Hazuda, 2012). This presents major challenges as poor tolerance to 
drugs, drug interactions of antiretroviral agents with other medications 
and non-adherence can all lead to suboptimal levels of circulating 
drug, driving the evolution of drug resistance (Arts and Hazuda, 2012). 
In fact, drug resistance has been documented for all existing drug 
classes currently used in the treatment of HIV-1. This emphasises the 
need for developing new molecules that target HIV-1. A notable 
exception appears to be Dolutegravir (DTG), the most recent Integrase 
Inhibitor to be approved by the FDA. DTG is the only drug that has not 
selected for resistance mutations in the clinic (Mesplede and 
Wainberg, 2014). This is likely attributed to the long binding time of the 
drug to the integrase enzyme as well as the greatly reduced 
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replication capacity of the viruses that might become resistant to DTG 
(Bastarache et al., 2014, Mesplede and Wainberg, 2014). 
 
 
Figure 1-11: Antiretroviral agents targeting steps in the HIV-1 replication cycle (Suzuki, 2011) 
1.6.1 Reverse Transcriptase Inhibitors 
1.6.1.1 HIV-1 Reverse Transcriptase 
HIV-1 RT is an asymmetric heterodimer composed of two related sub-
units p66 and p51 (di Marzo Veronese et al., 1986, Lowe et al., 1988, 
Sarafianos et al., 2009). These sub-units come from the Gag-Pol 
polyprotein synthesised from unspliced virus mRNA and cleaved by the 
viral Protease (PR) following viral assembly and budding. RT possesses 
two enzymatic functions essential for copying the single stranded virus 
RNA into double stranded DNA that can be integrated into the host 
cell genome (Sarafianos et al., 2009, di Marzo Veronese et al., 1986, 
Lowe et al., 1988). The p66 sub-unit of RT contains the active sites for 
both enzymatic activities of the enzyme while the p51 sub-unit plays 
mainly a structural role. The crystal structure of unliganded RT has been 
solved and the three-dimensional structure of p66 is often compared to 
a right hand, with four domains (Kohlstaedt et al., 1992, Jacobo-Molina 
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et al., 1993): fingers (residues 1-85 and 118-155), palm (residues 86-117 
and 156-236), thumb (237-318) and connection (319-426). The p51 sub-
unit folds into the same four domains as the polymerase domain of p66, 
however the positioning of the sub-domains relative to each other is 
different in p66 and p51. The structural analyses of RT with various 
templates indicate that despite the sequence homology, p66 assumes 
a flexible structure while p51 is more compact playing a purely 
structural role devoid of any catalytic activity. This has led to the 
elucidation of the mechanism of action for the RT in which the “fingers” 
close around the primer-template and dNTP unit, allowing the precise 
alignment of the 3’-OH of the primer, the α -phosphate and the 
polymerase active site, before the phosphodiester bond is formed 
(Huang et al., 1998, Kati et al., 1992, Sarafianos et al., 2009). The 
lengthening of the growing chain causes a relaxation of the “fingers”, 
which open and allow the pyrophosphate to leave the active site 
(Sarafianos et al., 2009, Meyer et al., 2007, Kati et al., 1992). The nucleic 
acid substrate then translocates relative to RT to free the nucleotide-
binding site so that the enzyme can bind to the incoming dNTPs 
(Sarafianos et al., 2009). The well recognised pivotal role of RT in the life-
cycle of HIV-1 which has been discussed earlier, has led to the 
development of antiviral therapies specifically targeting RT. Nearly half 
of the drugs currently licensed for treating HIV-1 infection are reverse 
transcriptase inhibitors RTIs. Though some specific inhibitors of RNase H 
activity have been identified and tested in vitro, none have so far been 
approved for antiretroviral therapy (Sarafianos et al., 2009). 
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Figure 1-12: Ribbon representation of the active domain of HIV-1 RT illustrating the hand-like 
structure, showing fingers (blue), palm (pink) and thumb (green) the active site (red atoms) 
where DNA is elongated, is in the palm region. Also shown in yellow is an RT inhibitor drug in the 
pocket where it binds (Sarafianos et al., 2009). 
1.6.1.2 Nucleoside and Nucleotide Reverse Transcriptase 
Inhibitors (NRTIs) 
NRTIs were the first established class of antiretroviral agents approved 
by the FDA and now constitute the backbone of cART. They are 
analogues of naturally occurring 2’-deoxy-nucleosides and nucleotides 
within the host cell. NRTIs are administered as pro-drugs and require 
phosphorylation by host cell kinases and phosphotransferases (Furman 
et al., 1986, Mitsuya et al., 1985, St Clair et al., 1987, Hart et al., 1992) to 
form the deoxynucleotide triphosphate analogues capable of 
inhibiting viral replication (Cihlar and Ray, 2010, Arts and Hazuda, 
2012). Once converted to their triphosphate forms NRTIs compete with 
the natural dNTPs and become incorporated into the nascent proviral 
DNA chain. For some NRTIs the addition of the first phosphate is rate 
limiting and this has led to the development of NRTI pro-drugs, which 
already contain the first phosphate. An example of this is Tenofovir 
(TFV), which is administered as a pro-drug Tenofovir Disoproxil Fumarate 
(TDF) that only requires addition of the second and third phosphate 
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groups once in the cell. NRTIs lack a 3’-OH group on their 2’-
deoxyribosyl moiety and this prevents the formation of a 3’-5’-
phosphodiester bond between the NRTIs and incoming 5’-nucleoside 
triphosphate thus resulting in termination of the growing DNA chain 
(Mitsuya et al., 1985, Furman et al., 1986, St Clair et al., 1987, Hart et al., 
1992). RT incorporates NRTI triphosphates with differing efficiencies, 
which may have some bearing on the relative potencies of the 
different existing NRTIs. Currently there are eight NRTIs approved by the 
FDA: Abacavir (ABC), Didanosine (ddI), Emtricitabine (3TC), Stavudine 
(d4T), Zidovudine (AZT) and Tenofovir disoproxil fumarate (TDF), the 
latter a nucleotide reverse transcriptase inhibitor (Cihlar and Ray, 2010, 
Arts and Hazuda, 2012). 
 
Treatment with NRTIs as with all antiretroviral agents leads to the 
selection of drug-resistant HIV-1 variants, with a reduced susceptibility 
to these drugs. Drug resistance to NRTIs occurs by two well-elucidated 
mechanisms (Arts and Hazuda, 2012, Cihlar and Ray, 2010). The first 
mechanism of resistance affects the binding and rate of incorporation 
of the incoming nucleotide analogue and primarily implicates residues 
that are in direct contact with the incoming NRTI-triphosphate. 
Mutations in these residues enhance discrimination of the NRTI-
triphosphate from naturally occurring triphosphates and as such 
prevent incorporation of NRTIs into the nascent chain. The classical 
example of such a mutation is M184V/I, a mutation that causes steric 
interference to the proper binding of 3TC and FTC in the HIV-1 RT 
binding site (Schinazi et al., 1993, Sarafianos et al., 1999). The second 
mechanism of drug resistance is through ATP-dependent removal of 
the NRTI-Triphosphate from the 3’ end of the nascent chain after it has 
been incorporated, and the reversal of chain termination in a process 
known as pyrophosphorylysis. This mechanism of excision has been 
extensively studied and mutations linked to it are collectively known as 
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thymidine analogue mutations (TAMs). They promote 
pyrophosphorolysis and are implicated in resistance to AZT and 
d4T(Arion et al., 1998, Meyer et al., 1999, Boyer et al., 2001). Resistance 
mutations to NRTIs have been shown to reduce the fitness and 
replicative capacity of the virus to varying degrees when compared to 
wild-type virus (Arts and Hazuda, 2012, Cihlar and Ray, 2010).  
 
Figure 1-13: Chemical structure of approved NRTIs (Cihlar and Ray, 2010) 
1.6.1.3 Non-Nucleoside Reverse Transcriptase Inhibitors  
(NNRTIs) 
NNRTIs are a class of chemically diverse molecules with over 50 families 
(de Bethune, 2010, Jochmans, 2008). These non-competitive inhibitors 
of HIV-1 RT exert their inhibitory function by binding to the enzyme in a 
hydrophobic pocket located near the catalytic site of the enzyme at a 
distance of approximately 10Å. NNRTIs interact with this hydrophobic 
pocket, inducing a change in the spatial conformation of the binding 
site of RT that reduces its polymerase activity (Kohlstaedt et al., 1992, 
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Spence et al., 1995, Rodgers et al., 1995, Hsiou et al., 1996). The 
hydrophobic pocket is only created when the NNRTI binds to the 
enzyme and in the crystal structures of unliganded RT, the NNRTI 
binding pocket is not observed (Hsiou et al., 1996, Rodgers et al., 1995). 
Aromatic residues (Y181, Y188, F227, W229 and Y232), hydrophilic 
residues (K101, K103, S105, D132 and E224) and hydrophobic residues 
(Y181, Y188, F227, W229 and Y232) of the p66 subunit and two residues 
(I135 and E138) of the p51 subunit of RT line the hydrophobic 
pocket(de Bethune, 2010, Arts and Hazuda, 2012). It is worth noting 
that the shape of the pocket does not change significantly even 
though the NNRTI compounds are structurally very different (Spence et 
al., 1995, de Bethune, 2010). NNRTIs are highly specific to HIV-1 RT and 
do not inhibit the RT of other lentiviruses such as HIV-2 and SIVs 
(Kohlstaedt et al., 1992). There are currently four NNRTIs compounds 
approved for use in the treatment of HIV-1 and these include; 
Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETV) and Delaviridine 
(DLV). Rilpivirine is in phase III clinical trials and there are several more in 
development. 
 
Resistance to NNRTIs is generally the result of amino acid substitutions in 
the NNRTI binding pocket. These single nucleotide substitutions though 
capable of inducing high levels of resistance only cause a slight loss of 
replicative fitness for the virus (Dykes et al., 2001). The patterns of NNRTI 
resistance mutations are complex and alternative pathways to 
resistance have been described in individuals infected with non-
subtype B viruses (Tantillo et al., 1994, Bacheler et al., 2000, Bacheler et 
al., 2001). K103N and Y181C are the most common NNRTI drug 
resistance mutations in subtype B viruses (Bacheler et al., 2000, de 
Bethune, 2010, Arts and Hazuda, 2012), however these mutations are 
also frequently selected in non-subtype B viruses (Akinsete et al., 2004) 
although the pathways to the development of resistance may be 
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slightly different (Lai et al., 2010). Most NNRTI drug resistance mutations 
engender varying degrees of cross resistance among the different 
NNRTIs and the selection of drug resistance to one member of the class 
generally limits the use of other members of the class in salvage 
second-line therapies following treatment failure (de Bethune, 2010). 
This is especially true for the first-generation NNRTIs (Nevirapine and 
Efavirenz), which are cornerstones of many first-line treatment regimens 
(Delaviridine is no longer used in clinical practice). The low barrier to 
development of drug resistance has confined these drugs to first-line 
treatments. This has driven the development of second generation 
NNRTIs with an improved resistance profile, with the aim of offering 
treatment experienced patients the chance to benefit from the 
convenient dosing and good tolerance profile of NNRTIs (de Bethune, 
2010). Etravirine is the first of the new generation NNRTIs approved by 
the FDA and has been shown to be effective in the treatment of drug 
experienced adult patients with drug resistance to first generation 
NNRTIs and other antiretroviral agents (Madruga et al., 2007, Lazzarin et 
al., 2007). Rilpivirine is currently being assessed in phase III clinical trials 
for the same purpose. 
 
Figure 1-14: Chemical structure of first generation and next generation NNRTIs (de Bethune, 
2010) 
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1.6.2 Protease Inhibitors (PIs) 
1.6.2.1 HIV-1 Protease - Structure and Function 
HIV-1 protease belongs to the family of aspartic proteases and exists as 
a homodimer consisting of two identical sub-units of 99 amino acids 
(Navia et al., 1989, Wlodawer et al., 1989). The active site is at the 
interface of the two sub-units and has three residues from each 
monomer Aspartic acid 25, Threonine 26 and Glycine 27. Residues 49-
52 of each monomer form a flexible flap-like structure that extends 
over the substrate binding cleft (Wlodawer et al., 1989, Navia et al., 
1989). The three important regions in the structure of the enzyme are 
therefore the active site cavity, the flexible flaps and the dimer 
interface. The flexibility of the flap region appears to be essential for the 
enzymatic activity of protease (Kräusslich et al., 1989, Weber and 
Agniswamy, 2009). The opening and closing of the flaps allow the 
movement of the substrate into and out of the active site. When 
inhibitors bind to the catalytic site with the flaps closed, the enzyme is 
essentially locked down preventing the processing of the substrates 
(Weber and Agniswamy, 2009).  
 
HIV-1 protease cleaves precursor viral proteins, Gag and Gag-Pol, 
which accumulate at the plasma membrane during or shortly after the 
release of virus particles from infected cells (Park and Morrow, 1993, 
Miller, 2001). The viral protease therefore plays an essential role in the 
maturation of the virus, leading to the production of infectious virus 
particles. The HIV-1 protease recognises the asymmetric shape of the 
peptide substrates rather than specific amino acid sequences and all 
the cleavage sites on which the protease acts have a superimposable 
structure (Erickson-Viitanen et al., 1989, Wensing et al., 2010). Cleavage 
is an ordered and highly regulated process occurring at different rates 
for the various cleavage sites in Gag and following a set sequence 
(Wensing et al., 2010, Kräusslich et al., 1989, Pettit et al., 1994, Wiegers 
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et al., 1998, Erickson-Viitanen et al., 1989). The first cleavage event 
occurs at the C-terminal portion of p2 (MA-CA-p2/NC-p1-p6), this is 
followed by the cleavage of MA from CA-p2 (MA/CA-p2) and NC-p1 
from p6 (NC-p1/p6), the two spacer proteins are the last to be cleaved 
p2 from CA (CA/p2) and p1 from NC (NC/p1). This processing of 
polyproteins by protease occurs during accumulation of the precursor 
polyproteins at the plasma membrane during or shortly after the 
assembled virions are released from the cell. Thus protease is not 
required for the production and release of virions but rather for the 
maturation of newly assembled virions into infectious particles. 
 
1.6.2.2 Protease Inhibitor drugs 
 Solving the structure of the HIV-1 protease and its substrate led to the 
development of specific inhibitors of the viral protease (Craig et al., 
1991, Kempf et al., 1995, Wensing et al., 2010, Arts and Hazuda, 2012). 
These molecules are designed to bind to the viral protease with a high 
affinity and by so doing prevent the enzyme from binding to and 
acting on its natural substrate. This leads to the production of immature 
non-infectious virions. In addition to its direct effect on HIV-1 protease, 
PIs have recently been shown to have multiple effects targeting other 
steps in the HIV-1 life cycle, with an inhibitory effect on viral entry, 
reverse transcription and post reverse transcription steps of viral 
replication (Rabi et al., 2013). In fact at therapeutic doses, 
approximately half of the inhibitory potential of PIs can be attributed to 
a block to viral entry, likely reflecting interactions between uncleaved 
Gag and the cytoplasmic tail (CT) of the envelope protein (Rabi et al., 
2013). 
 
The advent of PIs in the mid-nineties was a key moment in the 
development of antiretroviral therapy, which made possible the 
introduction of Highly Active Antiretroviral Therapy (HAART) combining 
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three active drugs from two different classes for the treatment of HIV-1 
infection. Ten PIs are currently approved: Amprenavir (APV), Atazanavir 
(ATZ), Darunavir (DRV) Fosamprenavir, Indinavir (IDV), Lopinavir (LPV), 
Nelfinavir (NFV), Ritonavir (RTV), Saquinavir (SQV) and Tipranavir 
(TPV)(Arts and Hazuda, 2012, Wensing et al., 2010). Due to extensive 
toxicity and high pill-burden associated with therapeutic doses of 
Ritonavir, it is no longer used as an antiretroviral in its own right. 
However its ability to reduce the metabolism of concomitantly 
administered PIs through inhibition of intestinal and hepatic 
cytochrome P450 3A4 enzyme, has led to its use as a pharmacokinetic 
enhancer for other PIs (Kempf et al., 1997). “Boosting” with Ritonavir 
enabled enhanced pharmacokinetics and more convenient twice-
daily dosing schedules of other PIs (Kempf et al., 1997), except 
Nelfinavir which failed to show enhanced bioavailability when 
boosted, leaving this drug with a limited role as a relatively safe PI for 
use during pregnancy (Wensing et al., 2010). Boosting of Indinavir led to 
high peak plasma levels causing nephrotoxicity and as such has not 
been widely implemented (Voigt et al., 2002). 
 
When they were initially developed, it was expected that resistance to 
PIs would be rare due to the small size of the viral protease (11kDa) and 
its vital role in the life cycle of the virus (Arts and Hazuda, 2012). 
However the protease gene has great plasticity and resistance has 
been described for all approved PIs, with polymorphisms observed in 
49 of the 99 codons which constitute the protease gene and more 
than 20 substitutions shown to be associated with drug resistance (Arts 
and Hazuda, 2012, Wensing et al., 2010). Resistance to PIs develops in a 
step-wise manner and a mutation in the substrate-binding cleft is 
usually the first observed change (Molla et al., 1996). Resistance 
mutation in the binding site of the enzyme leads to its overall 
enlargement and reduces the ability of the inhibitor to bind, thus 
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leading to a decrease in the susceptibility of the drug (Wensing et al., 
2010). This is generally accompanied by a decrease in the binding of 
the natural substrate and imposes a replicative and fitness cost to the 
mutated virus (Croteau et al., 1997, Mammano et al., 2000, Nijhuis et 
al., 1999). These mutations, which are first selected, and directly impact 
susceptibility to the PIs, are called primary or “major” resistance 
mutations. Secondary mutations or “minor” mutations do not by 
themselves confer resistance to PIs but emerge later to compensate for 
the loss in replicative fitness caused by the primary mutations (Nijhuis et 
al., 1999, Wensing et al., 2010). In addition to resistance mutations in the 
viral protease, several studies have also identified that mutations within 
the Gag protein, a substrate of protease, can also lead to PI drug 
resistance (Dam et al., 2009, Clavel et al., 2000, Gupta et al., 2010). 
These changes, which can occur within the eight major protease 
cleavage sites, improve the affinity of the substrate for the mutated 
protease and thus at least partially compensate for loss of viral fitness 
caused by primary protease resistance mutations (Doyon et al., 1996, 
Mammano et al., 1998, Miller, 2001, Nijhuis et al., 2001).  All PIs share 
relatively similar chemical structures and as a result cross-resistance is 
commonly observed within this drug class. 
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Figure 1-15: Structure of FDA approved Protease inhibitors (Wensing et al., 2010) 
1.6.3 HIV-1 Entry Inhibitors 
HIV-1 entry is a process that occurs through multiple steps mediated by 
interactions between the viral envelope proteins and cellular surface 
receptors and co-receptors as discussed earlier. Entry inhibitors have 
been developed to target specific steps including attachment of the 
virus particles to receptors on the target cell and fusion and entry into 
the cell. The drugs in this class can be divided into two main sub-
groups: the fusion inhibitors and CCR5 small molecule antagonists. 
 
1.6.3.1 Fusion Inhibitors 
Fusion inhibitors disrupt gp41-mediated membrane fusion of the viral 
cellular membranes during entry (Tilton and Doms, 2010). Enfurvitide (T-
20) was the first entry inhibitor approved for the treatment of HIV-1 in 
2003 (Kilby et al., 1998, Lalezari et al., 2003). These drugs are synthetic 
peptides, which correspond to the HR1 and HR2 domains of gp41 
(Tilton and Doms, 2010, Arts and Hazuda, 2012). These two domains 
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must interact with each other to promote fusion. The presence of a 
heterologous protein that is able to mimic these domains disrupts the 
interactions of these viral protein domains and as such prevents fusion 
from occurring. T-20 is a synthetic peptide with a sequence identical to 
part of the HR2 domain of gp41 and competes for binding to HR1 (Arts 
and Hazuda, 2012, Kilby et al., 1998). It has demonstrable potency 
against HIV-1 in clinical trials (Lalezari et al., 2003, Arts and Hazuda, 
2012) and is currently used in salvage therapies for highly treatment-
experienced patients (DHHS, 2014). However peptidic fusion inhibitors 
are not orally bioavailable and have to administered via parenteral 
routes. This has further limited their wider use in clinical practice. 
 
Development of drug resistance to T-20 is mediated by mutations, 
which cluster within the HR1 domain of gp41 to which the drug binds 
(Wei et al., 2002, Tilton and Doms, 2010). While these mutations reduce 
the susceptibility of gp41 to T-20 they also reduce the efficiency of the 
six-helix bundle formation and the overall rate of fusion (Tilton and 
Doms, 2010). 
 
1.6.3.2 CCR5 Antagonists 
CCR5 antagonists are small molecules, which bind to the 
transmembrane helices of CCR5 (Dragic et al., 2000, Tsamis et al., 
2003). They induce a conformational change of the receptor that 
causes it not to be recognised by the HIV-1 envelope (Tsamis et al., 
2003, Tilton and Doms, 2010). Three CCR5 receptor antagonists 
Vicriviroc, Aplaviroc and Maraviroc, have so far shown inhibitory 
activity against HIV-1 in humans. Of these, Maraviroc (MVC) is currently 
the only one approved by the FDA since 2007 (Tilton and Doms, 2010, 
Arts and Hazuda, 2012). MVC binds a hydrophobic trans-membrane 
cavity of CCR5 causing a change in the conformation of the 
chemokine receptor that prevents interaction with the V3 loop of 
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gp120 (Dragic et al., 2000, Tilton and Doms, 2010, Arts and Hazuda, 
2012).  
 
The development of drug resistance to MVC follows a different pattern 
from other antiretroviral agents because MVC targets a host cell 
protein.  Possible resistance mechanisms include; tropism switching i.e. 
the virus uses the CXCR4 co-receptor instead of CCR5 for entry, 
increased affinity for the co-receptor, using the inhibitor bound co-
receptor and a faster rate of entry (Arts and Hazuda, 2012, Tilton and 
Doms, 2010). During the early stages of HIV-1 infection, most patients 
carry viruses that exclusively use CCR5 as co-receptor for infection 
(Lobritz et al., 2010). As infection progresses, variants, which use the 
CXCR4 co-receptor as well as dual tropic viruses begin to appear 
(Schuitemaker et al., 1992). In patients with a mixed population of 
circulating viruses i.e. CCR5-tropic and CXCR4-tropic viruses, 
administering CCR5 inhibitors can lead to outgrowth of CXCR4 viruses 
and treatment failure (Lobritz et al., 2010). Genotypic or phenotypic 
tropism testing is therefore a prerequisite for treatment with CCR5 
inhibitors and only patients in whom no CXCR4 tropic viruses are 
detected are eligible for treatment with these drugs. 
 
1.6.4 Integrase Inhibitors 
Integrase inhibitors are the latest addition to the armamentarium of 
antiretroviral agents (Espeseth et al., 2000, Hazuda et al., 2004a, 
Hazuda et al., 2004b). The integrase enzyme catalyses two important 
reactions during the replication of HIV-1, notably the 3’ processing of 
the double-stranded viral DNA ends and the transfer reaction which 
incorporates the viral DNA into the host chromosomal DNA forming a 
functional integrated viral DNA (Sherman and Fyfe, 1990, LaFemina et 
al., 1991, McColl and Chen, 2010). Integrase inhibitors are small 
molecules, which specifically target the strand transfer reaction 
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(McColl and Chen, 2010, Arts and Hazuda, 2012), and thus are more 
specifically referred to as Integrase strand transfer inhibitors (InSTIs). The 
FDA licensed Raltegravir (RAL) in 2007 and more recently Elvitegravir 
(2012) and Dolutegravir (2013). Elvitegravir like some PIs described 
above is co-formulated with the pharmacological enhancer 
Cobicistat, a CYP3A4 enzyme inhibitor, to improve the bioavailabilty of 
the drug. InSTIs bind to the specific complex between integrase and 
the viral DNA. These drugs interact with the essential Mg2+ ion cofactor 
in the active site of the enzyme and the DNA (McColl and Chen, 2010). 
InSTIs are comprised of 2 essential components, a phamacophore, 
which binds the Mg2+ cofactor, and a hydrophobic group which 
interacts with the viral DNA and with the enzyme (McColl and Chen, 
2010, Arts and Hazuda, 2012). This characteristic makes InSTIs the only 
antiretroviral drug class that interacts with two essential components 
explaining at least in part their broad efficacy against a wide variety of 
HIV-1 variants (Arts and Hazuda, 2012). 
 
Mutations that cause drug resistance to InSTIs, are selected in the 
integrase-binding site, near the amino acid residues that are essential 
for the proper functioning of the Mg2+ cofactors (Arts and Hazuda, 
2012, Hazuda et al., 2004a, Hare et al., 2010).  Resistance mutations in 
integrase affect the replicative capacity of the virus as well as the 
functioning of the integrase enzyme (Marinello et al., 2008, Quercia et 
al., 2009). Three independent pathways have been identified for the 
development of drug resistance to Raltegravir, defined by primary 
signature mutations in residues Y143, N155 or Q148 of the integrase 
gene (Fransen et al., 2009, McColl and Chen, 2010, Arts and Hazuda, 
2012).  Cross-resistance is commonly observed with the drugs in this 
class, though low levels of clinical experience limits the understanding 
of the true impact of these resistance mutations in patients treated with 
InSTIs. In current clinical practice InSTIs are mostly used in second and 
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third-line therapies for highly treatment-experienced patients although 
rarely they can be used as part of first-line regimens for treatment naïve 
patients (DHHS, 2014). 
 
1.7 Development and use of combination 
antiretroviral therapy 
Before 1996, HIV-1 infection was a fatal disease with very few available 
therapeutic options. Treatment relied mainly on prophylaxes against 
opportunistic pathogens and treating AIDS-related conditions. This 
changed dramatically in the mid-nineties following a series of seminal 
studies that clearly described the viral dynamics and brought into 
sharp focus the fact that this was a viral infection requiring treatment. 
Ho et al., Perelson et al. and Wei et al. demonstrated the high turnover 
rate of HIV-1 and estimated that in an untreated individual there were 
104-105 or more particles per ml of plasma with a turnover rate of 10 
billion virions per day (Ho et al., 1995, Wei et al., 1995, Perelson et al., 
1996). Owing to its highly error-prone reverse transcription process, it 
was also estimated that a new mutation was introduced for every 
1000-10000 nucleotides synthesised (Mansky and Temin, 1995, O'Neil et 
al., 2002, Abram et al., 2010). This high diversity leads to virus quasi-
species within the host increasing the probability that HIV-1 variants 
with a reduced susceptibility to one or two antiretroviral drugs will exist 
even before treatment is initiated (Coffin, 1995, Frost and McLean, 
1994). Using this knowledge on HIV-1 replication dynamics, 
mathematical modelling studies suggested that combinations of at 
least three drugs would be capable of providing durable inhibition of 
viral replication and would be better than combinations of two drugs 
(Frost and McLean, 1994, Coffin, 1995, Nowak et al., 1997, Stengel, 
2008). These models were quickly verified in several randomised clinical 
trials (Staszewski et al., 1999, Walmsley et al., 2002, Robbins et al., 2003, 
Gallant et al., 2004, van Leth et al., 2004, Gulick et al., 2004) leading to 
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the birth of triple combination drug therapy initially popularised as 
Highly Active Antiretroviral Therapy (HAART)(Arts and Hazuda, 2012). 
 
1.7.1 Antiretroviral drugs in current clinical practice 
The antiretroviral drugs currently used in the treatment of HIV-1 
infection cannot eradicate the virus from the body even when potent 
drugs are added to treatment regimens that already fully suppress viral 
replication below detection thresholds (Arts and Hazuda, 2012).  This is 
a direct consequence of the existence of a virus reservoir consisting of 
a pool of latently infected CD4+ T cells, which is established in the very 
early stages of HIV-1 infection (Whitney et al., 2014). Antiretroviral 
therapy as currently prescribed therefore has the following aims: 
 
• To reduce the morbidity and mortality associated with HIV-1 
infection. 
• To restore and preserve immune function. 
• To suppress viral replication and reduce the plasma viral load. 
• To prevent transmission from one person to another. 
 
The World Health Organization (WHO) currently recommends initiating 
antiretroviral therapy with at least three drugs from two different drug 
classes in all patients with a confirmed diagnosis of HIV-1 infection, who 
have a CD4+ T cell count <500 cells/mm3, with priority given to 
initiating therapy among those with severe or advanced disease and 
CD4+ T cell counts of 350 cells/mm3 or less (WHO, July 2012). It also 
recommends that treatment be started regardless of the CD4+ T cell 
count in all infected patients with active Tuberculosis, Hepatitis B co-
infection with chronic liver disease, all pregnant and breastfeeding 
women with HIV-1, children younger than 5 years infected with HIV-1 
and all HIV-1 infected individuals in sero-discordant relationships (WHO, 
July 2012).  
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1.7.2 First-line antiretroviral therapy 
The optimal antiretroviral treatment for a treatment-naïve patient 
consists of two NRTIs in combination with a third antiretroviral drug from 
one of three drug classes; an NNRTI, a PI boosted with ritonavir or an 
InSTIs. Below are listed preferred recommended first-line triple drug 
combinations (WHO, July 2012, DHHS, 2014, WHO, 2013). 
 
NNRTI based treatment 
EFV + 3TC(or FTC) +TDF 
EFV + 3TC + AZT 
NVP+3TC(or FTC) + TDF 
NVP + 3TC (or FTC) + TDF 
 
PI based treatment 
LPV/r + 3TC(or FTC) + AZT 
ATV/r + 3TC(or FTC) + AZT 
ATV/r (or LPV/r) + 3TC (or FTC) + TDF 
DRV/r + TDF + FTC 
 
INSTI based treatment 
DTG + ABC + 3TC (or FTC) 
DTG + TDF + 3TC (or FTC) 
ELV/cobi + TDF + 3TC (or FTC) 
RAL + TDF + 3TC (or FTC) 
 
It is worth mentioning that the treatment options available to patients 
in resource limited settings especially sub-Saharan Africa, the region 
most affected by the HIV-1 pandemic and home to an estimated 27 
million HIV-1 infected individuals, are not the same as for patients in 
developed countries. Here NNRTI based treatments are the mainstay of 
first-line therapy with a limited pool of boosted PI-based regimens 
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mostly reserved for second-line treatment when first-line therapeutic 
options fail. This inequality in resources and treatment options is mainly 
due to existing patents on more recently approved drug classes and 
the overall cost of providing free anti-retroviral therapy to those who 
need treatment (WHO, 2013). 
 
1.7.3 Monitoring antiretroviral therapy 
Regular monitoring of patients who receive cART is essential to ensure 
successful treatment, promptly identify and correct adherence issues 
and to determine when to switch to second-line therapy in the event 
of treatment failure. The measurement of HIV-1 RNA (viral load) and the 
CD4+ T cell count are the two surrogate markers used to assess 
response to cART and disease progression in HIV-1 infected patients. 
Viral load is the most important indicator of an initial and sustained 
response to ART and is recommended as the preferred approach to 
diagnose and confirm treatment failure (DHHS, 2014, WHO, 2013). Viral 
load measurement not only provides an early and more accurate 
indication of treatment but also helps distinguish between treatment 
and non-adherence and can serve as an indicator for the transmission 
risk within a given population (Murnane et al., 2012, Das et al., 2010). 
With effective cART in a patient not harbouring any drug-resistant 
viruses, virological suppression is expected in 8-24 weeks following the 
initiation of cART (Thaker and Snow, 2003). The WHO recommends 
routine viral load monitoring every 6-12 months (WHO, 2013). In 
resource limited settings virological monitoring is challenging and not 
always available.  CD4+ T cell counts, coupled with clinical monitoring 
are the main tools available for defining treatment failure and deciding 
when to switch to second-line therapy in this context. The CD4+ T cell 
count is the most important means of assessing immune function in HIV-
1 infected patients. For most treated patients an adequate response to 
therapy is defined by a rise in the CD4+ T cell count of 50-150/mm3 
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during the first year of treatment (WHO, 2013, DHHS, 2014). The WHO 
recommends CD4+ T cell count monitoring every 6-12 months (WHO, 
2013). 
 
1.7.4 Treatment failure, drug resistance testing and 
salvage therapy 
Failure of antiretroviral therapy can be defined by clinical, 
immunological and virological criteria: 
 
• Clinical failure is determined by a new or recurrent event 
indicating severe immunodeficiency after 6 months of effective 
cART (WHO, 2013, DHHS, 2014). 
• Immunological failure: A fall in CD4+ T cell counts below baseline 
levels or a CD4 count persistently <100cells/mm3 in a patient 
receiving effective cART (WHO, 2013, DHHS, 2014). 
• Virological failure: A plasma viral load above 1000 copies/ml on 
2 consecutive viral load measures after 3 months following 
initiation of cART with adherence support (WHO, 2013, DHHS, 
2014). 
 
Drug resistance mutations have been described for all antiretroviral 
drugs currently used as part of cART and remain the main cause of 
treatment failure in patients receiving treatment. Poor adherence to 
therapy, drug interactions between antiretroviral drugs and other 
medications as well as the side effects of treatment are also factors 
contributing to treatment failure. Drug resistance testing is 
recommended for patients presenting with virological failure after 
receiving adequate active triple combination therapy and at baseline 
for all HIV-1 infected patients entering care, to guide the choice of 
initial and second line therapies (DHHS, 2014). 
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Genotyping and phenotyping assays are currently available to test for 
drug resistance. Standard genotyping assays for drug resistance 
involve testing for mutations in HIV-1 genes (usually RT and PR), which 
can confer resistance to RTIs and PIs. These assays involve amplifying 
HIV-1 sequences from plasma samples with detectable viral load and 
identifying drug resistance mutations through sequencing. The main 
limitation with genotyping is that most commercially available assays 
do not assess determinants of drug resistance outside the virus RT and 
PR genes (such as Gag for PIs and Integrase for InSTIs) and could fail to 
identify the cause of drug resistance in some patients failing on 
regimens containing drugs from these classes (Hirsch et al., 2008).  
 
Phenotyping assays measure the ability of clinically derived HIV-1 
isolates to grow in the presence of drugs. They enable the assessment 
of virus replication at different drug concentrations and the results are 
used to calculate 50% and 90% inhibitory concentrations (IC50 and 
IC90) of a given drug for the isolate under investigation. Commercially 
available phenotyping assays amplify HIV-1 PR and RT as a unit from 
the plasma virus and generate a recombinant virus with other genes 
from a laboratory construct. Using reporter gene based systems the 
drug susceptibility of the construct carrying clinically derived RT and PR 
is assessed.  With both standard genotyping and phenotyping assays 
only the predominant circulating viruses in the circulating pool of 
viruses are sampled, and as such minority drug-resistant species which 
can cause treatment failure or transmitted resistance are often missed 
(Hirsch et al., 2008). Ideally drug resistance testing should be performed 
while the patient is still taking the failing ARV regimen or within four 
weeks of discontinuing treatment (DHHS, 2014). Identifying treatment 
failure and making a decision to switch to second-line therapies relies 
mainly on clinical assessment in resource-limited settings, where the 
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cost and availability of technical capacities render wider use of drug 
resistance testing difficult (WHO, 2013). 
Once treatment failure has been established, treatment guidelines 
currently recommend that the failing regimen be replaced with 
second-line therapies. Second-line treatments usually comprise of three 
drugs from at least two different drug classes which were not part of 
the initial treatment regimen and to which the patient doesn’t have 
resistance mutations based on phenotyping or genotyping resistance 
assays (DHHS, 2014). In highly treatment-experienced patients with 
complicated drug resistance profiles the entry inhibitors Enfurvitide and 
Maraviroc as well as second generation NNRTIs that are currently not 
part of initial treatment options may be considered as part salvage 
therapy (DHHS, 2014). 
 
1.7.5 Antiretroviral therapy for prevention of HIV-1 
infection 
Besides their use in treating patients infected with HIV-1, antiretroviral 
drugs have also been successfully used in strategies aimed at 
preventing infection. Currently there are four scenarios for which 
antiretroviral prophylaxes has proven successful and these have now 
been implemented to varying degrees globally in public health 
programs aimed at HIV-1 prevention. 
 
1.7.5.1 Prevention of mother to-child-transmission (PMTCT) 
of HIV-1 
In the absence of any intervention the natural history of HIV-1 
transmission during pregnancy carries a risk of 25-45%. In the mid-
nineties following the FDA approval of increasing numbers of drugs for 
the treatment of HIV-1, the usefulness of antiretroviral therapy as a 
strategy to prevent mother-to-child transmission was demonstrated in 
several clinical trials (Connor et al., 1994, Shaffer et al., 1999, Wiktor et 
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al., 1999, Guay et al., 1999, Lallemant et al., 2004).  These studies found 
that using AZT or NVP in monotherapy and dual therapy combinations 
antepartum, intrapartum and for the newborn, led to a reduction in 
the risk of mother-to-child transmission to 5-8% (Lallemant et al., 2004, 
Guay et al., 1999, Wiktor et al., 1999, Shaffer et al., 1999, Connor et al., 
1994). These initial interventions where recommended by the WHO and 
other leading public health agencies and very quickly led to a 
significant reductions in the incidence of vertical transmission of HIV-1.  
Following the advent of HAART in the early 2000s, triple therapy 
combinations where assessed for PMTCT and found to be even more 
effective, cutting the transmission risk down to 1-2% (Marazzi et al., 
2007, Marazzi et al., 2009, Marazzi et al., 2010).  
 
The WHO now recommends cART for all pregnant and breastfeeding 
women with the option of discontinuing cART once the MTCT risk period 
has ceased for women not meeting the treatment eligibility criteria or 
lifelong cART for all pregnant women (WHO, 2013). ARVs as PMTCT 
reduce the circulating maternal viral load considerably and by so 
doing, reduce the likelihood that the baby will be exposed to infectious 
virus during pregnancy, at delivery and through breastfeeding. It is 
worth noting that due to limitations in resources, monotherapy and 
dual therapy interventions for PMTCT are still used in many middle and 
low-income countries despite the current recommendations. PMTCT 
has been associated with the development of drug resistance in the 
mother and transmitted drug resistance in babies born to infected 
mothers (Eshleman et al., 2001, Jourdain et al., 2004). Drug resistance 
associated to PMTCT may compromise future cART options and should 
be considered when choosing cART regimens for women who have 
previously received single or dual therapy ARVs for prophylaxes. 
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1.7.5.2 Pre-exposure prophylaxes (PreP) 
PreP is a fairly recent intervention for prevention aimed at individuals 
who are not infected with HIV-1 but have a substantial risk of becoming 
infected.  The efficacy of oral PreP, a combination of two NRTIs 
Tenofovir and Emtricitabine in a single pill (Truvada®), has been 
demonstrated in several clinical trials assessing the impact of this 
intervention in different risk groups. In men who have sex with men 
(MSM), PreP reduced the risk of acquiring HIV-1 infection by as much as 
92% (iPrex study)(Grant et al., 2010); among heterosexually active men 
and women the risk of transmission was reduced by 62% (TDF2 study) 
(Thigpen et al., 2012); in HIV-1 discordant couples PreP reduced 
transmission by up to 90% (Partners PreP study) (Baeten et al., 2012) and 
among injecting drug users a single dose of Tenofovir, one of the 
components of Truvada® used in the  other three studies, reduced the 
risk of getting HIV-1 infection by 49% (Bangkok Tenofovir 
study)(Choopanya et al., 2013). The use of topical agents for PreP has 
also been assessed and the CAPRISA study showed 2% Tenofovir gel 
applied before and after sexual intercourse vaginally, reduced the risk 
of HIV-1 transmission by 54% for the women who used the intervention 
effectively (Abdool Karim et al., 2010).  
 
Macaque models of vaginal infection with SIVs have given some insight 
into the early events around the mucosal transmission of HIV-1 (Heneine 
and Kashuba, 2012). These studies suggest that with mucosal 
transmission, there is an initial phase during which HIV-1 replicates at 
low levels at the point of entry (Heneine and Kashuba, 2012). PreP is 
designed to target this brief window period of vulnerability to block the 
virus infection from taking hold and establishing reservoirs within the 
host (Heneine and Kashuba, 2012). Despite the success seen in the 
PreP trials cited above, there remains considerable controversy in this 
area due to the failure of some trials to show any benefit in reducing 
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the risk of HIV-1 transmission with this intervention. The FEM-PreP (Van 
Damme et al., 2012) and VOICE trials were discontinued before 
completion because of futility. Also the variation in the degree of 
protection observed in the studies where PreP was found to be 
beneficial remains for the most part unexplained (Van Damme et al., 
2012). Several factors could possibly account for the observed 
differences in results including; the different study populations enrolled 
in these trials, the degree of adherence to the prophylactic regimen 
and the route of transmission (rectal, vaginal or parenteral) for the 
population under study (Cohen and Baden, 2012). 
 
 With the recent observations on the reduced sensitivity of cell-to-cell 
viral spread to inhibition by antiretroviral drugs (Sigal et al., 2011, 
Duncan et.al, 2013), it is reasonable to contemplate whether this 
reduced sensitivity to drugs could confer an advantage to the virus 
allowing it to spread from the initial site of introduction and establish 
infection in the presence of PreP. This is especially important given that 
there is substantial evidence, albeit mainly derived from primate based 
transmission studies (Anderson et al., 2010), that cell-to-cell spread 
plays a role in the early steps of HIV-1 transmission at the mucosa. Cell-
associated infection was demonstrated in SIV vaginal challenge of 
macaques and the concentration of infected cells needed for 
transmission in this model were shown to be within the physiological 
range, while cell-free infections required supra-physiological doses to 
establish infection (Salle et al., 2010, Weiler et al., 2008). The impact of 
antiretroviral drugs on cell-free and cell-to-cell modes of HIV-1 infection 
could have implications for the choice of ARVs used in PreP strategies. 
 
The CDC and the WHO now recommend the use of oral PreP as a 
single daily dose of Truvada® for individuals who fit well-defined risk 
criteria for acquiring HIV-1 infection (Prevention, 2014, WHO, 2013). In 
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sub-Saharan Africa PreP is currently not widely used outside the context 
of clinical trials although mathematical modelling studies suggest that 
over a period of 10 years an effective PreP program could prevent 2.7-
3.2 million new HIV-1 infections in this region (Heneine and Kashuba, 
2012). Preliminary data on the risk of developing drug resistance 
following the implementation of PreP indicate that the benefits of PreP 
by far outweigh the risk associated with developing drug resistance in 
individuals who become infected despite receiving prophylaxis (van 
de Vijver and Boucher, 2010). Tenofovir and Emtricitabine, the 
components of Truvada®, are recommended as first-line choices for 
cART and as such monitoring for drug resistance in populations where 
PreP is being rolled out is important and recommended (Prevention, 
2014). 
 
1.7.5.3 Post-exposure prophylaxis (PEP) 
PEP is short-term antiretroviral treatment to reduce the likelihood of HIV-
1 infection after potential risky exposure to the virus which can be 
either occupational or through sexual intercourse. Data from simian 
infection models suggests that the post-exposure window during which 
infection can be cured ranges from 24 hours for IV injection (Tsai et al., 
1998) to 48-72 hours for vaginal challenge (Otten et al., 2000). After the 
first few days elapse this curative window closes as HIV-1 drug 
insensitive reservoirs become established within the host (Sigal and 
Baltimore, 2012).  PEP targets this window of opportunity to limit and 
possibly eliminate viral replication at the site of entry and prevent 
seeding of the virus in the lymphoid tissues and established infection. 
The WHO currently recommends using any of the first-line cART 
regimens for 28 days with the first dose being offered as soon as 
possible within 72 hours of the exposure (WHO, 2013). 
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1.8  Thesis Overview and Scope 
Recent observations on the reduced susceptibility of HIV-1 cell-to-cell 
infection to inhibition by RTIs have raised questions on the bearing this 
mode of spread may have for the successful treatment of HIV-1, the 
maintenance of viral reservoirs and viral pathogenesis. RTIs are major 
components of first-line and second-line cART as previously discussed. 
This thesis presents a detailed assessment of the individual drug classes 
(PIs, RTIs and INIs), which constitute first-line and second-line 
antiretroviral therapies with regards to their ability to inhibit cell-to-cell 
HIV-1 infection in comparison to cell-free infection. Special emphasis is 
given to the study of PIs, which have a mechanism of action different 
from RTIs, present a higher barrier to the development of drug-resistant 
mutants, are highly potent and are very important for first-line and 
second-line treatment options. The results obtained from this study are 
presented in three sections as briefly summarised below: 
 
In chapter 3, two assay systems, one with an indirect output measure 
(Tat-driven luciferase expression) and another with a direct output 
measure (HIV-1 pol DNA transcripts) of HIV-1 infection, are assessed for 
their use in studying the effect of inhibitors on HIV-1 cell-to-cell 
infection. The results presented in this section highlight specific 
limitations of using indirect output measures of infection when studying 
cell-to-cell spread of HIV-1, especially in the context of some types of 
inhibitors. It also justifies the use of the assay with a direct output 
measure of infection for the drug studies in my thesis. PI and RTI resistant 
mutants used in this thesis are also constructed, characterised and 
assessed for their ability to spread efficiently by a cell-to-cell 
mechanism in this section. 
 
In chapter 4, a detailed study of the impact of PIs on cell-to-cell spread 
of wild type and drug-resistant HIV-1 is presented and compared to RTIs 
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already studied by other groups. This section highlights the variable 
effects of the different drug classes used in cART on cell-to-cell spread 
of HIV-1 and clearly demonstrates that PIs are equally effective at 
blocking all modes of virus infection, whereas RTIs show reduced 
efficacy, with NRTIs being a lot less effective than NNRTIs. The effect of 
INIs on cell-to-cell spread of HIV-1 between T cells is also studied and 
Raltegravir is shown to be effective against this mode of virus 
dissemination. 
 
Chapter 5 addresses the question of drug combinations and cell-to-cell 
spread of HIV-1. Here cell-to-cell spread of HIV-1 is studied in the 
presence of clinically relevant PI and RTI-based combinations and 
compared to cell-free spread of the virus.  The median effect principle 
is applied to assess the impact of the mode of virus transmission and 
drug resistance on drug interactions in the combinations tested.  
 
Overall the study aims to provide a better understanding of the impact 
of antiretroviral therapy on cell-to-cell spread of HIV-1 and within 
reason, bearing in mind the limitations of in vitro models, gives some 
insight on the possible clinical implications of these observations for 







Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 
Chapter Two  - Materials and methods 
 
93 
2 Materials and Methods 
This section contains a detailed listing of the reagents, organisms and 




Taq DNA polymerase was purchased from Invitrogen® (Life 
Technologies Ltd, Paisley, UK). Hot Gold Star DNA polymerase used for 
real-time PCR was supplied in a RT-PCR Master mix plus low ROX from 
Eurogentec ® (Seraing, Belgium). Proofreading Pfx DNA polymerase 
was obtained from Invitrogen® (Life technologies Ltd, Paisley, UK). 
 
Restriction endonucleases 
Restriction enzymes and their 10x concentrated reaction buffers were 
obtained from New England Biolabs (NEB) (Ipswich, UK) Ltd and from 
Promega® UK Ltd (Southampton, UK). 
 
Alkaline Phosphatase 
Recombinant Alkaline phosphatase from bovine intestine was 
purchased from Roche® Diagnostics (Mannheim, Germany). 
T4 DNA Ligase 
T4 DNA ligase was obtained from Roche® Diagnostics (Mannheim, 
Germany). 
 
2.1.2 Molecular weight markers (DNA and Protein) 
1Kb plus DNA Ladder (Life Technologies Ltd, Paisley, UK) 
DNA fragment sizes (base pairs): 12216, 11198, 10180, 9162, 8144, 7126, 
6108, 5090, 4072, 3054, 2036, 1636, 1018, 517, 369, 344, 298, 220,201, 154, 
134, and 75. 
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Protein molecular weight marker 
Pre-stained Amersham® SDS molecular weight standard mixture was 
obtained from GE healthcare Life Sciences (Uppsala, Sweden).  
 
2.1.3 Deoxyribonucleotides (dNTPs) 
dNTPs were supplied  by Invitrogen®  (Life Technologies Ltd  Paisley, 
UK). 
2.1.4 Oligonucleotide primers 
Primers for PCR and DNA sequencing were designed using the 
computer software Sequencher® Gene Codes Corporation (Ann 
Arbor, Michigan, USA). All oligonucleotides were ordered from 
Eurogentec® (Seraing, Belgium). A list of oligonucleotide names and 
sequences is provided in the methods section. 
2.1.5 Plasmids and molecular clones 
pNL4.3 
The HIV-1 clone was obtained from the NIH AIDS Research and 
Reference Reagent Program (ARRP). It is a plasmid that contains the 
full-length replication, and infection competent chimeric HIV-1 DNA 
derived from subtype B clinical isolates. Upon transfection, this clone 
directs the production of infectious virions in a wide variety of cells 
(Adachi et al., 1986). 
 
pCR®2.1TOPO 
This cloning vector was supplied in the TOPO® TA Cloning Kit from 
Invitrogen® (Life Technologies, Paisley, UK) and used for cloning to 
design drug-resistant HIV-1 molecular clones created by site directed 
mutagenesis of pNL4.3. 
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2.1.6 Bacteria strains 
Escherichia coli 
One Shot® TOP10 chemically competent Escherichia coli from 
Invitrogen® (Life Technologies Ltd, Paisley, UK) was used for plasmid 
propagation through out this thesis. The genotype of this strain is: F- 
mcrAΔ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara-leu)7697 galUgalKrpsL (StrR) endA1 nupG. 
 
2.1.7 Cells 
Human embryonic kidney (HEK) 293T cells 
HEK293T cells were originally from ATCC® (American Type Culture 
Collection, Virginia, USA). The 293T cell line, originally referred to as 
293tsA1609neo, is a highly transfectable derivative of human 
embryonic kidney 293 cells, and contains the SV40 T-antigen. 
 
HeLa TZM-bl cells 
HeLa (Henrietta Lacks) TZM-bl cells were obtained from the Center for 
AIDS reagents, National Institutes of Biological Standard and Control, 
UK (CFAR, NIBSC) and donated by J.Kappes, X.Wu and Tranzyme Inc. 
This cell-line is an engineered HeLa cell clone that expresses human 
CD4, CCR5 and CXCR4 and contains HIV-Tat regulated genes for firefly 
luciferase and β-galactosidase. HeLa TZM-bl is highly sensitive to 
infection with diverse isolates of HIV and SIV. 
 
Jurkat CE6.1 
This is a CD4+/CXCR4+ T cell line obtained through the AIDS Research 
and reference reagent program, Division of AIDS, NIAID, NIH (ARRP). 
The cell line was cloned from cells obtained from Dr. Kendall Smith and 
donated by Dr. Arthur Weiss. 
1G5  
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This is a Jurkat derivative containing a stably integrated HIV-LTR 
luciferase construct. It was obtained from the AIDS Research and 
reference reagent program (ARRP), Division of AIDS, NIAID, NIH, 
donated by Dr. Estuardo Aguilar-Cordova and Dr. John Belmont. 
 
ACH-2 
This is a HIV-1 latent T cell clone with one integrated proviral copy. 
These cells are CD4-, CD5+, transferrin receptor +, Leu-1+ and HIV-1+. 
They are derived from A3.01 cells infected with LAV and cloned by 
limiting dilution. ACH-2 is a clone that survived infection and constantly 
produces low levels of RT and p24. The subclone A.3.01 is derived from 
CEM, a human T cell line originally isolated from a four year old 
caucasian female with acute lymphoblastic leukemia. This cell line is 
obtained from the NIH AIDS reagent program ARRP), division of AIDS, 
USA. Donated by Dr. Thomas Folks. 
 
2.1.8 Antibodies 
Coating anti-HIV-1 p24 antibody (D7320) 
 D7320 is a sheep polyclonal antibody, which was used for the p24 
ELISA. Supplied by Aalto® Bioreagents (Dublin, Ireland). 
 
Biotinylatedα-p24 (BC1071-BIOT) 
BC1071-BIOT is a mouse monoclonal antibody, which was used for the 
p24 ELISA. Supplied by Aalto® Bioreagents (Dublin, Ireland). 
 
HIV-1 anti-Tat antibody (02-002) 
Mouse raised monoclonal antibody against recombinant Tat protein 
Tat protein of HIV-1 (BH10) origin with epitope mapping to amino acids 
6-12. Supplied in a vial containing 100µg IgG1 in 1ml of PBS with < 0.1% 
sodium azide from Santa Cruz Biotechnology (Heidelberg, Germany). 
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Normal Mouse IgG1 (purified) 
Mouse IgG1 isotype control antibody (supplied by Life Technologies 
Ltd, Paisley, UK). Supplied in a vial containing 100μg IgG1 in 1ml of PBS 
with <0.1% sodium azide. 
 
Anti-HIV-1 Gag p55 and p24 antibody  
This is a rabbit raised polyclonal IgG antibody that recognises p55Gag 
and p24CA it was obtained from the Center for AIDS research (CFAR) 
NIH, ARRP, and donated by Dr. G. Reid. This antibody was used for 
western blotting. 
 
Anti-HIV-1 p24 antibody-FITC 
This is an IgG goat polyclonal antibody to HIV-1 p24 which is 
conjugated to FITC (Fluorescein isothiocynate) obtained from Abcam® 
plc (Cambridge, United Kingdom). 
 
2.1.9 General laboratory chemicals 
General chemical reagents such as salts, alcohols, organic 
compounds and detergents were obtained from a range of suppliers 
including Fisher Scientific (Loughborough, UK), Sigma-Aldrich Company 
Ltd (Poole,UK), Life Technologies (Paisley, UK). 
These include: agarose powder, acrylamide solution, sodium dodecyl 
sulphate (SDS), Tris, Ethylenediaminetetraacetic acid (EDTA), Dimethyl 
sulphoxide (DMSO), Tetramethylethylenediamine (TEMED), Ammonium 
Persulphate (APS), Acrylamide solution, NaOH (sodium hydroxide), 
NaCl (sodium chloride), HCl (hydrochloric acid), H2SO4 (sulphuric acid) 
, glacial acetic acid. Methanol, Ethanol, Ethidium Bromide, glycerol, X-
gal. Tetramethylbenzidine (TMB), NaHCO3 (Sodium hydrogen 
carbonate). 
 
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 
Chapter Two  - Materials and methods 
 
98 
2.1.10 Electrophoresis gels 
 1% Agarose gel 
1g of agarose powder (Sigma-Aldrich) + 100ml of 1x TAE buffer. 
Microwaved for 2min or until the agarose dissolved and the solution 
became clear. Allowed to cool before pouring into cast. 
 
10% acrylamide gel (resolving gel) for SDS-PAGE 
 The formula for two gels: 2.64ml 40% Acrylamide solution (Sigma-
Aldrich Ltd, Poole,UK) + 2.96ml 1M Tris (Sigma-Aldrich) pH 8.8 + 
79.2µl10% SDS + 2.3ml dH2O, 26.5µl Ammonium persulphate (APS) 
(Sigma-Aldrich Ltd, Poole, UK)+ 5.3µl TEMED (Sigma-Aldrich Ltd, Poole, 
UK ). 
 
Stacking gel for SDS-PAGE 
The formula for two gels: 1.66ml 40% Acrylamide solution  + 1.24ml 1M 
Tris pH 6.8 + 99.2µl 10%SDS + 9.94ml dH2O + 49.6µl APS  + TEMED. 
 
2.1.11 Buffers and other solutions 
DMEM maintenance medium 
Dulbecco’s Modified Eagle’s Medium (DMEM) (with L-glutamine, 
4500mg/l D-glucose and without sodium pyruvate) before use 
supplemented with 1% antibiotic solution and 10% fetal calf serum 
(FCS) and stored at 2°-8°C. Purchased from Life technologies Ltd, 
(Paisley, UK). 
 
RPMI-1640 maintenance medium 
Roswell Park Memorial Institute (RPMI)-1640 medium (with L-glutamine, 
without sodium pyruvate) before use supplemented with 1% antibiotic 
solution and 10% FCS and stored at 2°-8°C. Purchased from Life 
technologies Ltd (Paisley, UK). 
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Luria Bertani (LB) medium 
To make 1L of LB broth 10mg of Bacto-tryptone, 5g-yeast extract and 
5g NaCl were dissolved in one liter of water, and the pH was adjusted 
to 7.5 with 5M NaOH. 
 
Luria Bertani (LB) plates 
10g of agar powder (Sigma-Aldrich) was added to 1L of LB broth. The 
solution was autoclaved and allowed to cool to approximately 50°C 
before antibiotics were added and plates poured. Ampicillin was 
added to a final concentration of 100µg/ml. 
 
S.O.C Medium 
Composition: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose. Supplied by 
Invitrogen® Life Technologies Ltd (Paisley, UK). 
 
Trypsin solution 
Composed of 0.025% trypsin and 0.01% EDTA in Phosphate Buffered 
Saline (PBS) purchased from Invitrogen® Life Technologies Ltd (Paisley, 
UK). 
 
Antibiotic stock solutions 
Ampicillin 100mg/ml in sterile water and stored at -20°C. 
Penicillin/Streptomycin solution from Invitrogen® Life Technologies Ltd 
(Paisley, UK) , 5000U/ml stored at -20°C. 
 
6x DNA loading buffer 
Bromophenol blue 0.25%(v/v), 0.25% xylene cyanol and 30% (v/v) 
glycerol in water, from Invitrogen® Life Technologies Ltd (Paisley, UK). 
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Obtained from Invitrogen®, Life technologies Ltd (Paisley, UK). Without 
magnesium and calcium, pH=7.4. 
 
10x Dulbecco’s Phosphate buffered saline (DPBS) 
Obtained from Invitrogen, Life technologies Ltd (Paisley, UK). With 
magnesium and calcium, pH=7.4. 
 
10x Tris buffered saline (TBS) 
168.32g NaCl, 60.6g Tris (Sigma-Aldrich), 2L distilled H20.  30ml 
concentrated HCL was added to 2L TBS solution to adjust pH to 7.5. 
 
TBS/E/S (TBS with Empigen and serum) 
 For 10ml of TBS/E/S: 1ml FCS (Life technologies Ltd, Paisley, UK), 1ml 10x 
TBS, 333µl Empigen® (Sigma-Aldrich Ltd. Poole, UK), 8.667µl distilled H20. 
 
TMT/SS 
Composition: 1xTBS, 2% Bovine serum albumin (Sigma-Aldrich), 20% FCS 
(Life Technologies Ltd, Paisley, UK). 
 
Streptavidin Horse Radish Peroxidase (HRP) 
Enzyme purified from Streptomyces avidii and supplied in PBS from Life 
Technologies Ltd (Paisley, UK). 
 
Coating Buffer (for p24 ELISA) 
100mM NaHCO3. For 20ml of coating buffer solution 168mg of NAHCO3 
(Sigma-Aldrich Ltd, Poole, UK) in 20ml of dH2O. 
 
10x running buffer (Western blotting) 
30g Trizma base® (Sigma-Aldrich, Ltd, Poole, UK) + 144g glycine (Sigma-
Aldrich Ltd, Poole, UK) + 1l dH20. 
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1x running buffer (Western blotting) 
100ml of 10x running buffer + 10ml 10% SDS (Sigma-Aldrich Ltd, Poole, 
UK) + 1l H2O. 
 
Transfer buffer (Western blotting) 
100ml 10x running buffer + 700ml dH2O + 200ml methanol (Sigma-
Aldrich Ltd, Poole, UK). 
 
50x TAE buffer stock solution (1l) 
100ml 0.5M EDTA solution (Sigma-Aldrich Ltd, Poole, UK) + 57.1ml glacial 
acetic acid (Sigma-Aldrich) + 242g Tris base (Sigma-Aldrich Ltd, Poole, 
UK) + 750ml H2O. Solutions were mixed thoroughly to dissolve the salts 
then the  volume was adjusted to 1;. The stock solution was diluted as 
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2.2.1 Transfecting plasmid DNA into chemically 
competent Escherichia coli (E.coli) 
OneShot® TOP10 chemically competent E.coli  (Invitrogen®) was used 
for all transformation procedures. 10pg-100ng of plasmid DNA was 
gently mixed with a vial of OneShot® cells thawed on ice according to 
manufacturer’s instructions. The mixture was incubated on ice for 30min 
and then heat-shocked at 42°C for 30sec without shaking. The vials 
were placed on ice for 2min after heat shock and 250µl of pre-warmed 
S.O.C® medium added to each vial. The vials were placed for 1hour in 
a shaking incubator at 250rpm. 20-200µl of each transformation was 
spread unto a pre-warmed selective LB agar plate and incubated 
overnight at 37°C. The plates with colonies were stored at 4°C for a 
maximum of two weeks. 
 
2.2.2 Glycerol stocks of plasmids 
Bacterial glycerol stocks were made for long-term storage of all the 
plasmids used in the experiments. The addition of glycerol stabilises the 
frozen bacteria, preventing damage to the cells and keeping them 
alive. 0.5ml of overnight culture was added to 0.5ml 50% glycerol 
(Sigma-Aldrich Ltd, Poole, UK) in a 2ml cryovial and mixed thoroughly 
by gently pipetting.  The cryovials were stored at -80°C. 
 
2.2.3 Purification of plasmid DNA 
 DNA was extracted from a single transformed E.coli colony grown in 
4ml of LB broth containing 100µg/ml of Ampicillin, overnight at 37°C in a 
shaking incubator at 250rpm. Mini-preps of the plasmid DNA were 
prepared using the QIAprep® spin miniprep kit (QIAGEN, Venlo 
Netherlands) according to manufacturer’s instructions. Briefly, bacterial 
cells grown overnight were harvested by centrifugation at 3000rpm for 
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10min. All traces of supernatant were removed from the pelleted 
bacterial cells. The bacterial cells were re-suspended in 250µl P1 buffer 
and transferred to a microcentrifuge tube. 250µl of P2 buffer was 
added and mixed thoroughly by inverting the tube 4-6 times. 350µl 
buffer N3 was added and mixed thoroughly by inverting the tubes 4-6 
times. The tubes were centrifuged for 10min at 13000rpm in a 
microcentrifuge. The supernatants were applied to the QIAprep® spin 
column by decanting and the columns centrifuged for 1min at 
13000rpm and flow-through was discarded. To wash the QIAprep®, 
0.5ml PB buffer was added to the column, centrifuged at 13000×g for 
1minute and flow through discarded, this was followed by a wash with 
0.75ml PE buffer. To elute DNA, 50µl elution buffer was added to the 
center of the column and columns centrifuged for 1minute.  All DNA 
was stored at -20°C until use. 
 
2.2.4 Extraction of DNA from cells 
Total DNA from cells was purified using the DNeasy® blood and tissue 
kit (QIAGEN, Venlo, Netherlands) according to manufacturer’s 
instructions. The cells from which DNA was to be extracted were re-
suspended in 200µl PBS. 20µl proteinase K and 200µl buffer AL were 
added to cell suspension and mixed thoroughly by vortexing. The 
mixture was incubated at 56°C for 10min. After the incubation 200µl 
ethanol (100%) was added to the sample and mixed thoroughly by 
vortexing. The mixture was transferred to the DNeasy® mini spin column 
and placed in a 2ml collection tube and centrifuged at 8000rpm for 
1min and the flow-through discarded. The column was washed first by 
adding 0.5ml buffer AW1 and centrifuging for 1min at 8000rpm, then 
adding 0.5ml buffer AW2 and centrifuging for 14000rpm for 3min to dry 
the DNeasy® membrane. The flow-through was discarded after each 
of the washes. The DNeasy® mini spin column was transferred to a 
clean 1.5ml microcentrifuge tube and 200µl buffer AE was added to 
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the DNeasy® membrane to elute the DNA and the columns 
centrifuged at 8000rpm for 1min. DNA was stored at -20°C. 
 
2.2.5 Gel extraction of DNA 
Gel extraction of DNA was performed using the QIAquick® gel 
extraction kit (QIAGEN, Venlo, Netherlands). Briefly, the PCR product 
was excised from the agarose gel and 3x the volume of QG buffer 
added to the gel (e.g. 300µl QG buffer to every 100µg of gel weight). 
The gel+QG buffer was incubated at 50°C until the gel had completely 
dissolved. The sample was then applied to a QIAquick® column and 
centrifuged at 10000g for 1minute to bind DNA to the column. 500µl 
buffer QG was added to the column and the column was centrifuged 
at 10000×g for 1minute to ensure the removal of all traces of agarose. 
750µl buffer PE was added to wash the column and centrifuged at 
10000×g for 1minute.  Finally the DNA was eluted in 30µl DNAse/RNAse 
free elution buffer followed by one final 1min centrifugation at 
10000×g. DNA was stored at -20°C. 
 
2.2.6 DNA quantification 
DNA was quantified in 1µl of purified DNA sample on a Nanodrop® ND-
1000 UV-vis spectrophotometer (Nanodrop®, ThermoScientific, 
Wilmington, USA). Ethidium Bromide (Sigma-Aldrich Ltd, Poole, UK) 
staining and agarose gel electrophoresis were also used to quantify 
DNA by running a 5µl aliquot of purified DNA along with a DNA 
molecular marker (Invitrogen® Life technologies Ltd, Paisley, UK). 
 
2.2.7 Agarose gel electrophoresis 
Electrophoresis on a 1% agarose gel was used to separate and visualise 
DNA fragments. 5µl of Ethidium Bromide (Sigma-Aldrich Ltd, Poole, UK) 
was added to the pre-prepared gel before pouring it into a sealed gel 
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plate to a depth of 4-8mm.  An appropriate sized comb was inserted 
into the gel and the gel was allowed to cool. Once cooled and 
solidified, the comb was removed and the gel submerged in 1× TAE 
buffer in the electrophoresis chamber. 1/5 sample volume of 6× 
loading dye (Invitrogen® Life Technologies Ltd, Paisley, UK) was added 
to each sample and loaded in the wells and DNA separated by 
electrophoresis at 120V for 1hour. 
 
2.2.8 Restriction enzyme digestion of DNA 
A typical digest reaction was set-up as detailed below using the 
recommended buffer. 
DNA digest reaction: 
2µg DNA 
1U/µg of DNA restriction enzyme  
5µl of 10× restriction enzyme buffer 
Sterile deionised water up to 50µl  
The reaction was incubated on a thermocycler for 1hour at the 
recommended temperature for the enzyme according to 
manufacturer’s instructions. 
 
2.2.9 Molecular cloning using TOPO pCR®2.1 and 
site-directed mutagenesis (SDM) 
In order to create the full-length HIV-1NL4.3 drug-resistant mutants used 
in experiments in this thesis, the desired HIV-1NL4.3 fragment for SDM, 
from nucleotide position 740-2940, was amplified by PCR using a high 
fidelity polymerase enzyme, Platinum® Taq (Invitrogen®, Life 
Technologies Ltd, Paisley, UK) and target specific primers RT-forward 
and RT-reverse (Table 2-2: Sequencing and PCR primers). The DNA was 
then digested using the restriction enzymes SpeI and AgeI (New 
England Biolabs) according to manufacturer’s instructions. The 
digested DNA fragments were visualised alongside a molecular ladder 
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marker using Ethidium Bromide (Sigma-Aldrich Ltd, Poole, UK) staining 
and agarose gel electrophoresis to check the fragment size. PCR 
products were purified using QIAquick® PCR purification kit  (QIAGEN, 
Venlo, Netherlands) according to manufacturer’s instructions.  
 
PCR reaction mixture: 
10x High Fidelity Buffer: 5µl 
10mM dNTP mix: 1µl 
50mM MgSO4: 2µl 
Platinum® Taq: 0.2µl 
10µM forward primer (RT forward): 2µl 
10µM forward primer (RT reverse): 2µl 
DNA template: 10ng 
PCR-grade H2O: up to total reaction volume of 50µl 
 
PCR program 
94°C for 2min 
94°C for 15s 
55°C for 30s 
68°C for 2min 
Steps 2-4 repeated 30 times 
72°C for 3min 
4°C hold 
 
2.2.10 Cloning of PCR products 
To facilitate the cloning of products generated by the high fidelity 
polymerase into the TOPO® TA cloning vector pCR®2.1, 100ng of the 
PCR product with 15µl of 2mM dATP and 5 units of GoTaq® (Promega 
Ltd, Southampton UK) in a total reaction volume of 20µl was heated at 
72°C for 30mins. 2µl of the freshly poly-A tailed PCR product was used 
for the TOPO® cloning reaction according to manufacturer’s 
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instructions by mixing it with 1µl salt solution, 4µl of sterile water and 1µl 
of TOPO® vector in a total reaction volume of 6µl. The mixture was 
incubated for 5-20min and a2µl aliquot of this mixture was used to 
transform chemically competent OneShot® TOP10 cells (Invitrogen®, 
Life Technologies, Paisley UK), as previously described. The 
transformation reaction mixture was spread unto pre-warmed selective 
plates enriched with X-gal (Promega Ltd, Southampton, UK) and 
incubated overnight at 37°C. To analyse the transformants 6-10 white 
colonies where picked for DNA purification. The plasmid DNA 
wasdigested with the appropriate restriction enzymes and visualised by 
Ethidium Bromide staining and agarose gel electrophoresis to confirm 
the presence and orientation of the DNA insert in the cloning vector. 
 
2.2.11 Site-directed mutagenesis (SDM) 
Mutagenesis PCR was performed with Accuprime® pfx polymerase 
(Invitrogen® Life Technologies Ltd, Paisley, UK) according to the 
manufacturer’s protocol.   
PCR reaction mixture: 
Accuprime® pfx supermix: 22.5µl 
 Forward and reverse mutagenesis primers (5µM): 0.5µl each 
Plasmid DNA (20ng): 1µl 
PCR-grade water: up to 25µl 
 
SDM PCR-program: 
95°C for 15min 
95°C for 15s 
60°C for 30s 
68°C for 2min 
Steps 2-4 30 times 
68°C for 15min 
4°C hold 
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The SDM PCR product was digested with DpnI restriction enzyme at 
37°C for 1 hour. A 2µl aliquot of the DpnI digested PCR product was 
then used to transform TOP10 chemically competent cells. The 
transformations were plated on selective X-gal enriched agar plates as 
previously described. 6 white colonies were picked for DNA purification 
and subsequent sequencing to check for the presence of the desired 
mutation and any errors introduced by PCR. 
 
Table 2-1: Mutagenesis Primers 

















V82A-forward GTAGGACCTACACCTGCCAACATAATTGGAAG V82A mutagenesis 










2.2.12 DNA sequencing 
DNA sequencing was carried out by COGENICS® (Beckman Coulter 
Genomics, Essex, UK). Typically, 100ng of plasmid DNA or gel purified 
PCR DNA was sent for DNA sequencing with the relevant primers at 
5µM concentration. Sequencing was performed with BigDye® 
terminator chemistry and a 3730×1 analyser (Applied Biosystems®, Life 
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Table 2-2: Sequencing and PCR primers 
Primer/Probe name             Sequence (5’-3’)              Function 
HXB2 forward GTGCTGGAATCAGGAAAGTACTA  HIV-1 pol qPCR (primer) 
HXB2 reverse ATCACTAGCCATTGCTCTCCAATT  HIV-1 pol qPCR (primer) 
HXB2 probe TGTGATATTTCTCATGTTCATCTTGGGCCTTATCT  HIV-1 pol qPCR (probe) 
Albumin forward GCTGTCATCTCTTGTGGGCTGT  HIV-1 pol qPCR (primer) 
Albumin reverse AAACTCATGGGAGCTGCTGGTT  HIV-1 pol qPCR (primer) 
Albumin probe CCTGTCATGCCCACACAAATCTCTCC  HIV-1 pol qPCR (probe) 
2-LTR forward AACTAGAGATCCCTCAGACCCTTTT HIV-1 2-ltr qPCR (primer) 
2-LTR-reverse CTTGTCTTCGTTGGGAGTGAATT HIV-1 2-ltrqPCR (primer) 
2-LTR-junction  TTCCAGTACTGCTAGAGATTTTCCACACT HIV-1 2-ltrqPCR (probe) 
Seq1-forward CATAGCAGGAACTACTAGTACC            Sequencing 
Seq2-reverse GCATTAGTAGAAATTTGTACAG            Sequencing 
Seq3-forward GTATGGTAAATGCAGTATACTTC            Sequencing 
Seq4-reverse AGAATCTCCCTGTTTTCTGCCA            Sequencing 
RT-forward GGAGGTTTTATCAAAGTAAGAC                PCR 
RT-reverse TCTTTTGATGGGTCATAATACACTCC                PCR 
 
2.2.13 Sub-cloning into HIV-1NL4.3 backbone 
The DNA insert with the desired mutation (confirmed by sequencing) 
was extracted from the gel following electrophoresis of the double 
digest with AgeI and SpeI restriction enzymes of the TOPO® clone 
containing the insert. The DNA band corresponding to the HIV-1NL4.3 
backbone was extracted from the agarose gel, following 
electrophoresis of the double digest of HIV-1NL4.3 with AgeI and SpeI. 
The DNA was stored at -20°C if not used immediately in ligation 
reactions. All ligation reactions were set-up using the Roche® Rapid 
DNA Dephos and ligation kit (Roche Diagnostics, Mannheim, 
Germany). The purified DNA of the vector backbone was first 
dephosphorylated prior to ligation to prevent vector re-ligation.  
 
Dephosphorylation reaction 
Vector DNA =x µl (up to 1µg) 
10× Rapid Alkaline Phosphatase Buffer (Roche®) = 2µl 
Rapid Alkaline Phosphatase (Roche®) = 1µl (1U) 
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Sterile water:  added to make up a total volume of 20µl 
The reaction was incubated at 37 °C for 30min and at 72°C for 5min to 
inactivate the alkaline phosphatase (Roche).  The dephosphorylated 
vector DNA was used immediately in the ligation reaction or stored at -
20°C. 
 
Ligation reaction (molar ratio of vector DNA: insert DNA = 1:3) 
Vector DNA = x µl (50ng) 
Insert DNA = x µl (150ng) 
5× DNA dilution buffer (Roche): 2µl 
Sterile water: added to make up to a volume of 10µl and mixed 
thoroughly 
2× T4 DNA ligase (Roche) added = 10µl 
T4 DNA ligase (Roche) = 1µl (5U) 
 
The ligation reaction was incubated at room temperature for 30min 
and 1/10 of the ligation reaction was used to transform competent 
E.coli as previously described. 
 
2.2.14  Tissue culture techniques 
All the cell and virus cultures described in this thesis were maintained in 
humidified incubators at 37°C with 10% CO2 for human embryonic 
kidney (HEK) 293T cells and 5% CO2 for all other cell lines. 
 
2.2.14.1 Thawing cells 
For long-term storage, frozen cell aliquots were stored in liquid nitrogen. 
The cells were removed from liquid nitrogen and rapidly thawed in a 
water bath at 37°C. Once thawed the cells were pelleted by spinning 
them at 1400rpm for 5min after which they were re-suspended in 15ml 
of culture media in a T25 tissue culture flask. The media were changed 
the next day and replaced with fresh pre-warmed media. HEK 293T 
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and HeLa TZM-bl cells were grown and maintained in DMEM 
(Invitrogen®, Life Technologies, Paisley UK). Jurkat cells and ACH-2 cells 
were grown and maintained in RPMI-1640 medium (Invitrogen® Life 
Technologies Ltd, Paisley, UK). The culture media were enriched with 
10% FCS (Invitrogen® Life technologies Ltd, Paisley, UK) for cell lines and 
20% FCS for primary T cells. 100U/ml penicillin and 100µg/ml 
streptomycin (Invitrogen®, Life Technologies, Paisley, UK) were added 
to the media used for growing and maintaining cell lines. 
 
2.2.14.2 Passaging cells 
Adherent cells HEK 293T and HeLa TZM-bl cells were passaged when 
the cells were 90-100% confluent, as judged by inspecting cell cultures 
under a microscope. Under sterile conditions, 10ml of PBS was added 
to the T75-flask containing the cells and then aspirated in order to wash 
away the medium. 4ml of trypsin was added to the cells and left to 
incubate for 5min at 37°C. The flask was tapped several times to ensure 
the detachment of the cells and 6ml of culture medium added to 
dilute the trypsin (Invitrogen® Life Technologies Ltd, Paisley, UK). 
Depending on the desired density, an appropriate volume of the cell 
suspension was transferred into a new T75-flask and topped up with 
fresh medium. Suspension T cell lines (Jurkat and ACH-2 cells) were 
passaged when cultures reached a density of 1×106 cell/ml. This was 
usually every 4-5 days for cultures split to 1:10 (e.g. 3ml aliquot of cell 
suspension re-suspended in 27ml RPMI).  
 
2.2.14.3 Freezing cells 
Freezing media consisted of 60% culture medium, 20% FCS and 20% 
Dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Poole, UK). Cells were 
pelleted by centrifuging at 1400rpm for 5min and re-suspended to a 
density of 1×107cells/ml. The suspension was aliquoted into sterile 
cryovials and placed into a Styrofoam container. The cells were initially 
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frozen overnight at -80°C and subsequently transferred to liquid 
nitrogen for long-term storage. 
 
2.2.15 Isolating PBMCs from buffy coat 
Buffy coat in blood bags was obtained from the national blood service 
(London, UK). The buffy coats from different donors were kept separate 
at all times. The blood was drained under standard sterile tissue culture 
conditions into a T75 flask. A Ficoll-Paque® (Sigma-Aldrich, Poole, UK) 
gradient was used to separate the white blood cells (WBCs) and serum 
from the red blood cells (RBCs). 10ml of Ficoll® was placed in a clean 
50ml falcon tube and 25ml of blood transferred from the T75 flask was 
slowly layered on the Ficoll®. The falcon tubes containing blood 
layered on Ficoll® were centrifuged at 2000rpm for 20min at room 
temperature without brake. After the spin, a transfer pipette was used 
to carefully transfer the white layer containing PBMCs into a new falcon 
tube and topped up with 40ml of PBS. The PBMCs were centrifuged at 
2000rpm for 10min to pellet the cells and the liquid was aspirated off. 
The cells were washed twice more by re-suspending them in 20ml PBS 
and spinning at 1500rpm for 5min at room temperature. After the 
washes, the cells were counted and re-suspended at a density of 
1×106/ml in a T75 flask. PBMCs were maintained in RPMI-1640 medium 
with 20% FCS, 1µg/ml of phytohaemagglutinin (PHA), (Sigma-Aldrich, 
Poole, UK) and 10U/ml of interleukin-2 (IL-2), (NIBSC). PHA was removed 
after 2-3 days and cells were maintained thereafter in RPMI-1640 
medium with 10U/ml of IL-2.  
 
2.2.16 Isolating CD4+ T cells from activated 
PBMCs-Magnetic activated cell sorting 
(MACS®) depletion of non-CD4+ T cells 
CD4+ T cells were sorted from activated PBMCs by negative selection, 
3 days after isolation using the MACS® cell separation technology 
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(Miltenyi, Biotec®, Cologne, Germany) according to manufacturer’s 
instructions of the CD4+ T cell isolation kit (Miltenyi, Biotec, Cologne, 
Germany). Briefly, PBMCs were washed in PBS and re-suspended in 
sterile and filtered MACS buffer (MACS buffer: PBS+0.5% FCS+2mM 
EDTA) - 40µl MACS® buffer/107 cells. 10µl/107 cells of biotin antibody 
cocktail was added to the cells, mixed thoroughly and incubated for 
10min at 4°C. 30µl MACS® buffer and 20µl anti-biotin micro-beads/107 
cells, mixed thoroughly and incubated for 15min at 4°C. Ten times the 
labelling volume of MACS® buffer was then added to the labelled cells 
suspension and centrifuged at 2000rpm for 5min (twice) after which the 
cells were re-suspended in 500µl of MACS buffer in preparation for 
magnetic separation (a maximum of 108 cells per column).Pre-chilled 
magnetic columns were equilibrated with 3ml of MACS buffer. The 
labelled cell suspension was then applied to the separation column 
and the flow-through collected in a cold 15ml falcon tubes. The flow-
through was passed through the column a second time and 6ml of 
MACS buffer run through the column and collected into the same 
falcon tube. The cells were then pelleted and re-suspended at a 
density of 106 cells/ml in RPMI-1640 + 20% FCS (Invitrogen® Life 
Technologies Ltd, Paisley, UK). 
 
2.2.17  Transfection of HEK 293T-cells with full-
length HIV-1 molecular clones 
Full-length HIV-1 was produced by transfecting HEK 293T cells with 
molecular clone DNA.  For transfection in a 6 well plate, 5×105 cells per 
well were plated 18-24h prior to transfection so that the monolayer cell 
density was optimally confluent (95% confluent) at the time of 
transfection. Complete culture medium supplemented with 10% FCS 
and 1% Penicillin/Streptomycin was freshly added to each well 30-
60min before transfection. Fugene®HD (Promega® Ltd, Southampton, 
UK) transfection reagent was used for all transfection reactions. For 
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each well the complex was prepared by adding 9.9µl of Fugene®HD 
to 155µl of 0.020µg/l plasmid DNA solution in Opti-MEM® (Invitrogen®, 
Life Technologies Ltd, Paisley,UK). The complex was mixed by pipetting 
(15 times) then incubated at room temperature for 5-10min. 150µl of 
complex was added in a drop-wise manner to each well of cells and 
incubated at 37°C for 48h. After 48h the virus containing supernatant 
was collected, centrifuged to remove any cell debris carried over and 
aliquoted into cryovials for storage in liquid nitrogen. All transfections 
with full-length HIV-1 DNA and replication competent infectious virus 
were carried out in the containment level 3 facility following standard 
procedures as defined by the University College London (UCL) risk 
assessment guidelines.   
 
2.2.18  Titration of virus stocks in HeLa TZM-bl cells 
To assess the infectivity of the virus stocks, the tissue culture infectious 
dose was estimated using a HeLa TZM-bl based TCID50 assay adapted 
from the Duke University laboratory protocol for the titration of HIV-1 
pseudotyped viruses and the TCID50 values were calculated using the 
method of Reed and Muench (Reed, 1938) and a TCID50 excel macro 
available from: http://www.hiv.lanl.gov/content/nab-reference-
strains/html/TCID501.xls.  A 5-fold dilution series of the virus stock was 
titrated on a white 96-well flat-bottomed tissue culture plate. 100µl of 
DMEM was placed in all wells on the plate. 25µl of neat thawed virus 
was added to the first 4 wells of a dilution series and a 5-fold dilution 
series was done. The 12th column wells were reserved as negative 
control wells. 1×104 HeLa TZM-bl in a volume of 100µl was added to 
each well. The plate was placed in an incubator at 37°C. After 48h, 
100ul of medium was removed and 75µl SteadyGlo® luciferase added 
to lyse the cells for 5min. The plate was read using the SteadyGlo® 
protocol on a GloMax® 96 MicroplateLuminometer (Promega® Ltd, 
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Southampton, UK). The data was exported into Microsoft®Excel to 
calculate the TCID50. 
 
2.2.19  HEK 293T drug susceptibility assay 
An in-house assay designed by Dr. Chris Parry was used to determine 
the drug susceptibility of the drug-resistant mutant viruses compared to 
the wild-type virus (Gupta et al., 2010). HEK293T cells were transfected 
as described above, 16h after transfection the cells were seeded in the 
presence of a serial dilution of Protease Inhibitors. Virus supernatant 
was harvested 24h later and used to infect fresh target HeLa TZM-bl 
cells. For Reverse Transcriptase Inhibitors, the HeLa TZM-bl cells were 
infected in the presence of a serial dilution of the drug being tested. 
Replication was determined by measuring luciferase expression in 
infected target cells at 48h post-infection using SteadyGlo® Luciferase 
Assay system (Promega® Ltd, Southampton, UK) and expressed relative 
to that of a no-drug control. Fifty percent inhibitory concentrations 
(IC50s) were determined using Prism6® software (GraphPad, California, 




Figure 2-1: Drug susceptibility assay. For RTIs the HeLa TZM-bl cells were infected in the presence 
of a serial dilution of the drug. 
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2.2.20  Cell-to-cell and cell-free infection assays 
2.2.20.1  Infection of donor cells 
Jurkat T cells and Primary CD4+ T cells were used as donor cells in the 
experiments described. The cells were infected by adding 0.5-1 MOI of 
thawed virus stock to 3×106 cells re-suspended in a total volume of 
500µl of culture medium in 15ml falcon tubes. The cells were 
spinoculated by centrifuging the tubes at 2000×g for 2h. After 
spinoculation the cells were re-suspended in 10ml of culture medium in 
a T25 flask and incubated at 37°C. 
 
2.2.20.2 Gag p24 staining and FACS analysis of infected 
cells 
Infected Jurkat cells were fixed with 3% paraformaldehyde (PFA) 
(Sigma-Aldrich Ltd, Poole, UK). The fixed cells were permeabilised by 
incubating for 30min with 1X BD™ Perm Buffer (Beckman Dickson 
Biosciences, Oxford, UK) and stained with anti-HIV-1 p24 monoclonal 
antibody conjugated to fluorescein isothiocyanate (HIV-1 p24 (24-4) 
FITC, monoclonal antibody). Ten thousand events were collected using 
a FACS Calibur® flow cytometer with Cellquest® software (Beckman 
Dickinson, Plymouth, UK). Data were analysed using FlowJo® software 
(with appropriate gating) to determine the percentage of Gag-
positive cells. 
 
2.2.20.3  RT-PCR based infection assays 
To measure cell-to-cell transfer from an infected donor cell to an 
uninfected target cell, RT-PCR was used to detect de novo pol-
transcripts as described in previous studies using this assay, (Jolly et al., 
2007) with modifications to accommodate for the use of inhibitors 
(neutralising antibody, RTI and PIs). Donor cells were infected with 
either HIV-1NL4.3 (wild-type) or drug-resistant mutant virus. Three days 
after infection, the donor cells were stained for Gag and analysed by 
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flow cytometry. Only donor-cell cultures that were >80% infected were 
used for experiments. This minimised the background from spreading 
infection between donor cells after target cells were added to the 
culture.  The virus input for infecting donor cells was standardised using 
the multiplicity of infection (MOI) for the different viruses tested (i.e. 
wild-type and drug-resistant mutants). 72h after infection by 
spinoculation, cultures infected with either wild type or drug-resistant 
viruses were similarly 85-90% infected. The donor cells were washed 
three times with 10ml of culture medium to remove all cell-free virus 
particles. After the washes the cells were counted, 2x105 infected 
Jurkat cells (donors) per well on a 96 well plate were mixed with 8x105 
1G5 cells/well in the presence of the maximum plasma concentration 
(Cmax) of the inhibitor for time-course experiments or in the presence of 
a serial dilution of the inhibitor for IC50 determination. For time-course 
experiments, the co-cultures were incubated for 0h, 1h, 3h, 6h, 12h or 
24h at 37°C before the cells for each time-point were pelleted and 
stored at -80°C until DNA extraction. For experiments to calculate the 
IC50 of the inhibitor, co-cultures in the presence of a serial dilution of 
the inhibitor under study were incubated for 24h before DNA extraction 
and RT-PCR. Total DNA extraction was performed using the DNeasy® 
Blood and Tissue kit according to manufacturer’s instructions 
(QIAGEN®, Venlo, Netherlands) as previously described. Extracted DNA 
was stored at -20°C if RT-PCR was not performed on the same day.  
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Figure 2-2: qPCR based cell-to-cell assay 
 
For cell-free experiments, pre-washed 2x105 donor cells/well were 
allowed to produce virus over 24h.  100µl of the virus supernatant was 
used to infect 1x106 target cells/ well by spinoculation at 2000×g for 2h, 
in the presence of the maximum plasma concentration of the inhibitor 
under investigation for time-course experiments or in the presence of a 
serial dilution of the inhibitor for IC50 determination.  Following infection 
by spinoculation, the target cells were incubated for 24h after which 
they were pelleted for total DNA extraction and subsequent RT-PCR. 
 
 
Figure 2-3: Cell-free qPCR based assay 
2.2.21  RT-PCR  
RT-PCR was used for the detection of HIV-1 pol transcripts using primers 
and probes specific for HIV-1 pol DNA and the housekeeping gene 
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Albumin (Jolly et al., 2007) and for the detection of 2LTR circles using 
primers and probes specific for HIV-1 2LTR circles (Apolonia et al., 2007). 
All RT-PCRs were carried out using a TaqMan® probe based assay (Jolly 
et al., 2007, Apolonia et al., 2007) with custom made probes and 
primers (Eurogenetec® Seraing, Belgium). Reactions were set-up in 
triplicate with 2× qPCRMastermix (Eurogentec®, Seraing, Belgium) and 
run on the Applied Biosystems® 7500 RT-PCR machine (Life 
Technologies Ltd, Paisley, UK).  
 
2.2.21.1 HIV-1 pol RT-PCR   
HXB2 and Albumin master mixes were prepared separately. One 
master mix prepared with HXB2 pol primers and the other prepared 
with Albumin primers (see Table 2-1 for primer names and sequences)  
 
Master mix for 110 wells: 
Sterile deionised water: 528µl 
Eurogentec® 2x master mix: 657µl 
Probe (50µM): 2.75µl 
Forward primer (100µM): 4.2µl 
Reverse primer (100µM): 4.2µl 
 
DNA samples were diluted before use 1/10 with sterile deionised water 
(so that the unknowns fell within the range of the standards). The 
standards were prepared in duplicate. DNA extracted from ACH-2 cells 
was used as the standard. In a 96-well PCR plate 2.5µl of either HxB2 or 
Albumin master mix (without DNA) was pipetted into each well.  2.5ul 
of each standard in duplicate from the standard dilution plate was 
transferred to the qPCR plate. A no template control was included in 
duplicate in the final two wells. 2.5µl of sample was transferred into the 
qPCR plate. Standards were run in duplicate and samples in triplicate. 
The plate was sealed and centrifuged for 1min. The qPCR plate was run 
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on the Applied Biosystems® 7500 real-time PCR system (Life 
Technologies Ltd, Paisley, UK). 
 
2.2.21.2 HIV-1 2LTR circles RT-PCR 
Mastermix for 100 wells 
- Eurogentec® 2x Mastermix: 625µl 
- Forward Primer (100µM): 3.75µl 
- Reverse Primer (100µM): 3.75µl 
- Probe (50µM): 2.5µl 
- Sterile water: 365µl 
In a 96-well PCR plate 20µl of the master mix was pipetted into each 
well. 5µl DNA template was added to each well. Standards were run in 
duplicate and samples in triplicate. The plate was sealed and 
centrifuged for 1min, then run on the Applied Biosystems® 7500 real-
time PCR system. 
 
RT-PCR program: 
 The RT-PCRs were run on the Applied Biosystems® 7500 using the 
program detailed below: 
50°C for 2min 
95°C for 10min 
90°C for 15s 
60°C for 1min 
Steps 3-4 repeated 40 times 
50°C Hold 
 
2.2.22  Transwell based infection assays 
To assess the impact of the inhibitor Raltegravir on cell-to-cell and cell-
free spread, 2x105/well pre-washed infected donor cells were cultured 
directly together with 8x105/well target cells on a 24-well plate in the 
presence or absence of the Cmax of Raltegravir. Co-cultured cells were 
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pelleted and stored at -80°C for DNA extraction and 2LTR qPCR and 
the supernatants stored for p24 ELISA. For cell-free experiments donor 
cells were separated from target cells by a 3µM transwells to allow for 
full diffusion of virus but not migration of the cells. 2x105/well infected 
donor cells were suspended in 100µl of culture medium and placed in 
the top well and 8x105/well uninfected target cells were suspended in 
500µl and placed in the bottom well. Supernatant from untreated and 
drug treated targets were collected at 4, 7 and 10 days of culture. The 
target cells were pelleted and frozen down for subsequent DNA 
extraction and 2 LTR qPCR and the supernatants were stored at -80°C 
for measurement of p24 by ELISA. 
 
2.2.23 p24 ELISA 
p24 antigen detection was done using a twin site sandwich ELISA. 100-
150µl of sample was inactivated by adding 5µl of 21% Empigen®BB 
detergent (Sigma-Aldrich Ltd, Poole, UK) to obtain a final 
concentration of 1%, and incubated for 30min at 56°C. Briefly, in this 
assay, the p24 antigen is captured from a detergent lysate of virions 
onto a polyclonal antibody adsorbed onto a solid phase. Bound p24 is 
detected with a biotinylated conjugated anti-p24 monoclonal 
antibody. In detail, a 96-well clear flat bottomed ELISA plate (Nunc®) 
was coated with 100µl/well of 10µg/ml capture antibody D7320, Aalto® 
overnight at room temperature. On the 2nd day the plates were 
washed 3x with wash buffer using a TECAN® plate washer (Tecan, 
Reading, UK). 200µl/well blocking buffer was added to the wells for 
30min at room temperature. The wells were washed in 200µl of wash 
buffer 3x before transferring 100µl of diluted supernatant. A standard 
was prepared using a 2-fold serial dilution starting at 200ng/µl and 100µl 
transferred to the plate. Samples and standards were diluted in TBS/E/S. 
The plate was covered and incubated for 2h at 37°C. After this 
incubation the plate was washed 6x with 200µl/ well wash buffer. 100µl/ 
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well of 1/1000 diluted stock biotynylated α-p24 antibody in TMT/SS was 
added to the wells and incubated at room temperature for 2h. The 
plate was washed 6x with 200µl wash buffer per well. 100µl/ml 
Streptavidin–Horse Radish Peroxidase (Serotec® Bio-Rad Laboratories, 
California, USA) in TMT/SS was added to the wells and the plate 
incubated for 1hour. The plate was washed 6x as described above 
and 100µl/well of TetraMethylBenzidine (TMB) (Sigma-Aldrich.Poole, UK) 
added to the plate. The reaction was stopped with 100µl/well of 0.5M 
Sulphuric acid (H2SO4). The plate was read on a multiscan FC 
absorbance plate reader (Thermo Scientific, Massachusetts, USA) at 
450nm and the data were analysed using Prism® Software (GraphPad, 
California, USA). 
 
2.2.24  Luciferase based infection assays 
For cell-to-cell infection: 
The experiment was set-up on a 96-well plate. 2x105 donor cells/well 
were pre-incubated with a serial dilution of the inhibitor (PIs and NAb) 
under investigation (4h and 24h pre-incubation times were tested), in 
duplicate. No drug control wells were included on each plate. For 
experiments in which RTIs were used as inhibitors, donor and target cells 
were mixed in the presence of drug at the same time without prior pre-
incubation of donor cells with the drug. 8x105/well of 1G5/LTR-luciferase 
cells (target cells) were added to the donor cells and mixed 
thoroughly. When donor cells were pre-incubated with an inhibitor for 
24h, the cells were centrifuged down, supernatant discarded and re-
suspended in fresh inhibitor prior to the addition of target cells. This was 
to ensure that there was fresh non-degraded drug throughout the 48h 
of the assay. The co-culture (donor cells + target cells) was incubated 
for 24h to limit replication to a single cycle and minimise any cell-free 
infection.  The infection of target cells was quantified by a SteadyGlo® 
(Promega, Southampton, UK) luciferase system. The cells were 
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centrifuged at 2000rpm for 3min and the supernatant removed. 75µl of 
SteadyGlo® luciferase (Promega, Southampton, UK) was added to 
each well to lyse the cells and the luciferase activity was measured 
using a Glomax® Luminometer (Promega, Southampton, UK). It is worth 
noting that for experiments with PIs and RTIs the highest concentration 
of drug tested was the maximum plasma concentration. In order to 
plot dose-response curves and calculate IC50s for the inhibitors tested, 
the average luciferase signal in the target cells in the absence of drug 
was considered to represent 100% infection. The luciferase signal in 
target cells for each drug concentration was expressed as a fraction of 
the “no-drug” positive controls and plotted against the drug 
concentrations on a logarithmic scale. 
 
For cell-free infection: 
2x105 cells/well of pre-washed infected donor cells were incubated in 
the presence of a serial dilution of the PI drug on a 96 well plate for 24h. 
After 24h, the cells were pelleted and 100µl of the virus supernatant 
was used to infect 8x105/ml 1G5 cells (target cells) per well on a 96 well 
plate by spinoculating for 2h at 1200g.  The infected target cells were 
incubated for 24h after which they were lysed with SteadyGlo® 
luciferase (Promega, Southampton, UK) and luciferase activity 
measured as described above. 
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Figure 2-4:  Luciferase based cell-to-cell assay 
2.2.25  Drug combination studies 
The RT-PCR based infection assays described above were used for the 
drug combination studies. Antiretroviral agents from the RTI and PI 
classes were tested in clinically relevant combinations. The drugs were 
combined in a ratio based on the IC50s of the individual drugs for cell-
free infection. For example if the IC50 of drug A=50nM and the IC50 of 
drug B=100nM, to test these drugs in combination, A+B were combined 
in a ratio of 1:2 (Irene V. Bijnsdorp, 2011).  Cell-to-cell and cell-free 
infection was assessed in the presence of a serial dilution of the 
combination and infection determined by qPCR as described above.  
The percentage inhibition at each concentration was determined and 
expressed as a fraction of the “no-drug” positive control. These values 
were used to determine the combination indices for the drug 
combination using the drug synergy analysis software Compusyn® 
(Paramus, New Jersey, USA). 
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Figure 2-5: Scheme of drug combination experiments 
 
2.2.26  SDS-PAGE and Western blotting 
Cell-free virus supernatant collected from HIV-1 infected cell cultures 
treated with PIs was purified through a 25% sucrose gradient. 400µl of 
virus supernatant was carefully layered on 800µl of 25% sucrose solution 
in a 1.5ml micro centrifuge tube, followed by centrifugation at 10000×g 
for 90min at a temperature of 4°C. The sucrose was carefully poured off 
at the end of the centrifugation and the pelleted virus re-suspended in 
40µl of PBS and stored at -80°C for SDS-PAGE. Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate 
the purified virus prior to detection of virus proteins by western blotting. 
20µl of purified virus was loaded on the gel (see materials for 
composition of gel) along with 10µl of pre-stained protein marker 
(Invtrogen® Life Technologies Ltd, Paisley, UK) and proteins were 
separated by electrophoresis in 1x running buffer at 120V for 2h. 
Proteins were transferred unto a nitrocellulose membrane 
(Amersham®, Bioscience, Uppsala, Sweden) by electrophoresis at 4°C 
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overnight (18h) in transfer buffer. The membranes were blocked for 2h 
at in blocking buffer at room temperature and incubated for 1h on a 
rocker with the primary antibody (HIV-1 Gag antibody from CFAR, 
NIBSC), diluted in blocking buffer. Membranes were then washed 4 
times for 15min in wash buffer and incubated with HRP coupled 
secondary antibody (goat anti-rabbit HRP, from DAKO), diluted in 
blocking buffer for 30min, on a rocker at room temperature. The 
membranes were washed as above and proteins were visualised by 
enhanced chemiluminescence (ECL) (Amersham®, Uppsala, Sweden). 
 
2.2.27 Statistical methods 
A two-tailed student t-test was performed to compare the mean IC50s 
for cell-free and cell-to-cell spread for PIs and RTIs. For comparisons of 
data with more than two groups a two-way ANOVA with Bonferroni 
post-test for multiple comparisons was used. All statistical analysis was 
done using GraphPad Prism® Software (California, USA.
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3 Assessing two assay systems for 
studying the impact of drug inhibitors 
on cell-to-cell spread of HIV-1 
 
3.1 Introduction 
In studying the effects of antiretroviral drugs on cell-to-cell spread of 
HIV-1, in vitro co-culture systems using direct and indirect markers of 
infection have been used in the published literature, with conflicting 
results (Sigal et al., 2011, Permanyer et al., 2012b). Sigal et al. were the 
first group to report that HIV-1 cell-to-cell infection may be less 
susceptible to inhibition by RTIs than cell-free infection. In their 
experiments they used in vitro co-culture systems with surrogate 
markers of HIV-1 infection (p24 antigen staining and Tat-driven reporter 
gene expression) to test their hypothesis. Following the publication of 
these observations, Pemanyer et al. challenged the results by using in 
vitro co-culture systems with a direct marker of HIV-1 infection (qPCR 
detection of HIV-1 DNA transcripts) and obtained a different result 
finding that RTIs were effective inhibitors of cell-to-cell HIV-1 infection. 
They proposed that the use of surrogate markers for measuring target 
cell infection in co-culture assays, as used by Sigal et al., may be 
misleading due to the possibility of detecting these surrogate markers in 
the absence of true HIV-1 infection in target cells. These seemingly 
conflicting results led to some controversy with regards to the true 
impact of antiretroviral agents on HIV-1 cell-to-cell infection.  
 
The primary objective of the studies presented in this thesis is to define 
the role of antiretroviral agents on HIV-1 cell-to-cell spread. It was 
therefore desirable to re-evaluate the co-culture assays available in 
our laboratory that use both surrogate and direct markers of HIV-1 
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infection, in order to establish the best method to use in answering my 
research questions.  In this chapter, two co-culture assay systems, one 
using a surrogate marker of HIV-1 infection (Tat-driven reporter gene 
expression) and another using a direct marker of HIV-1 infection (qPCR-
based detection of HIV-1 pol DNA copies), are used to study cell-to-cell 
and cell free spread of HIV-1 in the presence and in the absence of 
drug inhibitors. The results obtained suggest that assays with an indirect 
infection read-out such as reporter gene expression, are high 
throughput and useful for screening some inhibitors (attachment and 
entry inhibitors). However HIV-1 Tat protein derived from infected donor 
cells in co-culture may lead to reporter gene activation in the absence 
of true infection in target cells, even in the presence of inhibitors (PIs 
and RTIs). These findings provide the rationale for using a direct 
measure of HIV-1 infection (qPCR-based detection of HIV-1 pol DNA 
copies), to answer the research questions posed in this thesis. In 
addition to comparing the assay systems for testing the effect of drug 
inhibitors on HIV-1 cell-to-cell spread, the drug-resistant and wild type 
viruses used through out this thesis are also characterised in this 
chapter. The resistant phenotype of the viruses is confirmed in a drug 
susceptibility assay and their ability to spread efficiently via a cell-to-
cell mechanism verified. 
 
3.1.1  Specific Objectives 
 
- To compare a reporter gene based assay and a qPCR-based assay 
for studying the effects of drug inhibitors on HIV-1 cell-to-cell spread. 
- To construct PI and RTI drug-resistant viruses and validate their 
phenotypes in a drug susceptibility assay. 
 - To assess cell-to-cell spread of PI and RTI drug-resistant viruses 
compared to wild-type virus. 
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3.2  Results 
3.2.1 Comparing direct and surrogate markers of 
infection for studying HIV-1 cell-to-cell spread 
Due to conflicting reports on the impact of antiretroviral drugs on HIV-1 
cell-to-cell spread, two assay systems with different output measures 
were compared for use in testing the effect of inhibitors on HIV-1 cell-
to-cell spread. This was in order to determine the best method to use 
for the subsequent studies presented in this thesis and to clear the 
controversy stemming from previous studies by other groups. The qPCR-
based assay directly quantifies infection of target cells by measuring 
HIV-1 pol DNA while the luciferase assay uses a surrogate marker of 
infection measuring Tat-driven reporter gene expression in target cells. 
Both assays have been used and validated in other studies of HIV-1 
cell-to-cell infection (Jolly et al., 2007, Jolly et al., 2011, Martin et al., 
2010). HIV-1 cell-to-cell spread was measured in the presence of drug 
inhibitors (PIs and RTIs) using these two assay systems.  
 
A Jurkat CD4/CXCR4+ T cell line was used as donor cells in the two 
assays. Donor cells were infected with an MOI = 0.3-0.5 of CXCR4 tropic 
NL4.3 wild-type virus (HIV-1WT), by spinoculating for 2h at 2000g. 72 hours 
after infection, an aliquot of the donor cell culture was fixed and 
stained for Gag and analysed by flow cytometry. Donor cell cultures 
were typically >80-90% infected by 72h. The use of a donor cell 
population in which >80% of cells are infected minimises background 
spreading infection between donor cells. A derivative of the Jurkat cell 
line (1G5) was used as target cells in both assays. 1G5 cells contain a 
stably integrated HIV-LTR-luciferase construct in which expression of the 
reporter gene is driven by HIV-Tat. The infected donor cells were 
washed three times with culture medium to remove as much cell-free 
virus as possible and co-cultured with the target cells in a ratio of 1:4 
(2×105 donor cells mixed with 8×105 target cells), in the presence of the 
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inhibitor. When PIs were tested, the donor cells were pre-incubated 
with the drug for 24h before co-culturing with target cells. With RTIs, the 
drugs were added at the time of mixing donor cells with target cells. 
The co-cultures were incubated for 24h for experiments with a single 
time-point and for variable durations: 1h, 3h, 6h, 12h and 24h for time-
course experiments.   
 
In the luciferase assay cell-to-cell infection was quantified by lysing the 
cells with SteadyGlo® luciferase and measuring luciferase expression 
on a GLOMAX® Luminometer. In the qPCR-based assay, pre-treated 
donor cells were co-cultured with target cells in the presence of the 
inhibitor as described above. Cell-to-cell spread of HIV-1 was 
measured by qPCR, to quantify de novo HIV-1 DNA pol copies arising 
from reverse transcription in the newly infected T cell population. The 
data were expressed as fold increase in HIV-1 pol DNA relative to the 
housekeeping gene Albumin. In this assay a synchronous population of 
HIV-1 infected donor cells, allows for reliable measurement of virus 
infection in target cells mediated by cell-to-cell dissemination with little 
or no contribution from the less efficient cell-free mode of infection  
(Jolly et al., 2007) (see methods for detailed description of assays).  
 
The effect of inhibitors on cell-free infections was also tested for 
comparison. For cell-free assays, pre-washed infected donor cells were 
left to produce virus in the presence of PIs over 24h. The virus 
supernatant was collected and used to infect target cells by 
spinoculating for 2h. Infection of the target cell was measured by 
luciferase gene expression and by qPCR detection of HIV-1 pol DNA as 
described above. 
 
As expected HIV-1 cell-free infection was potently blocked by LPV over 
a range of concentrations in both the luciferase assay system 
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(Figure3.1A) and the qPCR assay system (Figure 3.1B)). In contrast LPV 
appeared to be completely ineffective against cell-to-cell spread of 
HIV-1 over a wide range of concentrations when tested using the 
luciferase based assay (Figure 3.1C). RTIs also failed to inhibit cell-to-cell 
infection in this assay system (Figure 3.1D). To confirm these results the 
effect of LPV on HIV-1 cell-to-cell spread was tested in the qPCR-based 
assay system, which uses a direct output measure of infection, HIV-1 
pol DNA copies as described earlier. Co-cultures where either left 
untreated or treated with Cmax LPV (12µM), and HIV-1 pol DNA copies 
detected by qPCR at different time-points (1h, 3h, 6h, and 12h). 
Surprisingly LPV potently blocked HIV-1 cell-to-cell infection in the 
qPCR-based assay system, indicating that these drugs were in fact 
effective against this mode of virus spread. This was evidenced by the 
absence of HIV-1 pol DNA transcripts in co-cultures treated with Cmax 
LPV (12µM) compared to a ready detection and a time dependent 
increase in HIV-1 pol DNA transcripts in untreated co-cultures (Figure 
3.1E). These results seem paradoxical with LPV blocking HIV-1 cell-to-
cell infection in one assay system and being completely ineffective in 
another assay system and reflect the conflicting results reported by 
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Figure 3-1: Comparing a reporter gene assay system and a qPCR-based assay system for 
studying the effect of drug inhibitors on HIV-1 cell-to-cell spread- LPV potently blocks cell-free 
spread of HIV-1 in (A) a Luciferase–based assay system and in (B) a qPCR-based assay system. 
Infected donor cells were allowed to produce virus in the presence of LPV, and this virus 
supernatant was used to infect target cells by spinoculation. Following 24h incubation, 
infection of target cells was quantified either by measuring luciferase activity (A) or qPCR 
detection of pol DNA (B). One representative experiment is shown and error bars represent the 
standard deviation (SD) of the mean of triplicates. (C) Protease inhibitors (LPV) (D) and Reverse 
Transcriptase Inhibitors appear ineffective against cell-to-cell spread of HIV-1 in a luciferase 
assay system. Infected donor cells treated with a serial dilution of PI or RTI were co-cultured with 
target cells and cell-to-cell infection measured by quantifying luciferase expression in target 
cells. A representative experiment of two independent repeats is shown. (E) LPV potently 
blocks cell-to-cell spread of HIV-1 in a qPCR based assay system. Donor cells pre-treated with 
LPV or untreated were co-cultured with target cells and HIV-1 pol DNA detected by qPCR at 
several time-points post mixing. A representative experiment of two independent repeats is 
shown. Error bars represent the SD of the mean. 
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To explore this further, I decided to test the effect of a Llama derived 
HIV-1 neutralising VHH J3 on cell-to-cell infection in both assay systems. 
J3 binds to the viral envelope and prevents its interaction with the CD4 
receptor. By so doing J3 blocks the key interaction required for the 
formation of the virological synapse and hence should block HIV-1 cell-
to-cell spread (McCoy et al., 2012, McCoy, 2014). Also this mechanism 
of inhibition differs from that of PIs and RTIs, which do not disrupt 
formation of the VS but rather affect later steps in the virus replication 
cycle notably entry and post entry steps for PIs (Craig et al., 1991, 
Wensing et al., 2010, Rabi et al., 2013) and reverse transcription for RTIs 
(Cihlar and Ray, 2010, de Bethune, 2010). For the experiments with J3, 
the donor cells were incubated with VHH for 1h before co-culturing 
with target cells. Surprisingly, in contrast to the PIs and the RTIs, VHH J3 
potently blocked cell-to-cell infection across a range of concentrations 
in the luciferase assay system (Figure 2A) and qPCR assay system 
(Figure 2B and C). This suggests that in the luciferase-based assay Tat-
driven reporter gene expression that is observed in PI and RTI-treated 
co-cultures may be occurring in the absence of true cell-to-cell 
infection of these cells.  
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Figure 3-2: A Llama derived VHH J3 potently inhibits cell-to-cell spread of HIV-1 in a Luciferase 
based assay system and a qPCR-based assay system. Infected donor cells were co-cultured 
with target cells in the presence of the VHH J3. Following a 24h incubation, cell-to-cell infection 
was quantified by measuring luciferase expression and also by qPCR detection of HIV-1 pol 
DNA copies (A) J3 potently blocks cell-to-cell HIV-1 spread across a range of concentrations. A 
representative experiment is shown. Dotted line represents actual data points while bold line 
represents the non-linear regression curve fit, (B) and (C) J3 potently inhibits cell-to-cell spread 
of HIV-1 across a range of concentrations in the qPCR-based assay system. In (B) co-cultures 
were done in the presence of a titration of J3 VHH and in (C) co-cultures where treated with 
8µg/ml of J3 and cell-to-cell infection measured by qPCR detection of HIV-1 pol transcripts at 
different time-points and compared to untreated co-cultures. A representative experiment is 
shown. Error bars represent the standard deviation of the mean of triplicates. Two-way ANOVA 
with Bonferonni post-test was applied for comparisons. ****p<0.0001, ***p<0.001, ns=not 
significant. UT= untreated.  
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Based on these results, I hypothesised that HIV-1 Tat protein secreted 
from infected donor cells into the co-culture could drive reporter gene 
expression in target cells.  To test this hypothesis, donor cells were co-
cultured with target cells in the presence of a Cmax of LPV and a serial 
dilution of an anti-HIV-1 Tat specific monoclonal antibody. This anti-Tat 
antibody specifically binds HIV-1 Tat protein, and should bind to free 
Tat protein secreted by the donor cells into the co-culture medium. I 
anticipated that if free Tat secreted by donor cells was causing 
reporter gene expression in the target cells in the absence of infection, 
then the presence of an anti-Tat antibody in the culture medium would 
reduce free Tat and hence the luciferase signal. After 24h incubation 
the cells were lysed and luciferase expression measured as previously 
described. There was a significant reduction (but not complete 
suppression) of luciferase expression in the co-cultures treated with the 
highest concentration (50µg/ml) of the anti-Tat antibody possible in our 
assay (Figure 3.3). Treating co-cultures with either LPV, the antibody 
diluent (PBS) or an irrelevant antibody isotype control, had no effect on 
the luciferase signal measured (Figure 3.3). 
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Figure 3-3:An Anti-tat antibody reduces the luciferase signal in co-cultures treated with Cmax 
LPV in the Luciferase assay system. Co-cultures of donor cells and target cells were treated with 
Cmax of LPV (12µM) and a titration of an HIV-1 anti-Tat antibody. In the presence of 50µg/ml of 
anti-Tat antibody, the luciferase signal detected in the co-cultures was significantly reduced.  
In co-cultures treated with Cmax LPV, PBS or a titration of IgG Isotype control + LPV Cmax or left 
untreated the levels of luciferase activity detected in the co-cultures was not affected. A 
representative experiment is shown. Error bars represent the SD of the mean of duplicates. 
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3.2.2 Drug susceptibility of wild type and drug-
resistant viruses 
PI and RTI drug-resistant viruses are used for the experiments presented 
in the subsequent chapters of my thesis. These viruses were generated 
by site-directed mutagenesis of wild type NL4.3 HIV-1 gag and pol 
(protease and reverse transcriptase) (Figure3.4). After mutagenesis, the 
mutated fragments were sequenced to confirm that the desired 
mutation had been introduced (Figure 3.4). Three drug-resistant viruses 
were designed; the PI drug-resistant virus HIVDM has the V82A mutation 
in protease and the A431V mutation in gag, the NRTI resistant virus HIV-
1M184V that has the M184V mutation in reverse transcriptase and the 
NNRTI drug-resistant virus HIV-1K103N that has the K103N mutation in 
reverse transcriptase.  
 
Figure 3-4 Schematic of PI and RTI mutants showing point mutations introduced in Gag and Pol 
by site-directed mutagenesis. 
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Figure 3-5 Sequence alignments showing resistance mutations introduced by site-directed 
mutagenesis (SDM) compared to wild-type NL4.3 virus.  After SDM, the sequences of the 
mutated DNA fragments were aligned and compared to wild-type sequences to check for the 
presence of the desired mutation. All sequences were aligned using Sequencher®. The 
alignments show the RT drug-resistant mutants HIV-1M184V, and HIV-1K103N and the PI resistant 
mutant HIV-1DM. 
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The resistant phenotypes of these viruses compared to wild-type virus 
were verified in a drug susceptibility assay (Gupta et al., 2010) prior to 
testing these viruses in cell-to-cell infection assays. Briefly HEK293T were 
transfected with virus DNA and allowed to produce virus in the 
presence of a serial dilution of drug (PIs). The virus supernatant was 
harvested after 48 hours and used to infect HeLa TZM-bl cells. For 
susceptibility to RTIs the virus produced by transfection of HEK293T cells 
was used to infect HeLa TZM-bl cells in the presence of a serial dilution 
of the RTI drug. The infected HeLa TZM-bl were incubated for 48h then 
lysed with SteadyGlo® luciferase and luciferase activity measured on a 
GLOMAX® luminometer (a detailed description of the drug 
susceptibility assay is provided in the methods section).  
 
The PI drug-resistant virus HIV-1DM with a V82A mutation in protease and 
an A431V mutation in gag was 8.4 fold less susceptible to inhibition by 
LPV than HIV-1WT (Figure 3.6A and Table 3.1) but remained susceptible 
to DRV as expected (Figure 3.6B and Table 3.1). The NRTI drug-resistant 
mutant with an M184V mutation in reverse transcriptase (HIV-1M184V) 
remained susceptible to AZT as expected (Figure 3.6C and Table 3.1) 
and was 120 fold more resistant to 3TC compared to HIV-1WT (Figure 
3.6D and Table 3.1). The NNRTI drug-resistant mutant with a K103N 
mutation in reverse transcriptase (HIV-1K103N) was 28-fold less 
susceptible to inhibition by NVP (Figure 3.6E and Table 3.1) and 650-fold 
less susceptible to inhibition by EFV as expected (Figure 3.6F and Table 
3.1). 
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Figure 3-6: Drug susceptibility of drug-resistant viruses compared to wild-type virus: The drug 
susceptibility of the drug-resistant viruses was tested in a cell-free based HeLa TZM-bl drug 
susceptibility assay. The data were used to plot dose-response curves for the determination of 
IC50. The phenotypes of the viruses was confirmed in this assay and compared to wild-type 
virus  (A) HIV-1DM was 8.4 fold more resistant to LPV than HIV-1WT but was (B) equally susceptible 
to DRV as HIV-1WT. (C) HIV-1M184V was as expected susceptible to AZT but (D) 120 fold more 
resistant to 3TC than HIV-1WT. (E) HIV-1K103N was 28 fold more resistant to NVP than HIV-1WT, and 
was (F) 650 fold more resistant to EFV that HIV-1WT. The dotted lines represent actual data points 
while the bold lines represent the non-linear regression curve fit of the data in Prism® GraphPad 
software. The error bars represent the standard deviation of the mean and a representative 
experiment of two independent repeats is shown. 
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Table 3-1: Summary Table of IC50s of drug-resistant viruses compared to wild-type virus 
                           
             Drugs 
          
              IC50 (nM) 
 
   Fold-change in IC50 
      
       (p-value) 
PIs HIV-1WT HIV-1DM 
Lopinavir (LPV)         0.85     6.92                8.4      < 0.001 
Darunavir (DRV)         3.0     2.8                0.9        0.34 
NRTIs HIV-1WT HIV-1M184V   
Lamivudine (3TC)       84.6    10113              119.5      < 0.0001 
Zidovudine (AZT)       41.9     29.4                0.7         0.12 
NNRTIs HIV-1WT HIV-1K103N   
Nevirapine (NVP)      92.4     2605               28.2       < 0.0001 
EfavirenzEFV)        0.3    194.6               649      <  0.0001 
 
The IC50s were obtained from dose-response curves plotted using the drug susceptibility data.  
The IC50s of drug-resistant viruses were compared to the IC50 of wild-type virus using a paired 
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3.2.3 Wild-type and drug-resistant HIV-1 viruses 
spread efficiently from cell-to-cell 
After verifying and confirming the phenotype of the drug-resistant and 
wild type viruses, the qPCR assay described previously was used to 
assess the ability of these viruses to spread effectively by a cell-to-cell 
mechanism compared to a cell-free mechanism. Donor cells were 
infected with a standardised input of the virus being tested as 
previously described (MOI= 0.3-0.5).  The infected pre-washed donor 
cells were then co-cultured with uninfected target cells and incubated 
for 24h. Infection was quantified following incubation by qPCR 
detection of HIV-1 pol DNA. 
 
For HIV-1WT, cell-to-cell spread was 6 fold more efficient than its cell-free 
spread both using the luciferase based assay system (Figure 3.7A) and 
the qPCR-based assay system (Figure 3.7B). The same differences were 
observed with the drug-resistant viruses tested; cell-to-cell spread of 
HIV-1DM, HIV-1K103N and HIV-1M184V was 4-8 fold more efficient than their 
spread by a cell-free mechanism (Figure 3.7 C, D and E). Directly 
comparing cell-to-cell spread of the drug-resistant viruses to that of 
HIV-1WT showed that these viruses spread with a similar efficiency 
although subtle differences were noted for HIV-1M184V and HIV-1K103N, 
which were statistically more efficient spreading by a cell-to-cell 
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Figure 3-7: Comparing cell-to-cell spread vs. cell-free spread of wild type and drug-resistant 
HIV-1 viruses.  Cell-to-cell spread of HIV-1WT was orders of magnitude more efficient than cell-
free spread of this virus both in a luciferase assay system (A) and in the qPCR-based assay 
system (B). Cell-to-cell spread of the PI and RTI resistant viruses HIV-1DM (C), HIV-1K103N (D) and 
(E) HIV-1M184V was orders of magnitude more efficient than cell-free spread of these viruses. (F) 
cell-to-cell spread of the drug-resistant viruses was broadly similar in efficiency compared to 
cell-to-cell spread of wild-type virus with  cell-to-cell spread of HIV-1K103N and HIV-1M184V being 
statistically more efficient when compared to cell-to-cell spread of HIV-1WT. A representative 
experiment of two independent repeats is shown. Error bars represent the standard deviation 
of the mean. Statistical comparison were done using a paired student t-est. **** p<0.0001, *** 
p<0.001, **p<0.01, ns= not significant 
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3.3  Discussion 
In this chapter, I compare two assay systems for studying the impact of 
drug inhibitors on HIV-1 cell-to-cell infection; a reporter gene assay 
using luciferase expression as a surrogate marker for HIV-1 infection 
and a qPCR based assay directly quantifying HIV-1 infection by 
detection of HIV-1 pol DNA. The aim of this comparison is to address 
existing controversy in the field brought about by conflicting results 
reported by two independent groups (Permanyer et al., 2012b, Sigal et 
al., 2011) and also, to determine the best and most accurate assay 
system to use in subsequent experiments presented in this thesis. Two 
groups have studied the effects of RTIs on cell-to-cell spread of HIV-1 
using direct and indirect methods to measure target cell infection and 
come to different conclusions on the effects of RTIs on this mode of 
virus spread. In the present study, my results show that in a luciferase 
expression assay, Tat-driven reporter gene expression in target cells can 
occur in the absence of true infection. Direct measures of infection 
such as qPCR detection of HIV-1 DNA transcripts are less ambiguous 
and thus preferable when assessing the effects of inhibitors on this 
mode of virus spread. 
 
 Tat-driven expression of reporter genes can occur in 
the absence of HIV-1 infection 
The HIV-1 tat gene is an important regulatory gene in the HIV-1 
genome. It encodes for the viral protein Tat. Tat is a potent 
transactivator protein, which greatly enhances the expression of virus 
genes through its interaction with the HIV-1 promoter regions contained 
within the HIV-1-LTR at the 5’ end of the integrated provirus (detailed in 
the background). This property of Tat has been exploited to produce 
cell-lines containing stably integrated reporter genes under the control 
of the HIV-1-LTR promoter.  When infected with HIV-1, Tat drives 
expression of the reporter gene contained in these cell-lines and their 
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expression provides a surrogate marker for productive HIV-1 infection. 
Assays based on this model are very useful in the field of HIV-1 research 
as they are usually high throughput, easy to perform and provide a 
quick way for measuring HIV-1 infection in target cells.  The conflicting 
results obtained when using this system to assess the effects of drug 
inhibitors on cell-to-cell spread of HIV-1 suggests that there are factors, 
which may limit the usefulness of reporter gene assays when studying 
HIV-1 cell-to-cell spread in the context of some inhibitors.  
 
While PIs and RTIs failed to inhibit reporter gene expression in the target 
cells of drug treated co-cultures (Figure 3.1 C and D), a Llama derived 
VHH HIV-1 neutralising antibody (J3) effectively suppressed luciferase 
expression in target cells in a dose dependent manner (Figure 3.2 A). J3 
achieves its potent and broad neutralisation effect by directly 
interacting with the CD4 binding site on the HIV-1 envelope and 
preventing viral attachment to the target cell (McCoy et al., 2012, 
McCoy, 2014). This antibody is able to inhibit cell-to-cell spread both in 
the luciferase based assay and in the qPCR based assay (Figure 3.2 B 
and C) and also efficiently blocks cell-free infection (McCoy et al., 
2012, McCoy, 2014). Several groups have shown that monoclonal 
antibodies that block CD4-Env interaction can block both cell-to-cell 
and cell-free HIV-1 infection (Chen et al., 2007, Jolly et al., 2004, Hubner 
et al., 2009, Jolly et al., 2007, Malbec et al., 2013, McCoy, 2014). The 
CD4-Env interaction is an important event in the formation of the 
virological synapse, which precedes actual cell-to-cell transfer of 
virions from the effector cell to a target cell. Blocking the attachment 
of viral Env to the CD4 receptor inhibits the formation of the VS and 
subsequent events leading to infection. The disruption of this interaction 
explains the potent inhibition of HIV-1 cell-to-cell infection by J3.  
 
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 
Chapter Three - Assessing two assay systems for studying the impact of drug inhibitors on 
cell-to-cell spread of HIV-1 146 
We hypothesised that Tat-driven reporter gene expression in target 
cells that occurred in the absence of infection, was the result of Tat 
secreted from infected donor cells into the co-culture, driving reporter 
gene expression in the target cells. To test this hypothesis, co-cultures 
were performed in the presence of the drug inhibitor (Cmax LPV) and a 
serial dilution of an anti-Tat antibody (Figure 3.3). The presence of the 
anti-Tat antibody significantly reduced the luciferase signal detected in 
co-cultures in a dose-dependent manner but did not abolish the signal. 
Several studies have previously shown that the extracellular form of HIV-
1 Tat released from infected cells is able to enter nearby target cells 
and induce its effect of gene transactivation (Ensoli et al., 1990, Ensoli 
et al., 1993, Zauli et al., 1995, Ferrari et al., 2003, Zheng et al., 2005, 
Romani et al., 2010, Debaisieux et al., 2012). This extracellular secretion 
of Tat may play an important role in sustaining a paracrine loop 
required for optimal HIV-1 LTR transactivation (Zauli et al., 1995, Romani 
et al., 2010). It is reasonable to suggest that the presence of an anti-Tat 
mAb in the co-culture may interfere with the paracrine activation loop 
by binding free extracellular Tat and as such reduce luciferase 
expression in target cells.   
 
Free extracellular Tat is probably not the only factor driving the 
expression of luciferase in the target cells in the absence of infection. 
We think this because in the presence of the highest concentration of 
anti-Tat antibody (50µg/ml) possible with the assay set-up, a luciferase 
signal is still detected in the target cells, treated with PI (LPV). This 
suggests that active secretion of Tat protein could also be occurring 
across the virological synapse (VS) from infected donor cells into the 
target cells. Virus transfer across the VS from donor cells to target cells is 
characteristically rapid and delivers a large dose of infectious virions 
into the target cells. If Tat secretion does occur across the VS, this may 
like virion transfer be very rapid and efficient and as such effectively 
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reduce the window available for complete neutralisation by an anti-
Tat specific antibody as observed in this study. Before the first 
descriptions of the retrovirus induced virological synapse (Jolly and 
Sattentau, 2004, Igakura et al., 2003), an early study by Helland et al. 
suggested that direct cell-to-cell contact between an infected Tat 
producing effector cell (Jurkat-tat) and a target cell encoding a 
reporter gene under the control of the HIV-LTR promoter greatly 
enhanced  transactivation  of the reporter gene in the target cells 
(Helland et al., 1991). Was this early report a possible hint at Tat 
secretion across the VS? In the formation of the virological synapse, 
viral proteins such as Gag have been shown to co-localise   to the 
point of contact between cells (Jolly and Sattentau, 2004, Jolly and 
Sattentau, 2005). It is conceivable that a viral protein like HIV-1 Tat will 
be able to hijack the synapse in a similar manner to mediate its 
function of inducing transactivation of gene expression in neighbouring 
target cells, although this has not been specifically investigated. This 
would explain why even though the anti-Tat mAb significantly reduced 
the luciferase signal probably by binding free extracellular Tat in the 
culture medium, it did not completely block transactivation of the 
reporter gene in the target cells.  
 
The potent inhibition of Tat-driven luciferase gene expression in the 
target cells of co-cultures treated with the NAb J3 strengthens the case 
for possible Tat secretion across the VS as a source of HIV-1 LTR 
transactivation in target cells. J3 blocks the interaction between CD4 
and Env and as such prevents formation of the VS. In the luciferase 
assay 2µg/ml of VHH NAb only suppresses luciferase expression by 50% 
(IC50) in target cells (Figure 3.2A). However this same dose of NAb 
completely suppresses the formation of de novo HIV-1 DNA in target 
cells measured by qPCR (Figure 3.2B).  This supports the reasoning that 
the luciferase signal that is measured in the reporter gene based assay 
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system is very likely a combination of activation from extracellular free 
Tat from donor cells, Tat secreted across the synapse and possibly 
productive infection of target cells. It is difficult to say which of these 
modes of Tat driven expression predominates in a given co-culture 
system but this would likely depend on other variables such as the cell 
type used in the assay, the percentage of infected donor cells in 
culture, chronicity of donor cell infection etc. Another possible source 
of Tat induced reporter gene expression in the absence of target cell 
infection could be from the fusion of donor cells with target cells in co-
culture. This is however unlikely as syncytium formation and cell-cell 
fusion are not commonly observed in T cell co-cultures of infected 
donor cells and target cells (Jolly et al., 2004) and it has been shown 
that the tetraspanin CD9 inhibits cell-cell fusion and syncytium 
formation at the VS  (Weng et al., 2009). 
 
In their work investigating the effects of RTIs on cell-cell spread of HIV-1, 
Permanyer et al. made similar observations on the occurrence of 
reporter gene expression in the absence of true infection of target cells 
in co-cultures (Permanyer et al., 2012b). They however did not propose 
a mechanism to explain these observations as we have done. My data 
show that high-level Tat-driven reporter gene expression can occur in 
the absence of true infection of target cells. Using Tat driven reporter 
gene expression as a measure of infection when studying cell-to-cell 
spread of HIV-1 would tend to overestimate true infection in target cells 
due to confounding sources of Tat driven reporter gene expression not 
related to target cell infection. This was probably the case in the study 
by Sigal et al. that found cell-to-cell spread of HIV-1 to be two orders of 
magnitude more resistant (>200 fold) to inhibition by RTIs than cell-free 
spread when using a Tat driven reporter gene expression assay system 
(Sigal et al., 2011). Their findings however are still noteworthy and 
relevant as they were also able to show this reduced susceptibility of 
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HIV-1 cell-to-cell infection to RTIs, using another surrogate marker of 
HIV-1 infection, which is independent of Tat (staining target cells for p24 
antigen). This suggests that the reduced susceptibility though possibly 
over estimated when measured using a Tat driven reporter gene assay 
system is still genuinely present. Although Permanyer et al. contested 
this by using direct qPCR detection of HIV-1 DNA when assessing the 
impact of RTIs on HIV-1 cell-to-cell infection, in their study they adjusted 
the virus input so that cell-free and cell-to-cell spread resulted in a 
similar percentage of GFP+ infected cells in the untreated condition 
(Permanyer et al., 2012b). Under these conditions, the RTIs were found 
to be equally potent at inhibiting both cell-to-cell and cell-free 
infection. Normalising the virus input in this way removes the 
quantitative effects of high-multiplicity infection mediated by cell-to-
cell spread and as such does not offer a true assessment of the effects 
of the inhibitor being studied on this mode of virus infection in 
comparison to cell-free infection.  
 
Reporter gene assays remain useful for rapid screening of some 
inhibitors when studying the mechanisms of HIV-1 infection. However, 
their use warrants caution due to the existence of confounding factors, 
which may cause an overestimation of productive infection in target 
cells. In the subsequent chapters of my thesis, I use the qPCR based 
cell-to-cell assay for all other studies presented. 
 
Drug susceptibility and cell-to-cell spread of HIV-1 
drug-resistant mutants 
The PI and RTI drug-resistant HIV-1 viruses that are used in the 
experiments presented in this thesis were all tested in a drug 
susceptibility assay (Gupta et al., 2010) to confirm that they displayed 
the expected phenotype. The PI resistant mutant HIV-1DM has a V82A 
mutation in protease and an A431V mutation in gag (at the NC/p1 
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cleavage site). The V82A mutation is a common major PI resistance 
mutation, which is rapidly selected in patients who receive antiretroviral 
therapy containing Indinavir or Lopinavir (Luca, 2006). The presence of 
V82A reduces the ability of the viral protease to bind to its substrate 
and imposes a fitness cost on the virus (Zhang et al., 1997, Kantor et al., 
2005). It decreases the susceptibility of the virus to inhibition by all PIs to 
variable degrees (low to high levels of resistance) except Darunavir 
(Clavel and Hance, 2004).  In the evolution of PI resistance the 
selection of the V82A mutation is rapidly followed by the selection of 
the A431V mutation in gag. A431V is located at the NC/p1 cleavage 
site and its presence causes a conformational change that allows the 
binding and effective cleavage of the substrate  (cleavage site) by the 
mutated protease containing the V82A (Dam et al., 2009). This gag 
mutation by itself is also capable of inducing a reduced susceptibility 
to PIs in vitro (Dam et al., 2009). In the drug susceptibility assay HIV-1DM 
was resistant to LPV but remained susceptible to DRV as expected 
(Figure 3.5 A and B).  
 
The NRTI resistant virus HIV-1M184V has the M184V mutation in reverse 
transcriptase. M184V emerges very rapidly in all patients receiving non-
suppressive therapy with Lamivudine (3TC) or Emtricitabine (FTC), 
reducing the virus susceptibility to these drugs by >100-fold (Eron et al., 
1995, Marcelin, 2006). The changes in RT induced by M184V increase 
the fidelity of RT for the natural dNTP substrate but reduces the 
processivity of the enzyme thus leading to a reduction of viral fitness 
(Marcelin, 2006).  In contrast the selection of this mutation increases the 
susceptibility of the virus to Stavudine, Tenofovir and Zidovudine. This 
phenotype was verified and confirmed in the drug susceptibility assay 
for Zidovudine and Lamivudine (Figure 3.3 C and D).  
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The NNRTI resistant mutant HIV-1K103N has the K103N mutation in reverse 
transcriptase. K103N is rapidly selected in 30-50% patients who receive 
non-suppressive antiretroviral therapy containing Nevirapine (NVP) or 
Efavirenz (EFV). This mutation is located in the hydrophobic NNRTI 
binding pocket of RT and reduces the affinity of the viral enzyme to 
these drugs (de Bethune, 2010). This mutation leads to high levels of 
resistance >50-fold to NVP and EFV (de Bethune, 2010) and this was 
confirmed in the drug susceptibility assay (Figure 3.3 E and F). The 
presence of this mutation does not negatively affect the replicative 
fitness of the virus. 
 
The PI and RTI drug-resistant HIV-1 viruses were all able to spread 
efficiently from cell-to-cell similarly to wild type virus (Figure 3.7 C, D, E). 
The ability of HIV-1 to mutate its genome into resistant variants capable 
of circumventing the effect of drugs provides one of the biggest 
challenges to the success of HAART. Drug-resistant mutant viruses have 
a replicative advantage over wild-type variants in the presence of 
antiretroviral drugs. They achieve this through diverse mechanisms, 
discussed in detail in the background section of this thesis. Whether 
these drug-resistant variants are also better or less well adapted to 
spread from cell-to-cell when compared to wild-type variants is an 
interesting question that warrants further investigation. For example if 
these viruses are inherently fitter during cell-to-cell spread, this could be 
a contributing factor for the selection of resistant viruses in infected 
patients. This could be tested by directly comparing cell-to-cell and 
cell-free spread of these resistant viruses in the absence of inhibitors 
using a direct output measure like the qPCR assay described in this 
chapter. Given the apparent benefits of a cell-to-cell mode of viral 
dissemination over cell-free spread, it is reasonable to imagine that 
some drug-resistant viruses could evolve to be spread more efficiently 
by this means, providing them with an additional mechanism by which 
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to persist in the presence of therapy. Although our results hint at the 
existence of possible differences in the efficiency of cell-to-cell spread 
of some resistant viruses (Figure 3.7 F), we have only assessed three 
drug-resistant variants, which considerably limits our ability to make any 
meaningful conclusions. It is however interesting that a resistance 
mutation such as HIV-1M184V which has been shown to have a reduced 
replicative capacity in cell-free assays (Diallo et al., 2003) spreads 
efficiently in our in-vitro cell-to-cell assay system. A similar observation 
has been recently made with the drug resistant virus K263R selected by 
the integrase inhibitor Dolutegravir, which though unfit in the context of 
cell-free is not compromised in cell-to-cell transmission (Bastarache et 
al., 2014). Additional work with a larger panel of drug-resistant mutants 
is needed to explore the mechanisms underlying the apparent 
differences in the efficiency of spread of drug resistant virus by cell-free 
and cell-to-cell mechanisms.  This however is not the focus of the work 
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4  Protease inhibitors effectively inhibit 




Despite advances in the clinical management of HIV-1 infection, 
finding an effective vaccine or a definitive cure for the disease 
continues to elude researchers. One of the main reasons for this is the 
ability of the virus to persist within the host in reservoirs and re-emerge 
when treatment is interrupted. It has been suggested that ongoing viral 
replication in patients receiving antiretroviral therapy may be a 
contributing factor to the maintenance of cellular reservoirs of the virus. 
This is however debated in the field, with evidence both in support of 
and against ongoing viral replication in the presence of antiretroviral 
agents. In favour of complete inhibition of viral replication with cART, 
patients who fully adhere to effective cART regimens do not show 
evidence of continuing viral evolution or treatment failure (Frenkel et 
al., 2003, Kieffer et al., 2004, Bailey et al., 2006, Kearney et al., 2014, 
Dinoso et al., 2009, McMahon et al., 2010, Gandhi et al., 2010). 
Nevertheless, some (but not all) treatment intensification studies with 
Raltegravir have demonstrated that there is an increase in episomal 
DNA and a reduction in the size of the viral reservoir when this agent is 
added to a triple therapy combination (Buzon et al., 2010, Yukl et al., 
2010, Vallejo et al., 2012, Llibre et al., 2012). Also, several studies have 
demonstrated that low level viral replication may occur in specific 
anatomical compartments despite suppression of plasma HIV-1 RNA 
(Gunthard et al., 1998, Ruiz et al., 1999, Martinez et al., 1999, Martinez et 
al., 2001, Benito et al., 2004, Chun et al., 2008, Shiu et al., 2009). These 
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studies suggest that there may be a degree of ongoing residual viral 
replication with cART. 
 
A study by Sigal et al. was the first to propose that cell-to-cell spread of 
HIV-1 may be a mechanism for such ongoing virus replication in the 
presence of antiretroviral therapy (Sigal et al., 2011). In this study the 
authors hypothesised that the high multiplicity of infection that typifies 
HIV-1 cell-to-cell dissemination, would increase the chance of at least 
one virus particle being able to stochastically escape inhibition by 
antiretroviral drugs and establish infection in target cells. They tested 
this hypothesis by assessing the impact of RTIs on cell-to-cell spread of 
HIV-1 in an in vitro assay system and showed that this mode of virus 
infection was less susceptible to inhibition by RTIs when compared to 
cell-free infection (Sigal et al., 2011). This report was challenged by 
another study in which the use of similar in vitro cell-to-cell assays 
showed RTIs to be equally effective against both cell-to-cell and cell-
free modes of virus dissemination (Permanyer et al., 2012b).  
 
The discrepancies between these two studies raise questions on the 
true impact that antiretroviral drugs have on HIV-1 cell-to-cell 
dissemination. Furthermore, because both studies restricted their 
analyses to RTIs, it remains unclear whether other classes of 
antiretroviral drugs vary in their ability to inhibit viral dissemination by a 
cell-to-cell mechanism. In this chapter the impact of Protease Inhibitors 
on cell-to-cell spread of HIV-1 in comparison to cell-free spread is 
studied using the qPCR-based in vitro assay evaluated in the previous 
chapter. This system is also used to reassess RTIs tested in afore 
mentioned studies for their relative efficacy against cell-to-cell vs. cell-
free HIV-1 infection and comparing their effects to that of PIs. The 
reasons for focusing on PIs are manifold; PIs are important components 
of cART regimens by virtue of their potency in inhibiting viral replication 
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and the high barrier that they present against the selection of drug-
resistant viruses (Wensing et al., 2010, Arts and Hazuda, 2012). This has 
led to PIs being the only class of antiretroviral drugs to be considered in 
clinical trials for use as monotherapy in the treatment of HIV-1 infection 
(Bierman et al., 2009, Perez-Valero and Arribas, 2011, Perez-Valero et 
al., 2011, Katlama et al., 2010, Arribas et al., 2010, Clumeck et al., 2011). 
Also, PIs are part of recommended first-line treatment options for HIV-1 
infected patients, and constitute the mainstay of second-line regimens 
for patients who fail first-line therapies (WHO, 2013, DHHS, 2014). In 
resource challenged settings PIs are mainly reserved for use in second-
line therapies when first-line RTI-based options fail. However in recent 
years, increasing prevalence of baseline drug resistance to RTIs in 
treatment naïve patients has led to wider use of PI-based therapies for 
initial treatments (Gupta et al., 2012, WHO, July 2012). This further 
highlights the importance of this drug class for the future of cART.  
 
While the exact mechanisms by which PIs exert their potent inhibitory 
effects in vivo are not completely understood, recent studies suggest 
that in addition to preventing cleavage of viral polyproteins into 
functional sub-units leading to the production of immature non-
infectious virions (Wensing et al., 2010), PIs also affect viral entry and 
post-entry steps in the replication cycle (Rabi et al., 2013).  Cell-to-cell 
spread of HIV-1 is characterised by the polarisation of virus assembly 
and budding towards the point of contact between the donor cell 
and the target cell (Jolly et al., 2004, Jolly and Sattentau, 2004, Jolly et 
al., 2007, Jolly and Sattentau, 2007). It is therefore plausible that the 
assembly and maturation of newly formed virions at the virological 
synapse, coupled with more rapid virus transfer could limit the 
efficiency of PIs in blocking cell-to-cell dissemination of the virus. The 
impact of PIs on this mode of virus dissemination however has not been 
investigated prior to the present study. 
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In order to complete the panel of drugs tested, the impact of integrase 
inhibitors on T cell-to-T cell spread of HIV-1 was also tested. Integrase 
inhibitors are the latest addition to the arsenal of FDA approved 
antiretroviral agents and now constitute a part of first-line therapies as 
well as salvage therapy regimens for treatment-experienced patients 
who fail on first-line and second-line treatment options. For this reason it 
is interesting to assess their effect on T cell -to-T cell spread of HIV-1. 
 
The results show that PIs are equally effective against both cell-to-cell 
and cell-free modes of HIV-1 dissemination. Also a PI-resistant mutant 
retains its resistant profile during cell-to-cell spread. By contrast, cell-to-
cell spread is less susceptible to inhibition by RTIs. We also note existing 
intra-class variability in the ability of RTIs to effectively block this mode 
of virus dissemination, with NRTIs having much reduced potencies in 
comparison to NNRTIs against cell-to-cell infection. Lastly the results 
provide evidence that INIs are effective inhibitors of both cell-to-cell 
and cell-free spread of HIV-1 in T cells. These data suggest that if HIV-1 
cell-to-cell dissemination does indeed contribute to ongoing viral 
replication and the maintenance of reservoirs in treated patients, this 
will likely be drug class dependent.  
 
4.1.1 Specific objectives 
- To assess the impact of Protease Inhibitors on cell-to-cell vs. cell-free 
spread of HIV-1. 
- To assess the impact of Reverse Transcriptase Inhibitors on cell-to-cell 
vs. cell-free spread of HIV-1 and in comparison to PIs. 
- To assess cell-to-cell spread of PI and RTI drug-resistant mutants in the 
presence of these respective drug classes. 
- To assess the impact of Integrase Inhibitors on cell-to-cell spread of 
HIV-1. 
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4.2 Results 
4.2.1 Protease inhibitors effectively inhibit cell-to-
cell transfer of HIV-1 
To investigate the effect of PIs on cell-to-cell spread, the qPCR cell-to-
cell in vitro assay system that was assessed in the previous chapter was 
used. This assay has also been used and extensively validated in other 
studies of HIV-1 cell-to-cell spread (Jolly et al., 2007, Jolly et al., 2010, 
Casartelli et al., 2010). Briefly, infected donor cells (Jurkat T cells) 
untreated or pre-incubated with the PIs; Lopinavir (LPV) or Darunavir 
(DRV) for a maximum of 24h, were co-cultured with uninfected target T 
cells (Jurkat-1G5). The co-culture was incubated for 24h for 
experiments with a single time-point or for different durations (1h, 3h, 
6h, 12h), for time-course experiments. Cell-to-cell spread of HIV-1 was 
measured by qPCR, to quantify de novo HIV-1 DNA pol copies arising 
from reverse transcription in the newly infected T cell population. The 
data were expressed as a fold increase in HIV-1 pol DNA relative to the 
housekeeping gene Albumin. In this assay a synchronous population of 
HIV-1 infected donor cells, allows for the reliable measurement of virus 
infection in target cells mediated by cell-to-cell dissemination with little 
or no contribution from the less efficient cell-free mode of infection 
(Jolly et al., 2007). Furthermore, subtracting the pol signal at t = 0h 
(baseline) from all subsequent time points removes the HIV-1 pol DNA 
signal arising from integrated proviral DNA within the donor cell 
population.  
 
As expected, a time-dependent increase in the generation of HIV-1 pol 
DNA, indicative of cell-to-cell spread in the positive control (untreated 
co-cultures) was observed. In the co-cultures treated with the 
maximum plasma concentrations (Cmax) achievable in vivo of LPV 
(Figure 4.1A) or DRV (Figure 4.1B) (14µM and 12µM respectively), cell-to-
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cell spread was potently inhibited as evidenced by the absence of an 
increase in HIV-1pol DNA in these drug treated co-cultures.  
 
It is expected that inhibiting the synthesis of new HIV-1 pol transcripts by 
blocking cell-to-cell infection will have an effect on the appearance of 
episomal DNA forms such as 2 LTR circles.  This form of episomal DNA is 
frequently used as a marker for nuclear import, a step that precedes 
integration of proviral DNA into the host cell genome (Kalpana, 2008, 
Hazuda et al., 2000, Butler et al., 2001). After 24h incubation, 2 LTR 
circles were readily detected (635copies/100ng of DNA at 24h) in 
untreated co-cultures, however significantly fewer 2 LTR copies (p<0.05) 
were detected in co-cultures treated with PIs (<50 copies/100ng of 
DNA) (Figure 4.1C). Collectively, these results provide evidence that PIs 
are effective inhibitors of HIV-1 cell-to-cell infection between CD4+ T 
cells. 
 
To confirm the activity of the PIs tested on Gag maturation and to 
verify that there was no overall defect in virus budding affecting cell-
to-cell spread, a Western blot analysis of purified virus collected from 
PI–treated HIV-1 infected T cells was performed. Donor cells, which 
were treated with a Cmax of LPV or DRV displayed as expected a 
predominance of uncleaved p55Gag protein in virions, while in 
contrast untreated cell cultures or cell cultures treated with RTIs (Cmax of 
TFV=2µM or NVP=10µM) mainly generated virions with p24CA, 
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Figure 4-1: Protease Inhibitors effectively block cell-to-cell spread of HIV-1.(A) Quantification of 
cell-to-cell spread of HIV-1 in the presence of Cmax LPV (14µM) and (B) Cmax of DRV (12µM). HIV-
1 infected Jurkat cells (donors) were pre-incubated with PI for 24h prior to co-culturing with 
target cells or co-cultured without pre-treatment with drugs. After co-culture, HIV-1 pol DNA 
was detected by qPCR. The data were normalised to the housekeeping gene Albumin and 
expressed as the fold increase in HIV DNA copy number over time relative to the baseline 
value at t=0h. Data show the mean of triplicates, error bars represent the standard deviation of 
the mean (SD). **** p<0.0001, ***p<0.001, ns: not significant, two-way ANOVA plus Bonferoni 
post-test applied for comparisons. (C) Reduced detection of 2 LTR circles following cell-to-cell 
spread of HIV-1 in the presence of LPV (14µM). After 24h co-culture of donor cells and target 
with or without LPV, 2 LTR circles were detected by qPCR. **p<0.05, unpaired student t-test. (D) 
Confirmation of PR Gag maturation defect in HIV-1. HIV-1+ donor cells incubated with PIs, RTIs 
or left untreated for 24 hours. Virus-containing supernatants were harvested, purified and equal 
volumes of virus were analysed by SDS-PAGE and Western blotting for HIV-1 Gag. 
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4.2.2 Protease inhibitors are equally effective at 
blocking both cell-free and cell-to-cell spread 
of HIV-1 
In order to determine the efficacy of PIs over a range of 
concentrations at inhibiting both cell-to-cell and cell-free modes of 
HIV-1 dissemination infected donor cells mixed with target cells were 
co-cultured in the presence of serial dilutions of LPV or DRV. Cell-to-cell 
spread was measured by qPCR detection of HIV-1 pol DNA after a 24h 
incubation period as previously described, and these data were used 
to plot dose-response curves from which 50% inhibitory concentrations 
(IC50s) for the drugs tested were calculated. For cell-free infections, 
HIV-1 infected donor cells were incubated alone and allowed to 
produce virus in the presence of a serial dilution of PIs. Culture 
supernatants containing cell-free virus were subsequently harvested 
and used to infect target cells. Following 24h incubation, infection of 
target cells was measured by qPCR detection of HIV-1 pol DNA as 
previously described.  
 
There were no significant differences in the IC50 of LPV (Figure 4.2A, 
Table 4.1) or DRV (Figure 4.2B, Table 4.1) for either cell-free infection 
(3.0nM and 2.5nM respectively) or cell-to-cell infection (2.9nM and 
2.8nM respectively), demonstrating that PIs are equally effective 
against these two modes of virus dissemination. In the original study by 
Sigal et al., which showed that cell-to-cell spread of HIV-1 had a 
reduced susceptibility to inhibition by RTIs, the high MOI associated with 
cell-to-cell HIV-1 dissemination was proposed as the reason for this 
reduced susceptibility (Sigal et al., 2011). High multiplicity of infection 
has also been linked to the reduced susceptibility of cell-to-cell 
infection to inhibition by some neutralising antibodies (Martin and 
Sattentau, 2009, Abela et al., 2012, Durham et al., 2012, Massanella et 
al., 2009, Chen et al., 2007). Based on this, the effect of varying the 
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multiplicity of infection on the ability of PIs to remain effective at 
blocking HIV-1 cell-to-cell infection was assessed. This was done by 
modifying the donor cell to target cell ratio in the co-cultures to 5:1 
compared to 1:5 that was used for the experiments previously 
described. Increasing the number of HIV-1 infected donor cells in the 
co-cultures led to a reduced ability of LPV to inhibit cell-to-cell infection 
when testing a drug concentration close to the IC50 (8nM). Increasing 
the concentration of LPV three-fold (24nM) restored the ability of the 
drug to effectively block cell-to-cell spread in the co-cultures with 
higher donor cell to target cell ratios (Figure 4.2C). It is worth noting that 
the concentration of LPV which effectively inhibited cell-to-cell spread 
in the co-cultures with increased number of donor cells and therefore 
effectively higher MOI, is still well below the minimum plasma 
concentration of the drug achievable in vivo in patients treated with 
LPV (Cmin=3µM).  This suggests that PIs likely remain potent against cell-
to-cell infections over a wide range of physiologically relevant drug 
concentrations. 
 
The PI resistant mutant HIV-1DM was assessed for its ability to spread 
from cell-to-cell in comparison to HIV-1WT virus in the presence of LPV 
(Figure 4.2D) and DRV (Figure 4.2E). This drug-resistant virus carries the 
V82A mutation in protease and the A431V mutation in gag. In the drug 
susceptibility assay HIV-1DM is 14-fold more resistant to inhibition by LPV 
and is susceptible to DRV (see Chapter 3). This virus maintained its 
resistant phenotype to LPV (Figure 4.2D) and remained susceptible to 
DRV as expected (Figure 4.2E) when spreading by a cell-to-cell 
mechanism. These data indicate that the observations on the effects 
of PIs on cell-to-cell spread of HIV-1 are not a function of the viruses 
tested but really a reflection of the effect of the drugs assessed in our 
assays. 
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Figure 4-2: Protease Inhibitors are equally effective at inhibiting both cell-to-cell and cell-free 
spread of HIV-1. (A) LPV and (B) DRV equally block both cell-free and cell-to-cell spread of HIV-
1. Infected donor cells were incubated with a serial dilution of the PIs for 24h prior to co-
culturing with uninfected target cells. HIV-1 pol DNA was measured by qPCR following co-
culture. For cell-free infections, virus supernatant collected from infected donor cells pre-
incubated with PIs was used to infect target cells. 24h after infection, qPCR was performed to 
detect HIV-1 pol DNA and expressed as a fold increase relative to the Albumin housekeeping 
gene. The error bars represent the standard deviation of the mean of triplicates and a 
representative experiment is shown. (C) Increasing the donor: target cell ratio in co-culture 
reduces the efficacy of LPV in blocking cell-to-cell infection. **** p<0.0001, *** p<0.001, ns: not 
significant, two-way ANOVA with Bonferoni post-test applied for comparisons. (D) A PI drug-
resistant mutant HIV-1DM maintains its resistant phenotype when spreading by a cell-to-cell 
mechanism, being less susceptible to inhibition by LPV than HIV-1wt and remains as expected 
(E) susceptible to inhibition by DRV as wild-type virus. 
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Table 4-1: Summary table showing IC50 of Protease Inhibitors; Lopinavir and Darunavir with cell-
to-cell and cell-free spread of HIV-1. 
                                   Protease Inhibitors 
                 Drugs                     Lopinavir                   Darunavir 
        Mode of Spread       C-C    C-F      C-C    C-F 
        Mean IC50 (nM)         2.9     3.0        2.8      2.5 
                  SEM         0.2     0.2        0.4      0.1 
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4.2.3 PIs effectively inhibit cell-to-cell spread of 
HIV-1 mediated by infected primary T cells 
The potency of PIs against cell-to-cell infection mediated by HIV-1 
infected primary T cells was also tested. For this, CD4+ T cells were 
purified from PBMCs obtained from healthy donors. These CD4+ T cells 
were then stimulated with PHA and IL2 and infected with HIV-1. The 
infected donor cells (CD4+ T cells) were pre-incubated with Cmax of LPV 
(14µM) and then co-cultured with uninfected target cells (Jurkat T 
cells). The co-culture was incubated for 24h after which cell-to-cell 
infection was measured by qPCR as previously described. With primary 
CD4+ T cells as donor cells, it was not possible to obtain the same level 
of infection as with T cell lines (i.e. >90% Gag positivity by flow 
cytometry), only 60% HIV-1 Gag positivity was achieved in infected 
primary CD4+ T cell cultures. For this reason an additional control of 
infected primary CD4+ cells alone without addition of target cells was 
included in the experiment set-up, to control for spreading infection in 
this donor cell population. No increase in HIV-1 pol DNA overtime was 
observed in the donors cells cultured alone, indicating that there is 
minimal spreading infection in the primary CD4+ T cell population 
(Figure 4.3). The PI LPV effectively inhibited cell-to-cell spread from 
infected CD4+ T cells to Jurkat T cells as shown by the absence of a 
time dependent increase in the number of HIV-1 pol DNA copies 
detected in the drug treated co-cultures when compared to the 
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Figure 4-3: Protease Inhibitors block cell-to-cell transfer from HIV-1 infected primary T cells: HIV-1 
infected primary CD4+ T cells (donor cells) were incubated with LPV (14µM) for 24h and mixed 
with uninfected Jurkat cells (target cells). Cell-to-cell infection was measured by qPCR 
detection of HIV-1 pol DNA. A representative of two independent experiments performed with 
primary cells isolated from two different donors is shown. The data are the mean of triplicates 
and error bars represent the standard deviation of the mean. **** p<0.0001, *** p<0.001, a two-
way ANOVA with Bonferroni post-test was applied for comparisons. 
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4.2.4 Reverse Transcriptase Inhibitors are less 
effective inhibitors of HIV-1 cell-to-cell 
infection compared to cell-free infection 
In light of the conflicting reports on the impact of RTIs on cell-to-cell 
spread of HIV-1, the potency of RTIs against cell-to-cell spread was re-
assessed in this in vitro system and compared to the effects of PIs. To do 
this, co-cultures (infected donor cells mixed with uninfected target 
cells) and cell-free infection assays were performed in the presence of 
a serial dilution of RTIs; Zidovudine (AZT), Tenofovir (TFV), Lamivudine 
(3TC), Nevirapine (NVP), and Efavirenz (EFV). Infection was measured 
by qPCR detection of HIV-1 pol DNA as described earlier.  
 
These data were used to plot dose-response curves and determine the 
IC50s for both modes of virus spread with these drugs. The results 
showed that most of the RTIs tested though effective against cell-free 
infections displayed reduced potencies against cell-to-cell infection. 
AZT (Figure 4.4 A) and TFV (Figure 4.4 B) were the least effective of 
these drugs with cell-to-cell infection being >20-fold less susceptible to 
inhibition by AZT (Figure 4.4A) or >10-fold less susceptible to inhibition by 
TFV (Figure 4.4B) when compared to cell-free spread. 3TC had a 6-fold 
reduced potency (Figure 4.4C) and NVP a 4-fold reduced potency 
against cell-to-cell spread in comparison to cell-free spread (Figure 4.4 
D). The IC50s for cell-to-cell and cell-free infections are summarised on 
Table 4.2. Notably, EFV stood out in this drug class behaving in a similar 
fashion to PIs and displayed the same potency against both cell-to-cell 
and cell-free spread of HIV-1 (Figure 4.5E). 
 
The effect of varying the multiplicity of infection on the potency of the 
RTIs that showed a reduced effectiveness against cell-to-cell infection 
was also investigated. Reducing the virus input 10-fold by decreasing 
the number of infected donor cells used in the co-cultures significantly 
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improved the ability of TFV and AZT to inhibit cell-to-cell infection 
(Figure 4.4F), suggesting that high MOI associated with cell-to-cell 
spread may contribute to the poor inhibitory potential of RTIs. 
 
An NNRTI drug-resistant mutant HIV-1K103N (Figure 4.4G), which is 
resistant to inhibition by EFV and NVP and an NRTI drug-resistant mutant 
HIV-1M184V (Figure 4.4H), which is resistant to 3TC, maintained their 
resistant phenotypes when spreading by a cell-to-cell mechanism 
(Figure 4.4G and H). This indicates that the observations on the impact 
of the RTIs tested, on cell-to-cell spread of HIV-1, reflect the true effects 
of the drugs tested and are not a function of the viruses. 
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Figure 4-4:  Reverse Transcriptase Inhibitors are less effective inhibitors of cell-to-cell spread of 
HIV-1 compared to cell-free spread: Infected donor cells were co-cultured with uninfected 
target cells in the presence of a serial dilution of RTIs. (A) TFV, (B) AZT, (C) 3TC and (D) NVP 
displayed reduced potency in their ability to inhibit cell-to-cell infection in comparison to cell-
free infection. (E) EFV was equally effective at inhibiting both modes of virus spread. (F) 
Reducing the MOI by reducing the number of donor cells in the co-culture 10-fold restored the 
ability of an ineffective RTI, TFV to inhibit cell-to-cell spread of HIV-1. RTI mutants HIV-1K103N (G) 
and HIV-1M184V (H) maintain their resistance profile when spreading by a cell-to-cell mechanism. 
The data shown are a representative experiment from at least two independent repeats. Error 
bars represent the SD of the mean of triplicates. A two-way ANOVA with Bonferroni post-test 
was applied for group comparisons. **** p< 0.0001, *** p<0.001, ns = not significant 
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Table 4-2: Summary Table showing IC50s of Reverse transcriptase inhibitors for cell-to-cell and 
cell-free infection 
                                                         Reverse Transcriptase Inhibitors 
Drugs      AZT      TFV      3TC     NVP             EFV 
Mode of 
infection 
 C-C C-F  C-C C-F C-C C-F C-C  C-F C-C C-F 
IC50 >80µM 3.4µM >80µM 7.5µM 428nM 73nM 360nM 86nM 0.23nM 0.21nM 
SEM UD   0.3 UD   0.7      34   6.3    89.5 9.2    0.04  0.017 
p-value              UD             UD            0.001           0.03              0.62 
IC50s for NRTIs AZT, TFV, 3TC and NNRTIs NVP, EFV for cell-to-cell and cell-free infection are 
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4.2.5 Time of drug addition does not modify the 
effects of PIs and RTIs on HIV-1 cell-to-cell 
spread 
The effect of the time of drug addition in the assays on the potency of 
the drugs tested was also investigated. To test this for PIs, HIV-1 infected 
donor cells were mixed with uninfected target cells in the presence of 
LPV or DRV without prior pre-incubation of donors with the drug (time of 
addition, t=0h). We noted that the PIs LPV (Figure 4.5A) and DRV (Figure 
4.5B) remained effective against cell-to-cell infection regardless of the 
time of addition of the drugs i.e. either added at t=0h or with HIV-1 
infected donor cells pre-incubated with drug for 24h prior to co-
culturing with target cells as in the experiments previously described. A 
similar assessment was made for the RTIs with uninfected target cells 
pre-incubated with TFV (Figure 4.5C) or AZT (Figure 4.5D) for 24h prior to 
mixing with HIV-1 infected donor cells as opposed to adding the drug 
at t=0h. Infection was quantified by qPCR as previously described. 
Under these conditions we found that pre-incubating target cells with 
the RTIs as opposed to adding the drugs at the time of mixing the 
infected donor cells with the target cells, did not improve the ability of 
TFV (Figure 4.5C) and AZT (Figure 4.5D) to inhibit HIV-1 cell-to-cell 
spread. These data indicate that the effects of the tested antiretroviral 
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Figure 4-5: Time of drug addition does not modify the effects of PIs and RTIs on HIV-1 cell-to-cell 
spread. Infected donor cells were co-cultured with uninfected target cells in the presence of 
(A) LPV (14µM) and (B) DRV (12µM) without pre-incubation of the donor cells with the drug 
(time of drug addition t=0h). HIV-1 pol DNA was directed by qPCR for different time-points 
following co-culture. The data shown represent the mean of triplicates and the error bars are 
the standard deviation of the mean. For RTIs, uninfected target cells were pre-incubated with 
(C) TFV (2µM) or (D) AZT (10µM) for 24h prior to co-culture with infected donor cells. HIV-1 pol 
DNA was detected as previously described for different time-points following co-culture of 
donor and target cells and expressed as a fold increase relative to the Albumin housekeeping 
gene. Data show the mean of triplicates, error bars represent the SD of the mean. Comparisons 
were made using a two-way ANOVA with a Bonferroni post-test  **** p< 0.0001, ***p<0.001, ns: 
not significant. 
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4.2.6 Integrase inhibitors effectively inhibit cell-to-
cell spread of HIV-1 between T cells 
Although the main focus of the work presented in this chapter is the 
impact of Protease Inhibitors on cell-to-cell spread of HIV-1, while 
completing this thesis Duncan et al. published a study assessing the 
impact of antiretroviral drugs on macrophage-to-T cell spread of HIV-1 
(Duncan et.al, 2013). They studied the effects of RTIs and also Integrase 
Inhibitors (INIs) on this mode of virus dissemination. Given that the 
impact of INIs on T cell-to-T cell spread of HIV-1 has not been previously 
studied, to complete the panel of the drugs classes tested (RTIs and 
PIs); the impact of Raltegravir on cell-to-cell spread was tested. In the 
absence of a sufficiently accurate integrated DNA qPCR assay in our 
lab, a rapid assay using the quantification of p24 antigen in culture 
supernatants as a measure of infection was designed to explore the 
effects of the INI, Raltegravir (RAL) on T cell-to- T cell spread of HIV-1. 
 
For cell-to-cell infections, 2x105 infected donor cells (Jurkat T cells) were 
mixed with 8x105 target cells in the presence of the Cmax of Raltegravir 
(6µM). Co-cultures without Raltegravir and cultures of donor cells alone 
were included in control wells.  Culture supernatants were collected at 
4, 7 and 10 days after co-culture, for the detection of p24 antigen by 
ELISA. For cell-free infections, cultures were performed on 24well plates 
with 3µM transwells to separate donor cell and target cell populations. 
The transwells allow full diffusion of virus but not migration of cells. The 
infected donor cells were suspended in the culture medium and 
placed in the top well, while the uninfected cells were placed in the 
bottom well. Target cells were treated with Raltegravir Cmax (6µM), or 
left untreated. Supernatants were collected from the target cells at 4, 7 
and 10 days, for detection of p24 antigen by ELISA.  
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In the presence of INIs we expected to see an increase in non-
integrated forms of viral DNA resulting from the block to integration. 
Detection of 2 LTR circles can be used as an indirect measure for 
assessing the effect of INIs (Hazuda et al., 2000, Butler et al., 2001). It is 
expected that 2 LTR circles would increase in the presence of INIs 
relative to untreated controls because blocking integration provides 
more substrate for the ligation to form 2 LTR circles (Hazuda et al., 
2000). Cell-free and cell-to-cell infections in the presence of a serial 
dilution of Raltegravir were performed and generation of 2 LTR circles 
after 24h incubation detected by qPCR. More 2 LTR circles were 
generated in cell-to-cell co-cultures (Figure 4.6A) treated with 
Raltegravir, compared to cell-free infected cultures after 24h (Figure 
4.6B) indicating that Raltegravir is indeed blocking integration in both 
modes virus infection. In addition, the increased absolute number of 2 
LTRs detected in the cell-cell condition compared to cell-free likely 
represents the increase in viral transmission associated with cell-cell 
spread. In the p24 ELISA based assay, there was an increase in the 
amount of p24 antigen in untreated co-cultures over time, whereas in 
the Raltegravir treated co-cultures there was no increase in p24 
antigen over time (Figure 4.6D). This was also true for cell-free infections 
(Figure 4.6E). This shows that Raltegravir effectively blocks both cell-free 
infection as well as cell-to-cell infection in co-cultures. This rapid assay 
was less adaptable for testing drug titrations needed to determine 
IC50s of Raltegravir for cell-to-cell and cell-free modes of infection 
compared to the qPCR-based assay used for testing RTIs and PIs. For 
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Figure 4-6: Integrase Inhibitors effectively inhibit cell-to-cell and cell-free spread of HIV-1 (A) 
More 2 LTR circles are generated in co-cultures of donor cells and target cells in the presence 
of a serial dilution of Raltegravir (RAL) in comparison to (B) target cells infected with cell-free 
virus in the presence of a serial dilution of RAL. 2 LTR circles were detected by qPCR. A 
representative experiment is shown, data represent the mean of triplicates and error bars are 
the SD of the mean.  Graphs (A) and (B) are combined on one figure in (C), directly comparing 
cell-cell and cell-free infection.  Raltegravir effectively inhibits cell-to-cell (D) and cell-free 
spread (E) of HIV-1. For cell-to-cell infections, infected donor cells were co-cultured with 
uninfected donors cells in the presence of a Cmax of RAL, including untreated co-culture and 
donor cells only controls.  p24 antigen in the culture supernatant was detected at 4, 7 and 10 
days following co-culture. For cell-free infection donor and target cell population were 
separated by a 3µM transwell, which allows free diffusion of virus but prevents migration of cells.  
Untreated controls and donor cell only controls were included and p24 antigen detected in 
the target cell supernatant at 4, 7 and 10 days. One representative experiment is shown. The 
data represent the mean of duplicates and the error bars are the SD of the mean. A two-way 
ANOVA with Bonferroni post- test was applied for comparisons. **** p<0.0001, ***p<0.001 
,**p<0.01. 
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4.3 Discussion 
In this chapter, the impact of PIs and to a lesser extent INIs on T cell-to-T 
cell spread of HIV-1 is investigated. The results presented demonstrate 
for the first time that PIs and INIs are potent inhibitors of HIV-1 cell-to-cell 
infection between T cells. In contrast we show that RTIs (AZT, TFV, 3TC 
and NVP) are less effective inhibitors of HIV-1 cell-to-cell spread in 
comparison to cell-free spread, with the exception of EFV, which like 
the PIs is equally potent against both modes of virus dissemination. 
Among the RTIs tested, AZT and TFV exhibit the greatest reduction in 
potency against cell-to-cell infection. In fact, for these drugs, doses 
exceeding the Cmax 20-fold fail to inhibit cell-to-cell infection below 50% 
levels in co-culture. PI and RTI drug-resistant viruses maintain their 
resistant phenotypes when spreading by a cell-to-cell mechanism, 
indicating that the observations are not a function of the viruses tested 
but rather provide a true reflection of the effects of PIs and RTIs on the 
modes of virus dissemination studied.  
 
The difference in the potency of PIs and RTIs against cell-to-cell spread 
of HIV-1 is likely linked to the time window during which these drugs 
have to act, their biological functions and the multiplicity of infection 
that is a function of the mode of virus dissemination. PIs exert a wide 
range of biological effects, which likely account for their potency 
against HIV-1 dissemination. These drugs inhibit the cleavage of virus 
polyproteins into functional sub-units, an essential step required for the 
production of mature infectious virus (Wensing et al., 2010). Exposure to 
PIs therefore results in the generation of a pool of immature non-
infectious virions and essentially reduces the multiplicity of infection 
regardless of whether these immature non-infectious virions spread 
from cell-to-cell across a virological synapse or by a cell-free diffusion. 
This may explain why PIs are equally effective against both cell-to-cell 
and cell-free modes of virus dissemination. This is supported by the 
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similar IC50 values for these drugs obtained with either mode of virus 
dissemination (Table 4.1). 
 
One of the defining features of HIV-1 cell-to-cell spread is its high 
multiplicity of infection. This is the result of polarised virus budding at the 
VS, co-clustering of viral proteins and cellular receptors required for 
virus entry, and the close proximity between the infected donor cell 
and the target cell, all contributing to eliminate the need for prolonged 
virus diffusion (Jolly et al., 2004, Sourisseau et al., 2007, Hubner et al., 
2009, Martin and Sattentau, 2009, Jolly et al., 2011, Duncan et.al, 2013). 
RTIs exert their inhibitory effects by blocking reverse transcription, a 
post-entry step in the replication cycle of the virus. When HIV-1 cell-to-
cell infection is considered in the presence of RTIs, these drugs are 
faced with inhibiting a larger pool on incoming infectious virus particles. 
This may lead to RTIs becoming more easily saturated and tipping the 
scale in favour of the virus. As a result, infection of the target cell is 
more likely to occur, even in the presence of the RTI drug. This may 
explain why RTIs are less effective inhibitors of cell-to-cell spread 
compared to cell-free spread of the virus, which has a lower multiplicity 
of infection. In support of this proposition, when the multiplicity of 
infection in the assay was reduced by decreasing the number of 
infected donor cells in RTI treated co-cultures 10-fold, TFV regained 
potency to some degree against cell-to-cell spread of HIV-1 (Figure 
4.4F). The reverse was also true, with the highly efficient PIs losing some 
of their potency when the multiplicity of infection was increased by 
raising the number of infected donor cells in the co-cultures treated 
with LPV (Figure 4.2C). The results confirm reports by other groups on 
the impact of RTIs on cell-to-cell spread of HIV-1 and role of MOI as a 
factor affecting drug potency (Sigal et al., 2011, Duncan et.al, 2013). 
Sigal et al. found greater fold differences in the reduced potency of 
RTIs against cell-to-cell infection compared to cell-free infection than 
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this study. However in their assays they used indirect measures of viral 
infection to quantify cell-to-cell and cell-free infection (p24 antigen 
detection and Tat-driven luciferase expression), likely leading to an 
overestimation of the effect. In this study infection has been measured 
by direct quantification of HIV-1 pol DNA, a better reflection of true 
infection than indirect methods. A detailed comparison of the methods 
for studying the effects of antiretroviral drugs on the modes of HIV-1 
infection is provided in Chapter 3 of this thesis. In addition to their 
effects on blocking virus maturation, PIs also affect effective virus entry 
as well as post-entry steps in the virus replication cycle, notably reverse 
transcription and integration (Rabi et al., 2013). The ability of PIs to 
target multiple steps in the replication cycle of the virus probably also 
contributes to their superior potency against cell-to-cell infection in 
comparison to RTIs, which only target a single step in the virus 
replication cycle. 
 
To confirm the potency of PIs in blocking cell-to-cell spread, nuclear 
entry in the presence of PIs was indirectly assessed by quantifying 2 LTR 
circles in co-cultures treated with PIs. Following 24h of co-culture in the 
presence of PIs, virtually no 2 LTR circles were detected compared to 
the untreated co-cultures in which 2 LTR circles were readily detected 
(Figure 4.1C). 2 LTR circles are non-functional forms of intracellular HIV-1 
DNA, however they can serve as surrogate markers for the nuclear 
import of viral DNA as well as indicators for the completion of reverse 
transcription (Kalpana, 2008). In the presence of PIs, the earlier steps of 
HIV-1 replication leading to the formation of proviral DNA are blocked 
hence effectively reducing the substrate needed for the formation of 2 
LTR circles. The potency of PIs in blocking cell-to-cell spread of HIV-1 
was unchanged when primary CD4+ T cells were used as donor cells in 
the co-culture assay (Figure 4.3C) indicating that the observations are 
not affected by or dependent on the cell types mediating cell-to-cell 
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spread of HIV-1. This also shows that T cell lines provide a reliable model 
for studying the effect of inhibitors on cell-to-cell infection between T 
cells. 
 
As mentioned earlier it was interesting to observe that unlike the other 
members of the RTI class tested, EFV, like the PIs, was equally potent 
against both cell-to-cell and cell-free spread of HIV-1 (Figure 4.4E). EFV 
is a member of the NNRTI sub-class and exerts its inhibitory effect by 
binding to a hydrophobic pocket near the active site of RT, thus 
preventing the efficient movement of the enzyme in carrying out its 
function of reverse transcription (de Bethune, 2010). This drug has the 
pharmacologic property of being an effective inhibitor of HIV-1 
replication at very low drug concentrations its in vitro IC90 ranging 
between 1.7-25nM (www.hiv-druginteractions.org, 2011a). This is well 
below the minimum plasma concentrations of the drug achieved in 
vivo (Cmin= 5.6µM). This suggests that EFV might be inherently less easily 
saturated when compared to other members of the RTI drug class 
since a very small dose of the drug is capable of exerting a very potent 
inhibitory effect against virus dissemination. It is worth noting that 
potency in blocking HIV-1 infection at relatively lower drug 
concentrations is a feature EFV shares with the highly effective PIs 
discussed above and with INIs as well (www.hiv-druginteractions.org, 
2011b, www.hiv-druginteractions.org, 2011c). Furthermore compared 
to the first generation NNRTIs Nevirapine and Delaviridine, the greater 
potency of EFV has been attributed to its much greater binding affinity 
for HIV-1 RT (Kd EFV= 0.63+/- 0.34, Kd NVP= 1550 +/- 441), this may also 
explain the effectiveness of this drug against HIV-1 cell-to-cell infection 
(Geitmann et al., 2006, Sluis-Cremer and Tachedjian, 2008). 
 
Permanyer et.al reported contrasting findings to our observations and 
those of Sigal et al., reporting that RTIs were equally effective against 
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both modes of virus infection (Permanyer et al., 2012b). However in 
their study they adjusted the virus input such that both cell-to-cell and 
cell-free spread gave rise to a similar percentage of infected cells 
(GFP+ cells) in the untreated state. Normalising the input of virus in this 
manner removes the higher multiplicity of infection mediated by cell-
to-cell spread as a factor affecting the potency of the drugs tested. 
This as a consequence does not provide a true comparison of cell-to-
cell and cell-free modes of virus dissemination. Mechanistically the 
steps of viral infection are the same for both modes of infection i.e. 
virus budding, attachment and entry. The main difference however is 
that cell-to-cell infection compared to cell-free infection occurs over a 
shorter distance with virus budding and attachment occurring in the 
synaptic space where virus proteins and cellular receptors are 
concentrated. This allows rapid and efficient transfer of more virions (a 
high MOI) from the effector cell to the target cell. In the present study, 
the virus input was not adjusted to achieve the same level of infection 
for both cell-to-cell and cell-free mode of virus infection. Therefore the 
quantitative properties of cell-to-cell spread were fully considered in 
comparing the effect of antiretroviral drugs on the two modes of virus 
dissemination.   
 
The effect of Raltegravir on cell-to-cell and cell-free spread of HIV-1 
was also investigated to complete the panel of drug tested. The results 
show that this drug is effective against both modes of infection and 
suppresses the production of p24 antigen in cultures infected by either 
a cell-to-cell or a cell-free mechanism. The experimental approach, 
using quantification of p24 antigen in culture supernatants to measure 
infection limits determination of IC50s. This assay is more difficult to 
adapt for the drug titrations needed for the calculation of IC50s, 
compared to the qPCR-based assay applied for testing PIs and RTIs. It is 
therefore impossible to comment with certainty on the relative potency 
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of INIs against to cell-to-cell infection when compared to cell-free 
infection based on my results. 
 
INIs specifically target the viral integrase enzyme and prevent the 
integration of the proviral DNA into the host cell genome (Hazuda et 
al., 2000). The qPCR assay used to assess the effects of PIs and RTIs on 
cell-to-cell spread specifically detects HIV-1 pol DNA, because INIs act 
downstream of reverse transcription, HIV-1 pol DNA will still be detected 
in co-cultures treated with INIs regardless of a block to integration. This 
assay is consequently not appropriate for assessing the effect of INIs. 
Measuring 2 LTR circles is an indirect way of assessing the effect of INIs 
because an accumulation of episomal DNA is expected when nuclear 
entry and integration are blocked (Butler et al., 2001, Hazuda et al., 
2000). This was verified by performing cell-to-cell and cell-free infections 
in the presence of a serial dilution of Raltegravir. As expected, more 2 
LTR circles were detected in drug treated cultures regardless of the 
mode of infection, in comparison to untreated cultures (Figure 4.6A 
and Figure 4.6B). Significantly more 2 LTR circles were generated for 
cell-to-cell infections compared to cell-free infection in the presence of 
Raltegravir, probably reflecting the greater efficiency and higher 
multiplicity of the former mode of infection (Figure 4.6C). This indirect 
measure could however not be used to plot dose-response curves to 
calculate IC50s because of its limited accuracy.  
 
Alternatively, the ideal direct parameter for assessing the effect of INIs 
is measuring integrated DNA by qPCR assays such as Alu-PCR. Such an 
assay could provide a yes or no answer with regards to the potency of 
INIs against cell-to-cell spread of HIV-1 (which we had already 
obtained through the p24 ELISA based assay). Nevertheless due to the 
heterogenous nature of HIV-1 integration sites within the host genome, 
the available assays for measuring DNA integration lack the precision 
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required for generating reliable dose-response curves for INIs to 
estimate IC50s. A possible approach to overcome this challenge could 
be using a luciferase reporter infectious molecular clone of HIV-1 for 
infection assays and separating pre-labelled donor cell and target cell 
populations by FACS following infection. With this set-up, target cell 
infection could be determined by measuring luciferase activity and 
these data used to plot dose-response curves. Unfortunately the 
biosafety level three laboratories where this study was carried out did 
not have a FACS sorting facility within it, limiting our ability to use this 
approach. The results obtained with the p24 ELISA based assay 
nonetheless agree with the findings of Duncan et al. They found that 
Raltegravir was effective against Macrophage-to-T cell HIV-1 infection 
as well as cell-free infection, with a similar potency for both modes of 
infection (Duncan et.al, 2013). The effects of drugs on the different 
modes of virus dissemination so far appear to be mainly dependent on 
the multiplicity of infection and independent of the cell-type used or 
type of virus tested. This allows us to speculate that INIs, which like PIs 
and EFV potently inhibit HIV-1 infection at very low concentrations of 
the drugs (www.hiv-druginteractions.org, 2011c), are likely to be less 
easily saturated even with high virus multiplicity. As such they should be 
expected to exhibit similar potencies against both cell-to-cell and cell-
free spread of HIV-1, but this remains to be formally tested. 
 
Cell-to-cell transmission takes advantage of interactions between 
immune cells allowing for effective delivery of virus from an infected 
cell to a target cell. Such interactions are likely to occur predominantly 
in lymphoid tissues where there is an abundance of target T cells and in 
anatomical sanctuary sites where close physical contact between cells 
is more likely (Sewald et al., 2012, Murooka et al., 2012).  These sites 
have also been shown to have low penetration of antiretroviral drugs 
(Fletcher et al., 2014). Under these conditions it is feasible to speculate 
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that the high multiplicity of cell-to-cell spread combined with its 
reduced susceptibility to some antiretroviral drugs could indeed 
contribute to viral replication during ART (Fletcher et al., 2014, Sigal et 
al., 2011, Sigal and Baltimore, 2012). Although the studies assessing viral 
replication in treated patients have provided conflicting results till date, 
these studies have mainly relied on measuring plasma viraemia to 
assess ongoing infection (Frenkel et al., 2003, Kieffer et al., 2004, Bailey 
et al., 2006, Dinoso et al., 2009, McMahon et al., 2010, Buzon et al., 
2010, Vallejo et al., 2012, Yilmaz et al., 2010). With the development of 
new techniques enabling intravital imaging of cell-to-cell contacts 
(Sewald et al., 2012, Murooka et al., 2012) and in light of the data 
presented in this thesis, it would be interesting to revisit the question in 
future clinical studies, this time sampling sanctuary sites in treated 
patients. This could help provide a clearer answer for the role of cell-to-
cell spread of HIV-1 in the context of antiretroviral therapy in vivo. 
 
Here were have assessed the effect of single drugs on cell-to-cell 
spread of HIV-1. However for the treatment of HIV infection 
antiretroviral drugs are administered in combination and are effective 
in stopping disease progression. It is therefore interesting to expand this 
study by exploring the impact of ART combinations on both cell-to-cell 
and cell-free spread of HIV-1, a question that is addressed in the next 
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5 Impact of combination ART on cell-to-




The results presented in the previous chapter show that commonly 
used antiretroviral agents (PIs, INIs and RTIs) have variable effects on 
their ability to inhibit cell-to-cell spread of HIV-1 (Titanji et al., 2013). 
While PIs are equally effective at inhibiting both cell-to-cell and cell-
free spread of the virus (Titanji et al., 2013), RTIs especially those of the 
NRTIs class, have a significantly reduced efficiency against HIV-1 cell-
to-cell spread in comparison to cell-free spread (Sigal et al., 2011, 
Duncan et.al, 2013, Titanji et al., 2013). The data also suggest that the 
reduced efficiency of RTIs is likely a consequence of the high 
multiplicity of infection, characteristic of cell-to-cell infection, 
confirming the findings of other groups (Duncan et.al, 2013, Sigal et al., 
2011).  
 
The significance of the variable effects of single agents (monotherapy) 
on cell-to-cell spread of HIV-1 in vitro may appear paradoxical when 
considered in a clinical context.  This is because antiretroviral drugs are 
prescribed in combination and these effectively suppress viral 
replication in treated patients in vivo, improving their survival and 
clinical outcomes (Perelson et al., 1997, Gulick et al., 1997, Walensky et 
al., 2006, Hammer et al., 1997, Arts and Hazuda, 2012). The success of 
cART is mainly attributed to the fact that combining drugs directed at 
two or more distinct molecular targets inhibits viral replication more 
effectively. Also it allows for beneficial interactions (addition and 
synergism) between the single agents in the combination, increasing 
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the overall potency of the drugs (Arts and Hazuda, 2012). This 
enhanced potency raises the barrier for the selection of drug-resistant 
forms of the virus capable of causing treatment failure (Perelson et al., 
1997, Gulick et al., 1997, Arts and Hazuda, 2012).  
 
The concept of drug synergy is complex but generally refers to the 
combination of multiple drugs producing a much greater effect than 
the simple arithmetic summation of the effects of the individual agents 
in the combination (Chou, 2006). Synergy has been clearly 
demonstrated in vitro between the two sub-classes of RTIs (NRTIs and 
NNRTIs) (Feng et al., 2009, Kulkarni et al., 2014, King et al., 2002), within 
the NRTI class (King et al., 2002, Feng et al., 2009), within the NNRTI class 
(Kollmann et al., 2001), and between PIs and RTIs (King et al., 2002, 
Beale and Robinson, 2000, Drusano et al., 1998, Deminie et al., 1996).  
Among the approved antiretroviral drug combinations, RTI-based 
combinations consisting of 2NRTIs + 1NNRTI are the oldest and most 
extensively studied. Clinical trials that have directly compared RTI- 
based combinations to PI-based combinations have reported that 
these combinations are equally effective at suppressing virus 
replication (Daar et al., 2011, DHHS, 2014, WHO, 2013). However, 
regimens that contain PIs although associated with a higher pill 
burden, present a higher barrier to the selection of drug resistance 
mutations (Lathouwers et al., 2011, Soriano et al., 2011).  
 
RTI and PI based combinations therefore constitute the mainstay of first-
line and second-line therapies for HIV-1 infection in current treatment 
guidelines (DHHS, 2014, WHO, 2013). These combinations have been 
assessed for their ability to inhibit HIV-1 cell-free infection. Since most 
RTIs as single agents have reduced potencies against HIV-1 cell-to-cell 
infection, it is interesting to study the effect of RTIs and PIs in 
combination against this mode of infection. In this chapter, the 
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question is specifically addressed using the in vitro qPCR-based cell-to-
cell assay and the median effect principle of Chou and Talalay (Chou 
and Talalay, 1984, Chou, 2006, Chou, 2010) for drug interaction 
analyses. In addition, the effect of drug resistance to PIs and RTIs on 
combination antiretroviral therapy, in the context of cell-to-cell spread 
of HIV-1 is also explored. 
 
During the early years of developing cART, drug interaction studies 
played an important role in identifying synergistic and additive drug 
combinations, most likely to provide the greatest combined inhibitory 
effect on viral replication. These studies were informative in guiding 
early ART clinical trials and also allowed the identification of 
antagonistic non-beneficial combinations to avoid, notably the 
combination of the two NRTIs Zidovudine (AZT) and Stavudine (d4T) (Ho 
and Hitchcock, 1989, Havlir et al., 2000, King et al., 2002). In recent 
years antiretroviral agents have found new uses in the prevention of 
HIV-1 transmission through PreP and recent antiretroviral drug 
interaction studies have been directed at assessing the beneficial 
interactions between potential new drug candidates for use in PreP 
(Gantlett et al., 2007, Schader et al., 2011, Chaowanachan et al., 
2013). This further highlights the value of drug interaction studies in the 
process of drug development. There are several methods for analysing 
interactions (synergy, addition or antagonism) between drugs used in 
combination. One of the most widely used methods is the median 
effect principle of Chou-Talalay (Chou, 2010, Chou and Talalay, 1984). 
This method has been used and validated in several studies of 
antiretroviral drug combinations (Feng et al., 2009, Kulkarni et al., 2014, 
Beale and Robinson, 2000, Kollmann et al., 2001, King et al., 2002, 
Drusano et al., 1998, Deminie et al., 1996). We have adapted this 
method to assess antiretroviral drug combinations for synergy, addition, 
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or antagonism, in the context of cell-to-cell HIV-1 infection and 
antiretroviral drug resistance in this thesis. 
 
The median effect principle is a mathematical modelling system 
derived from the Michaelis-Menten, Hill, Henderson-Hassellbach and 
Scatchard equations in biophysics and biochemistry with basic mass-
action law considerations (Chou, 2010, Chou and Talalay, 1984). A full 
description of the mathematical derivations is beyond the scope of this 
thesis but I will briefly summarise its application in assessing the 
interactions between drugs in a combination. Applying the median 
effect principle to the study of drug combinations, Chou and Talalay 
introduced the combination index, which provides a numerical value 
to assess the combined effect of the drugs under study with regards to 
additive, synergistic or antagonistic interactions (Chou and Talalay, 
1984, Chou, 2006). The computer software Compusyn® allows a simple 
determination of synergy using data derived from in vitro assays. The 
median effect principle is based on the assumption that two or more 
drugs alone or in combination will result in a sigmoidal shaped dose-
response curve. Based on the slope of the curve (m), the 50% inhibitory 
concentration (Dm) can be estimated by transforming the dose-effect 
data to a logarithmic scale. A linear regression of the log-transformed 
data is then fitted to an equation in which the dose inhibitory effect of 
each drug (fa), the slopes of the curves (m) and the IC50s are 
incorporated, to calculate the combination index for each dose 
inhibitory effect (fa). The derived CI for two drugs is calculated using 
the following formula: 
 CI = [(D)1/(D1-fa)1] + [ (D)2/(D1-fa)2] + [α(D)1 (D)2/ (D1-fa)1 (D1-fa)2] 
 
Where (D)1 and (D)2 are the doses of the drugs in  a fixed ratio while 
(D1-fa)1 and (D1-fa)2  are the doses of the individual drugs resulting in 
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the effect  1-fa.andα=1 for mutually non-exclusive drugs (drugs with 
different mechanisms of action). 
 
The combination indices obtained can then be interpreted to 
determine if the interaction between the drugs under study is 
synergistic, additive or antagonistic. Table 5-1 below summarises the 
interpretation of combination index values. To simplify the presentation 
of the results, the following cut-offs for CI values will be applied:  
 CI<0.9 =synergy, CI 0.9-1.2= addition, CI > 1.2= antagonism. 
 
Table 5-1: Combination indices and their interpretation based on those described by Chou-
Talalay (Chou and Talalay, 1984). 
Range of combination index Description Graded symbols 
        <0.1 Very strong synergism         +++++ 
         0.1-0.3 Strong synergism          ++++ 
         0.3-0.7 Synergism           +++ 
         0.7-0.85 Moderate synergism            ++ 
         0.85-0.9 Slight synergism             + 
         0.9-1.2  Additive effect            +/- 
         1.2-1.45 Moderate antagonism            -- 
         1.45-3.3 Antagonism           --- 
         3.3-10 Strong antagonism           ---- 
        >10 Very strong antagonism          ----- 
   
 
In this chapter a panel of PI and RTI-based combinations commonly 
used in current clinical practice, have been tested for their ability to 
inhibit cell-to-cell spread of HIV-1. The results show that members of the 
RTI class, which are ineffective as single agents against this mode of 
spread, regain their potency upon combination with other members of 
this drug class or when combined with the highly effective PIs. Using the 
combination index as a measure of synergy, consistently stronger 
synergies are observed when RTI or PI-based combinations are tested 
on HIV-1 cell-free infection in comparison to cell-to-cell infection. 
Furthermore the results suggest that in the presence of a drug-resistant 
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mutation a virus spreading by a cell-to-cell mechanism can reduce the 
overall synergistic effects of a combination therapy.  
 
 
5.1.1 Specific Objectives 
• To assess the impact of RTI-based drug combinations on cell-to-
cell spread of HIV-1. 
• To assess the impact of PI-based drug combinations on cell-to-
cell spread of HIV-1. 
• To determine the impact of the mode of HIV-1 virus spread (cell-
to-cell vs. cell-free) on the interaction between antiretroviral 
agents in combination. 
• To determine the impact of antiretroviral drug resistance on 
combination antiretroviral therapy, in the context of cell-to-cell 
spread of HIV-1.  
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5.2.1 RTI-based combination therapies effectively 
block cell-to-cell spread of HIV-1 
The data presented in chapter 4 show that the RTIs; Tenofovir (TFV), 
Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) have 
significantly reduced potencies against HIV-1 cell-to-cell infection 
when compared to cell-free infection, with TFV and AZT being the least 
effective drugs. These drugs are not used as monotherapy for the 
treatment of HIV-1 infected patients due to the high risk of selecting for 
drug-resistant variants (Larder et al., 1989, Rooke et al., 1989). When 
administered in combination, RTIs are effective in the treatment of HIV-
1 (Gulick et al., 1997, Hammer et al., 1997, Perelson et al., 1997, 
Walensky et al., 2006). This appears paradoxical given observations on 
their inability to suppress cell-to-cell HIV-1 infection when administered 
as single agents. It was therefore interesting to assess the effect of RTIs 
in combination against HIV-1 cell-to-cell infection. 
 
The median effect analysis based on the median effect principle of 
Chou and Talalay was applied to calculate the combination index (CI) 
and determine whether the interactions between the drugs in the 
combinations tested were; additive, synergistic or antagonistic and to 
compare this between HIV-1 cell-to-cell and cell-free infection. The 
qPCR-based cell-to-cell and cell-free infection assays validated and 
used in the two preceding chapters were applied for the drug 
combination studies. Three dual RTI combinations: AZT+TFV, TFV+EFV 
and AZT+NVP were tested. The drugs were combined in ratios based 
on their individual IC50s, determined in a cell-free infection assay as 
previously described in Chapters 3 and 4. Briefly, virus supernatant 
collected from HIV-1 infected donor cells was used to infect target cells 
in the presence of a serial dilution of the drug being considered. 
Following a 24h incubation, target cell infection was quantified by 
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qPCR detection of HIV-1 pol DNA as previously described and 
expressed as a fold increase relative to the Albumin housekeeping 
gene. These data were used to plot dose-response curves and 
calculate the IC50s in GraphPad Prism® software. Once the IC50s of 
the individual drugs had been determined, the drugs where then 
combined in a fixed dose ratio based on their individual IC50s. Cell-to-
cell and cell-free infections were assessed in the presence of a serial 
dilution of this fixed dose combination by qPCR as previously described 
(see methods section). The inhibitory effect (fa) of each drug alone 
and as part of a combination was calculated and expressed as a 
fraction, representing inhibition of infection in the presence of the drug 
relative to the “no drug” control.  These fa values were inputted in 
Compusyn® to determine CIs for each drug combination tested. Each 
fixed-dose combination experiment was repeated twice the mean CI 
values for 50%, 75%, 90% and 95% inhibition levels obtained from two 
independent experiments and the standard error of the mean (SEM) 
are presented. The steps in the drug combination studies are 
summarised in the schematic below: 
 
 
Figure 5-1: Steps in drug combination studies 
IC50	  of	  individual	  drugs	  in	  the	  combination	  determined	  in	  a	  cell-­‐free	  infection	  assay.	  
Drugs	  combined	  in	  a	  ratio	  based	  	  on	  their	  IC50s	  and	  serially	  diluted	  3-­‐fold.	  
Cell-­‐to-­‐cell	  and	  cell-­‐free	  infection	  assessed	  for	  each	  dilution	  of	  the	  combination	  and	  inhibitory	  effect	  determined	  by	  qPCR.	  
Combination	  indices	  calculated	  using	  Compusyn	  software.	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Combining AZT and TFV, potently inhibited both cell-to-cell and cell-
free HIV-1 infections (Figure 5.2A), however cell-to-cell spread still 
maintained an advantage over cell-free spread. This was striking 
because individually, AZT and TFV are >10-20 fold less effective against 
HIV-1 cell-to-cell infection compared to cell-free infection. The potency 
of this combination against both modes of HIV-1 infection was 
reflected in the combination index values, which were in the range of 
additive to synergistic effects against cell-to-cell infection and 
moderately synergistic effects against cell-free infection (Table 5.2).  
 
AZT and TFV were then combined respectively with non-nucleoside 
reverse transcriptase inhibitors NVP and EFV. NVP as a single agent has 
a 4-fold reduced potency against cell-to-cell spread of HIV-1. 
Combining AZT+NVP potently inhibited both HIV-1 cell-to-cell and cell-
free infections although cell-to-cell infection maintained a replicative 
advantage (Figure 5.2B). This was reflected by combination index 
values indicating an additive effect on cell-to-cell infection and a 
synergistic effect on cell-free infection (Table 5.3). EFV as a single agent 
was the only RTI that showed the same potency against both cell-free 
and cell-to-cell modes of viral infection. When combined with the less 
effective TFV, the combination effectively inhibited both cell-to-cell 
and cell-free infection (Figure 5.1C) with combined moderate to 
strongly synergistic effects against both modes of viral infection (Table 
5.4). 
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Figure 5-2: RTI-based combinations effectively inhibit both cell-to-cell and cell-free spread of 
HIV-1. Cell-to-cell and cell-free infections were assessed in the presence of a serial dilution of a 
dual RTI combination (A) AZT+TFV, (B) AZT+NVP and (C) TFV+EFV. The drugs were combined in a 
ratio based on their IC50s determined from a cell-free infection assay. Infection was measured 
by the number of HIV-1 pol DNA transcripts generated at each dilution of the combination and 
expressed as a fraction of the no drug control. The data were used to plot the dose-response 
curves, which are displayed on the graphs above; one representative from 2 independent 
experiments is shown. The error bars represent the standard deviation of the mean. The bold 
lines represent the non-linear regression curve-fit and dotted lines represent actual data points. 
The curves were fitted using GraphPad Prism curve fitting software. 
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Table 5-2: Combination indices for the combination of Zidovudine (AZT)+Tenofovir (TFV). The 
mean and standard error  (SEM) (in parenthesis) obtained from two independent experiments 
are shown . 
Mode of Infection Combination 
(ratio=1:1) 
                   Combination index (CI)  Effect 
 50  75  90  95 
Cell-Cell AZT+TFV 0.9(0.1) 0.85(0.1) 0.82(0.05) 0.74(0.12) Additive/ 
synergistic 
Cell-Free AZT+TFV 0.41(0.06) 0.39(0.03) 0.42(0.1) 0.45(0.04) Synergistic 
 
 
Table 5-3: Combination indices for the combination of Zidovudine (AZT) + Nevirapine (NVP). 
The mean and standard error of the mean (in parenthesis) obtained from two independent 





                             Combination index (CI)          Effect 
50  75 90 95 
Cell-Cell AZT+NVP 0.95(0.05) 1.05(0.05) 1.1(0.13) 1.1(0.1) Additive 




Table 5-4:  Combination indices for the combination of Tenofovir (TFV) + Efavirenz (EFV). The 
mean and standard error of the mean (in parenthesis) obtained from two independent 





                               Combination index (CI)          Effect 
50 75 90 95 
Cell-Cell TFV+EFV 0.59(0.05) 0.46(0.07) 0.36(0.05) 0.35(0.02) Synergistic 
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5.2.2 PI-based combinations effectively block cell-to-
cell spread of HIV-1 
The results of chapter 4 showed that in contrast to RTIs, PIs are equally 
potent against HIV-1 cell-to-cell and cell-free infection. In the present 
study it was therefore interesting to explore the effects of combining PIs 
with less effective RTIs against cell-free and cell-to-cell modes of virus 
infection. Also, PIs are important components of second-line therapies, 
which are commonly recommended when first-line RTI-based 
combinations fail. The PI LPV was tested in combination with the NRTI 
TFV and in combination with the NNRTI NVP.  Both combinations 
(LPV+TFV and LPV+NVP) potently inhibited HIV-1 cell-to-cell and cell-
free infection (Figure 5.3). The combination of LPV+TFV was strongly 
synergistic for both modes of virus infection (Table 5.5) while the 
combination of LPV+NVP showed additive to synergistic effects for cell-
to-cell infection and moderate synergy for cell-free infection (Table 
5.6). 
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 





Figure 5-3: PI-based combinations effectively inhibit both cell-to-cell and cell-free spread of 
HIV-1. Cell-to-cell and cell-free infections were assessed in the presence of a serial dilution of a 
dual combination of a PI+RTI combination (A) LPV+TFV and (B) LPV+NVP. The drugs were 
combined in a ratio based on their IC50s determined from a cell-free infection assay. Infection 
was measured by the number of HIV-1 pol DNA transcripts generated at each dilution of the 
combination and expressed as a fraction of the no drug control. The data were used to plot 
the dose-response curves, which are displayed on the graphs above; a representative from 2 
independent experiments is shown. The error bars represent the standard deviation of the 
mean. The bold lines represent the non-linear regression curve-fit and dotted lines represent 
actual data points. The curves were fitted using GraphPad Prism curve fitting software. 
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Table 5-5: Combination indices for the combination of Lopinavir (LPV) + Tenofovir (TFV). The 
mean and standard error of the mean (in parenthesis) obtained from two independent 





                              Combination index (CI)     Effect 
50 75 90 95 
Cell-Cell LPV+TFV 0.03(0.06) 0.1(0.01) 0.12(0.04) 0.36(0.2) Synergistic 
Cell-Free LPV+TFV 0.02(0.01) 0.06(0.01) 0.15(0.02) 0.4(0.13) Synergistic 
 
 
Table 5-6: Combination indices for the combination of Lopinavir (LPV) + Nevirapine (NVP). The 
mean and standard error of the mean (in parenthesis) obtained from two independent 





                              Combination index (CI) Effect 
50 75 90 95 
Cell-Cell LPV+NVP 1.1(0.07) 0.92(0.2) 0.74(0.24) 0.71(0.26) Additive/ 
Synergistic 
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5.2.3 Cell-to-cell spread of drug-resistant HIV-1 may 
compromise combination ART 
The results presented so far show that PI and RTI-based combinations 
effectively inhibit HIV-1 cell-to-cell and cell-free infection, albeit with 
relatively weaker synergistic interactions against cell-to-cell infection 
compared to cell-free infection. The next question posed was whether 
drug-resistant viruses spreading by a cell-to-cell mechanism would 
affect the potency of combination therapies in fully suppressing HIV-1 
replication. To answer this question, cell-to-cell spread of a PI drug-
resistant virus HIV-1DM was tested in the presence of PI-based 
combinations and cell-to-cell spread of RTI mutants HIV-1K103N and HIV-
1M184V tested in the presence of RTI-based combinations. This was 
compared to cell-to-cell spread of HIV-1WT in the presence of the same 
drug combinations. The combination indices for the different 
combinations tested with these viruses were determined using 
Compusyn® as previously described for HIV-1DM and HIV-1K103N. The co-
culture assays were set-up in the presence of a serial dilution of the 
fixed-dose combination of the drugs being tested as described earlier. 
 
 Cell-to-cell spread of HIV-1DM was assessed in the presence of LPV+TFV. 
The HIV-1DM mutant has an A431V mutation in Gag and a V82A 
mutation in Protease, making it 14-fold less susceptible to inhibition by 
LPV when compared to wild-type HIV-1 (HIV-1WT). The results showed a 
replicative advantage of HIV-1DM over HIV-1WT in the presence of 
LPV+TFV (Figure 5.4A). This was reflected by an increase in CI values, 
shifting the combined effect of the drugs from strongly synergistic 
(observed with HIV-1WT (CI<0.3) to a moderately synergistic range 
(Table 5.7). Cell-to-cell spread of HIV-1DM was then tested in the 
presence of a triple combination of drugs, by adding EFV to the dual 
combination (LPV+TFV+EFV). In the presence of this triple combination, 
cell-to-cell spread of HIV-1DM was effectively suppressed to the same 
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extent as cell-to-cell spread of HIV-1WT (Figure 5.4C and D). 
Unfortunately, it was not possible to determine CIs for the triple 
combination because the dose-effect curves did not meet the criteria 
required for reliable CI estimates in Compusyn®. Due to nearly 
complete suppression of viral replication by the triple combination, the 
curves generated had R-squared values (goodness of fit, following 
non-linear regression) that were lower than the 0.9 which is required for 
accurate determination of combination indices. 
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Figure 5-4: Cell-to-cell spread of a PI resistance mutant compared to wild-type virus in the 
presence of combination antiretroviral therapy (A) and (B) cell-to-cell spread of HIV-1DM was 
assessed in the presence of a serial dilution of a fixed dose combination of LPV+TFV and 
compared to cell-to-cell spread of HIV-1WT with the same combination. The error bars represent 
the standard deviation of the mean. HIV-1DM has a replicative advantage over HIV-1WT in the 
presence of this dual combination. In (C) and (D) a triple combination of LPV+ 3TC+ TFV 
potently inhibits both cell-to-cell spread of HIV-1DM and HIV-1WT. The error bars represent the 
standard deviation and a representative of two independent experiments is shown. The bold 
lines represent the non-linear regression curve-fit and dotted lines represent actual data points. 
The curves were fitted using GraphPad Prism curve fitting software. UT=untreated control. 
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Table 5-7: Combination indices for the combination of Lopinavir (LPV) + Tenofovir (TFV) tested 
against cell-to-cell spread of a PI resistant mutant compared to wild-type virus. The mean and 





                      Combination index (CI) 
   Effect 
50 75 90 95 
HIV-1WT LPV+TFV 0.03(0.06) 0.1(0.01) 0.12(0.04) 0.36(0.2) Synergistic 
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The NNRTI drug-resistant mutant HIV-1K103N was also tested in a similar 
fashion.  Cell-to-cell spread of this virus was assessed in the presence of 
TFV+EFV. The K103N mutation in RT renders the virus >650-fold more 
resistant to inhibition by EFV in comparison to HIV-1WT. This combination, 
which efficiently suppressed cell-to-cell spread of HIV-1WT, was less 
effective at suppressing cell-to-cell spread of HIV-1K103N (Figure 5.5A 
and B). The reduced efficiency of the combination on the drug-
resistant virus was again reflected by an increase in the combination 
index, shifting the effect from a moderately synergistic range for HIV-1WT 
to a mildly synergistic to additive range for the HIV-1K103N (Table 5.8).   
 
A third drug; 3TC was then added to TFV+EFV and cell-to-cell spread of 
HIV-1K103N and HIV-1WT tested in the presence of this triple combination 
(TFV+EFV+3TC). The triple combination effectively suppressed cell-to-
cell spread of both the wild type and mutant virus (Figure 5.5 C and D), 
although HIV-1K103N appeared to maintain a small replicative 
advantage over the wild-type virus. The efficiency of the triple 
combination was reflected by a combined strongly synergistic 
interaction between the drugs in the combination against cell-to-cell 
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Figure 5-5: Cell-to-cell spread of a NNRTI resistance mutant compared to wild-type virus in the 
presence of combination antiretroviral therapy- (A) and (B) cell-to-cell spread of HIV-1K103N was 
assessed in the presence of a serial dilution of a fixed dose combination of EFV+TFV and 
compared to cell-to-cell spread of HIV-1WT with the same combination. The error bars represent 
the standard deviation of the mean. HIV-1K103N had a replicative advantage over HIV-1WT in the 
presence of this dual combination. In (C) and (D) a triple combination of EFV+ 3TC+ TFV 
potently inhibits both cell-to-cell spread of HIV-1K103N and HIV-1WT., though HIV-1K103N retains a 
small replicative advantage over HIV-1WT. The error bars represent the standard deviation of 
the mean and a representative from two independent experiments is shown. The bold lines 
represent the non-linear regression curve-fit and dotted lines represent actual data points. The 
curves were fitted using GraphPad Prism curve fitting software. UT=Untreated controls. 
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Table 5-8: Combination indices for the combination of Tenofovir (TFV) + Efavirenz (EFV). The 
mean and standard error of the mean (in parenthesis) obtained from two independent 




                        Combination index (CI) 
Effect 
50 75 90 95 
HIV-1WT TFV+EFV 0.69(0.05) 0.46(0.07) 0.36(0.05) 0.35(0.02) Synergistic 





Table 5-9: Combination indices for the combination of Tenofovir (TFV) + Efavirenz (EFV) + 
Lamivudine (3TC). The mean and standard error of the mean (in parenthesis) obtained from 
two independent experiments are shown. 
Virus 
Combination   
(1000:10:1) 
                           Combination index (CI) 
Effect 
50 75 90 95 
HIV-1WT TFV+3TC+EFV 0.08(0.03) 0.09(0.01) 0.12(0.04) 0.18(0.01) Synergistic 
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Finally, cell-to-cell spread of the NRTI drug-resistant virus HIV-1M184V was 
tested. The M184V mutation in RT mutation was particularly interesting 
for this study because while it confers a 120-fold resistance to inhibition 
by 3TC compared to wild-type virus in the drug susceptibility assay (see 
Chapter 3), this mutation is also well described for increasing the 
susceptibility of the virus to other NRTIs, notably TFV and AZT (Naeger et 
al., 2001, White et al., 2002, Diallo et al., 2003, Wolf et al., 2003). This 
feature was confirmed in the cell-free drug susceptibility assay (see 
Chapter 3). It was interesting to contemplate whether the increased 
susceptibility of HIV-1M184V to AZT would remain evident when infection 
was mediated by cell-to-cell mechanism of dissemination. This was 
even more interesting considering that cell-to-cell spread HIV-1WT is 
highly impervious to inhibition by AZT. To answer this question, cell-to-
cell spread of the mutant virus was directly compared to that of the 
wild-type virus in the presence of AZT. While AZT was unable to fully 
suppress cell-to-cell spread of HIV-1WT, the drug effectively inhibited 
cell-to-cell spread of HIV-1M184V, (Figure 5.6A). Cell-to-cell spread of this 
resistant mutant was then tested with drug combinations. With the 
combination of 3TC+AZT, both HIV-1WT and HIV-1M184V cell-to-cell 
infections were effectively inhibited although HIV-1M184V showed a 
replication advantage albeit a modest one in the presence of this 
combination in comparison to HIV-1WT (Figure 5.6B). The triple RTI 
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Figure 5-6: Cell-to-cell spread of NRTI mutant HIV-1M184V compared to cell-to-cell spread of HIV-
1WT in the presence of RTI mono (A), dual (B), and triple therapy(C). (A) AZT effectively inhibits 
cell-to-cell spread of HIV-1M184V, though it is ineffective against cell-to-cell spread of HIV-1WT. (B) 
In the presence of a serial dilution of a fixed dose combination of AZT+3TC cell-to-cell spread of 
HIV-1WT and HIV-1M184V are effectively blocked though HIV-1M184V has a replicative advantage 
over wild-type virus. (C) Triple combination of AZT+3TC+ EFV potently inhibits cell-to-cell spread 
of both HIV-1WT and HIV-1M184V. The error bars represent the standard deviation of the mean 
and a representative from two independent experiments is shown. The bold lines represent the 
non-linear regression curve-fit and dotted lines represent actual data points. The curves were 
fitted using GraphPad Prism curve fitting software. 
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The observations from this thesis and other studies on the variable 
potencies of commonly used antiretroviral drugs against HIV-1 cell-to-
cell infection (Sigal et al., 2011, Duncan et.al, 2013, Titanji et al., 2013), 
have sparked an interesting debate on the true role of this mode of 
infection in viral pathogenesis and disease progression in vivo. We have 
shown that while PIs and INIs are equally effective at suppressing both 
cell-free and cell-to-cell modes of infection (Chapter 4), members of 
the widely used RTI class, which make up the backbone for most 
combination ART, have greatly reduced abilities to inhibit the latter 
mode of HIV-1 infection (Sigal et al., 2011, Duncan et.al, 2013, Titanji et 
al., 2013) This presents an interesting conundrum because, treating HIV-
1 infected patients in the clinic with combinations of these seemingly 
“ineffective” drugs results in full suppression of virus replication and 
arrest of disease progression (Eron et al., 1995, Autran et al., 1997, 
Gulick et al., 1997, Lederman et al., 1998, Arts and Hazuda, 2012).  
 
Some in the field have interpreted this as an indication that HIV-1 cell-
to-cell infection may not be an important phenomenon in vivo, with 
cell-free infection which is susceptible to suppression by all currently 
approved RTIs, being likely predominant. In the present chapter this 
question is specifically addressed by testing RTI and PI-based 
combinations commonly prescribed in the clinic, on their ability to 
inhibit cell-to-cell spread of HIV-1 in comparison to cell-free spread. The 
role of drug resistance on the efficacy of cART in the context of cell-to-
cell virus infection is also explored. The results show that cART  potently 
inhibits both cell-to-cell and cell-free spread of HIV-1. This is most likely 
the result of the additive to synergistic interactions between 
antiretroviral drugs in combination being able to overcome the high 
multiplicity of infection that is a characteristic feature of cell-to-cell 
infection. Furthermore, consistently stronger combined synergistic or 
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additive effects are observed with the combinations tested when cell-
free infection is compared to cell-to-cell infection. Finally, drug-resistant 
viruses are shown to have a replicative advantage over wild-type virus 
when spreading by a cell-to-cell mechanism, in the presence of 
“inadequate” combination therapies. While completing the 
experiments for my thesis, Agosto et al. published a similar study looking 
at the impact of NRTI-based combination therapies on cell-to-cell 
spread of HIV-1 (Agosto et al., 2014). Although they applied a different 
method to assess the inhibitory potential of drugs in combination on 
the different modes of HIV-1 infection, their results are similar to the 
findings presented here. The present study has however been 
expanded by testing more combinations including PIs and NNRTIs and 
also testing a panel of PI and RTI drug-resistant mutants, in order to 
provide a more complete picture. 
 
 TFV and AZT are the two members of the RTI drug class, which have 
consistently demonstrated significantly reduced potency against HIV-1 
cell-to-cell infection in vitro when compared to cell-free infection 
(Agosto et al., 2014, Titanji et al., 2013, Duncan et.al, 2013, Sigal et al., 
2011). The studies published so far have reported between 20 to 1000-
fold decrease in susceptibility of this mode of virus infection to inhibition 
by TFV or AZT (Sigal et al., 2011, Duncan et.al, 2013, Titanji et al., 2013, 
Agosto et al., 2014). The effect of combining these two agents against 
HIV-1 cell-to-cell infection was investigated. Remarkably, when 
combined, both drugs were capable of potently inhibiting HIV-1 cell-
to-cell infection almost as effectively as cell-free infection (Figure 5.2A). 
High MOI of infection is a key feature of cell-to-cell spread of HIV-1, 
which has been clearly demonstrated in vitro (Del Portillo et al., 2011, 
Russell et al., 2013, Zhong et al., 2013) and supported by some in vivo 
observations (Gratton et al., 2000, Jung et al., 2002). This attribute of 
cell-to-cell HIV-1 infection has been implicated as the primary driver of 
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ongoing cell-to-cell infection observed with some antiretroviral drugs in 
vitro, notably RTIs (Sigal et al., 2011, Duncan et.al, 2013, Titanji et al., 
2013, Agosto et al., 2014). The synergistic interaction between TFV and 
AZT in combination, as determined by CI values (Table 5.2) explains the 
potency of this combination in blocking HIV-1 cell-to-cell spread. If we 
consider that cell-to-cell spread is 20 to 1000-fold less susceptible to TFV 
and AZT when these drugs are used as single agents (Duncan et.al, 
2013, Titanji et al., 2013, Agosto et al., 2014, Sigal et al., 2011), an 
additive effect from combining both drugs will only double their effect 
and as such be likely insufficient to overcome cell-to-cell infection. 
Synergy however by definition produces an effect much greater than 
the simple arithmetic sum of the effect of the agents in combination 
and in this case, this combined effect is strong enough to overcome 
cell-to-cell spread of HIV-1. It is important to note nevertheless that cell-
to-cell infection still maintains a slight advantage over cell-free 
infection, even in the presence of the combination, with stronger 
synergistic/additive effects observed between AZT and TFV for cell-free 
infection compared to cell-to-cell infection (Table 5.2).  
 
AZT and TFV were also tested in combination with NNRTIs. As single 
agents, cell-to-cell spread of HIV-1WT was 4-fold less susceptible to 
inhibition by NVP, however EFV like the PIs and INIs was equally potent 
against both cell-to-cell and cell-free spread of the virus. A 
combination of AZT+NVP and TFV+EFV strongly inhibited both cell-to-
cell and cell-free modes of infection (Figure 5.2B and C) with 
combined additive to synergistic effects (Table 5.3 and 5.4). Again, as 
observed with the AZT+TFV combination, the combined effect of the 
drugs was greater when the combinations were tested against cell-free 
infection in comparison to cell-to-cell infection. These observations 
show for the first time the effects of combining NRTIs + NNRTIs on HIV-1 
cell-to-cell infection. They also confirm the findings by Agosto et al. 
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who showed that combining NRTIs leads to increased inhibitory 
potentials and enhanced potencies sufficient to overcome the high 
multiplicity of cell-to-cell infection (Agosto et al., 2014). They used the 
instantaneous inhibitory potential (IIP) as a parameter to assess the 
ability of drugs as single agents or in combination to inhibit virus 
dissemination. Shen et al. first defined this parameter as a measure of 
antiviral activity (Shen et al., 2008, Shen et al., 2009). The IIP directly 
measures the degree of inhibition by a given antiviral drug by taking 
into consideration the slope of its dose-response curve (Shen et al., 
2008, Shen et al., 2009). Although it has been purported as a more 
accurate measure of antiviral activity, and in general correlates with 
clinical outcomes, its advantage over older methods is still debated 
(Henrich et al., 2010). Also there is limited experience with using this 
parameter as a method for assessing drug interactions in combination 
studies (Agosto et al., 2014). It is for this reason that the more extensively 
used median effect analysis and combination indices, validated in 
several combination studies of antiretroviral drugs was preferred (Chou 
and Talalay, 1984, Chou, 2006, Chou, 2010, Feng et al., 2009, Kulkarni et 
al., 2014, Kollmann et al., 2001, Beale and Robinson, 2000, Drusano et 
al., 1998, Deminie et al., 1996).  
 
Synergy between drugs of the NRTI class and between NRTIs and 
NNRTIs has been extensively studied and well described in cell-free 
infection models in vitro (Feng et al., 2009, Kulkarni et al., 2014, King et 
al., 2002). This is verified in vivo by the efficiency of RTI-based 
combinations for the treatment of HIV-1 infected patients (Perelson et 
al., 1997, Gulick et al., 1997, Gulick et al., 2004, Staszewski et al., 1999, 
van Leth et al., 2004, Arts and Hazuda, 2012). NRTIs are synthetic 
analogues of naturally occurring dNTPs but they lack a 3’-Hydroxyl 
group. Their incorporation into the nascent viral DNA during the process 
of reverse transcription, leads to premature chain termination and as 
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such inhibits viral replication. Several mechanisms have been proposed 
to account for the synergy observed with combinations of RTIs. The 
combination of TFV+3TC, a popular backbone for many first-line cART 
regimens, increases the intracellular phosphorylation of both drugs and 
the available active metabolite of the drugs, enhancing the ability of 
the combination to out compete naturally occurring nucleotides 
(Borroto-Esoda et al., 2006). Although this enhanced phosphorylation 
has not been specifically investigated for other NRTI combination pairs, 
it is possible that this mechanism could be a contributing factor to the 
synergistic effects observed in this study with the combination of 
AZT+TFV. In the context of cell-to-cell spread, having more active 
metabolite to counter the incoming flux of infectious virions tips the 
scale in favour of the drug, allowing effective inhibition of cell-to-cell 
infection.  
 
NNRTIs are non-competitive inhibitors, which bind to a hydrophobic 
pocket near the RT binding site and prevent movement of the protein 
domains of RT, which are required for effective reverse transcription, 
hence blocking viral replication (de Bethune, 2010). When NNRTIs are 
combined with NRTIs, the effects of the combination are additive to 
synergistic.  In these combinations, the presence of NNRTIs has been 
shown to diminish the binding of ATP (Odriozola et al., 2003, Radzio and 
Sluis-Cremer, 2008), which is essential for pyrophosphorylysis, a process 
by which incorporated NRTIs are excised from the newly synthesised 
virus DNA by the HIV-1 RT, reversing chain termination and allowing 
reverse transcription to proceed (Arion et al., 1998, Meyer et al., 1998, 
Meyer et al., 1999, Ray et al., 2003). By so doing, NNRTIs enhance chain 
termination by the NRTI, bolstering its inhibitory potential (Odriozola et 
al., 2003, Radzio and Sluis-Cremer, 2008). Also RNAse H activity is 
enhanced in the presence of NNRTIs, effectively reducing the window 
of opportunity for NRTI excision by pyrophosphorylysis (Radzio and Sluis-
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 




Cremer, 2008). Furthermore the formation of a stable complex 
mediated by NNRTI binding prolongs and promotes NRTI chain 
termination (Feng et al., 2009). All of these mechanisms collectively, 
likely account for the synergistic interactions between NRTIs and NNRTIs 
observed for both cell-to-cell and cell-free HIV-1 infection. It is worth 
noting that while the combination of the NRTI with EFV was strongly to 
moderately synergistic, combination of the NRTI with NVP only showed 
weakly synergistic to additive effects on both modes of virus infection. 
EFV has been shown in a large US and European cohort study of 
>20,000 patients to be a better NNRTI option than NVP for first-line 
treatment, in patients initiating cART for the first time (Collaboration, 
2012). These findings have been confirmed in smaller cohort studies 
and clinical trials in sub-Saharan Africa and Asia (Nachega et al., 2008, 
Bock et al., 2013, Bonnet et al., 2013, Pillay et al., 2013). Regimens 
containing EFV were found to be associated with fewer AIDS–related 
opportunistic infections, improved survival and lower rates of treatment 
failure than NVP containing regimens (Collaboration, 2012). The 
reasons for this are not fully understood, however in light of our 
observations it is tempting to cautiously suggest that the stronger 
synergies seen when EFV is combined with NRTIs in comparison to NVP 
against both cell-to-cell and cell-free HIV-1 infection, may be a 
contributing factor to its superiority in a clinical context. This will of 
course be in addition to other factors such as the higher toxicities 
associated with NVP regimens, which make interruptions of such 
regimens and hence decreased efficiency more likely. 
 
In chapter 4 we presented a detailed study of the impact of PIs on cell-
to-cell spread of HIV-1. This antiretroviral drug class is highly effective 
against both cell-to-cell and cell-free modes of infection even with 
high virus MOIs. The FDA approval of highly potent PIs in the mid-
nineties completely revolutionised antiretroviral therapy (Craig et al., 
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1991, Kempf et al., 1995, Deeks et al., 1997, Wensing et al., 2010). 
Today, PIs in combination with RTIs are part of recommended initial 
treatments for patients starting cART and more importantly, these drugs 
are the mainstay of salvage therapies used for patients who fail 
treatment on first-line therapies (WHO, 2013, DHHS, 2014). Also, this is the 
only drug class, which to date has been used successfully as 
monotherapy for the treatment of HIV-1 in clinical trials (Arribas et al., 
2009, Arribas et al., 2010, Clumeck et al., 2011, Valantin et al., 2012, 
Katlama et al., 2010). Despite the importance and great success of PIs, 
the precise steps in the virus life cycle affected by these agents under 
clinical conditions are yet to be clearly defined. In vitro studies have 
now identified that PIs target multiple steps in the virus replication cycle 
and this may explain their potency against HIV-1 infection and the high 
barrier that they present to the selection of drug-resistant viruses (Rabi 
et al., 2013). PIs inhibit the cleavage of virus precursor polyproteins into 
functional subunits required for maturation of the virus (Craig et al., 
1991, Kempf et al., 1995, Deeks et al., 1997, Muller et al., 2009, Wensing 
et al., 2010). Virus maturation is important for early post entry steps of 
the virus replication cycle, including uncoating and reverse 
transcription (Lori et al., 1988, Kawamura et al., 1997, Muller et al., 
2009). In the presence of PIs, recent findings show that interactions 
between uncleaved Gag and the cytoplasmic tail of Env present a 
barrier to effective viral entry. PIs therefore exert their inhibitory effects 
in vitro by inhibiting viral entry as well as post-entry steps of viral 
replication to varying degrees.  
 
When the effect of combining PIs to RTIs was assessed, these 
combinations displayed additive to synergistic effects on both cell-free 
and cell-to-cell virus infection. Strong synergy was observed for 
combinations of PIs + NRTIs (LPV+TFV) (Table 5.5) and additive to mildly 
synergistic effects were observed with PI+NNRTI combinations 
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(LPV+NVP) (Table 5.6). These results confirm findings from previous 
studies, which have demonstrated synergy between PIs and NRTIs for 
cell-free infections (Drusano et al., 1998, King et al., 2002, De Meyer et 
al., 2005) and show for the first time this effect on HIV-1 cell-to-cell 
infection. PI and NNRTI are not usually combined in cART regimens and 
were only tested here for the sake of completeness. It is however 
interesting to observe that again weaker synergies are seen between 
NVP and PIs, as is the case when NVP is combined with NRTIs, discussed 
earlier. The multiple effects of PIs on several steps of viral replication 
probably explain the strong synergy observed when these drugs are 
combined with NRTIs. 
 
It is tempting to speculate on a molecular mechanism for the reduced 
potency of NVP compared to EFV based combinations against cell-to-
cell infection noted in this study. Especially since this is a feature not 
seen with in vitro cell-free infection systems. Efavirenz is a second 
generation NNRTI well recognised for its improved potency against HIV-
1 RT compared to the first generation NNRTIs (Nevirapine and 
Delaviridine). Several studies on the interaction between NNRTIs and 
HIV-1 RT have shown that EFV has a greater affinity for HIV-1-RT 
compared to NVP and DLV (Kd NVP= 1550 +/- 441, Kd EFV= 0.63+/-0.34) 
(Geitmann et al., 2006, Sluis-Cremer and Tachedjian, 2008). The 
presence of hydrogen bonding between domains of the EFV molecule 
and HIV-1RT not seen with the HIV-1RT/NVP and HIV-1RT/DLV 
complexes contribute to the enhanced binding affinity of EFV (Nunrium 
et al., 2005). The effect of these differences in binding affinity on 
potency and ability to block RT may not be immediately obvious when 
these drugs are tested against cell-free HIV-1 infection. However when 
cell-to-cell infection is considered, the greater efficiency of EFV 
compared to NVP becomes more apparent due to the high MOI of this 
mode of infection. Combinations with EFV would likely be better at 
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binding and inhibiting HIV-1RT from a pool of incoming infectious virions 
compared to combinations containing NVP that binds RT with a lower 
affinity. The observations made with drug combinations are in line with 
the results presented in chapter 4, which show that while NVP is 4-fold 
less efficient against cell-to-cell infection compared to cell-free 
infection, EFV like PIs and INIs is equally potent against both cell-to-cell 
and cell-free HIV-1 infection. In addition to its high affinity for HIV-1 RT, 
EFV has the unique attribute within the NNRTI class of enhancing the 
processing of Gag and Gag-Pol polyproteins (Tachedjian et al., 2005, 
Figueiredo et al., 2006).  This enhanced processing of viral polyproteins 
by EFV is associated with a decrease in the production of infectious 
virus particles (Tachedjian et al., 2005, Figueiredo et al., 2006).  The 
binding of EFV to HIV-1 RT that is embedded in Gag-Pol is thought to 
promote the interaction between individual Gag-Pol polyproteins 
inducing the premature activation of the viral Protease and 
subsequent cleavage of the precursor polyproteins.  This effectively 
reduces the amount of full-length viral proteins available for virus 
assembly and as a consequence the number of infectious virions 
produced (Tachedjian et al., 2005, Figueiredo et al., 2006).  This 
additional function of EFV possibly contributes to reducing the MOI and 
this may provide an additional explanation for its superior effects over 
NVP in the context of HIV-1 cell-to-cell infection. 
 
Having established the efficacy of RTI and PI-based combinations 
against cell-to-cell and cell-free infection, we proceeded to 
investigate the impact of cell-to-cell spread of HIV-1 drug-resistant 
viruses on combination therapy. The development of drug resistance is 
one of the most common causes of treatment failure in HIV-1 infected 
patients. As antiretroviral coverage becomes more widespread, 
clinicians have to contend with rising levels of drug resistance in 
treated populations and the threat of transmitted drug resistance 
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continues to grow. Cell-to-cell spread of a PI drug-resistant mutant HIV-
1DM, as well as two RTI resistance mutants HIV-1K103N andHIV-1M184V was 
tested in the presence of PI and RTI-based combinations. The PI mutant 
HIV-1DM displayed a replicative advantage over the wild-type virus HIV-
1WT when spreading by a cell-to-cell mechanism in the presence of a 
combination of LPV+TFV.  We had already shown that this combination 
was strongly synergistic and effective at inhibiting cell-to-cell spread of 
HIV-1WT, however this synergy was reduced to moderate levels against 
HIV-1DM, evidenced by an increase in CI values (Table 5.7). This was 
expected because the virus is resistant to LPV, which is potent against 
cell-to-cell spread of HIV-1, leaving only TFV that is a poor inhibitor of 
cell-to-cell infection to counter the effective spread of the virus. When 
a third drug EFV was added to the combination, the triple combination 
effectively inhibited both HIV-1WT and HIV-1DM cell-to-cell spread to the 
same degree. The HIV-1DM confers a 14-fold resistance to LPV in the 
drug susceptibility assay (see Chapter 3).  
 
These results suggest that when combined with a drug such as TFV, 
which is ineffective in monotherapy against cell-to-cell spread, the 
drug-resistant virus is able to overcome the combined effects of the 
two drugs and still replicate efficiently when using a cell-to-cell mode 
of infection. EFV is very potent against cell-to-cell spread of HIV-1 unlike 
TFV, also the accumulation of multiple major and minor resistance 
mutations in Protease is usually required in a clinical context to 
compromise PI-based regimens (Molla et al., 1996). The PI mutant that 
has been tested in this thesis only carries two resistance mutations and 
therefore likely doesn’t exhibit a resistance phenotype strong enough 
to compromise a triple combination regimen even with the virus 
spreading by the highly efficient cell-to-cell mechanism. 
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Similar observations were made for the RTI resistant mutants. HIV-1K103N 
had a replicative advantage over HIV-1WT in the presence of RTI-based 
dual and triple combinations TFV+EFV and TFV+EFV+3TC respectively. 
HIV-1K103N is 650-fold less susceptible to EFV when compared to wild 
type virus. The presence of this single point mutation is sufficient to 
compromise NNRTI-regimens containing EFV (Bacheler et al., 2001). 
Both TFV and 3TC have reduced potencies in their ability to inhibit cell-
to-cell infections as has been previously demonstrated. A resistant virus 
such as HIV-1K103N with a strong resistance phenotype, gains an added 
advantage in its ability to compromise an antiretroviral combination by 
spreading through a cell-to-cell mechanism, especially when a priori 
some of the components of the combination have known reduced 
potencies against cell-to-cell infection.  
 
Mutations conferring resistance to one drug can sometimes cause 
hyper susceptibility to a different compound or re-sensitise strains that 
were resistant to that drug. The HIV-1 M184V mutation in RT is an 
example of such a mutation. This mutation is usually selected in 
patients following treatment with 3TC (Diallo et al., 2003) and the 
presence of this mutation increases the susceptibility of the virus to  
other NRTIs including AZT and TFV (Boucher et al., 1993, Tisdale et al., 
1993, Larder et al., 1995, Wainberg et al., 1999, Hertogs et al., 2000, 
Shulman et al., 2001). We hypothesised that this increased susceptibility 
to AZT and TFV, two drugs which when applied as monotherapy are 
highly inefficient against cell-to-cell infection, would restore the ability 
of these drugs to inhibit cell-to-cell spread of HIV-1M184V. To test this 
hypothesis cell-to-cell spread of HIV-1M184V was tested in the presence 
of the AZT alone (Figure 5.6A) and in the presence of two 
combinations: 3TC+AZT and 3TC+AZT+EFV in comparison to cell-to-cell 
spread of HIV-1WT. The results show that while the potency of AZT 
against cell-to-cell spread was restored for HIV-1M184V, cell-to-cell 
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spread of HIV-1WT was not fully inhibited by this same drug. This confirms 
that the increased susceptibility to AZT mediated by the presence of 
the M184V mutation remains operational during highly efficient cell-to-
cell mode of infection. The M184V mutation has been shown to reduce 
the selective excision of Zidovudine 5’ monophosphate (AZTMP) by the 
RT of HIV-1 (Boyer et al., 2001). This mutation alters the polymerase 
active site in a way that specifically interferes with ATP mediated 
excision of the nucleoside analogue from the end of the primer strand 
(Boyer et al., 2001).  In the presence of AZT and in the context of cell-to-
cell spread this increased incorporation of AZTMP may allow more 
efficient inhibition of HIV-1M184V compared to HIV-1WT by tipping the 
scale in favour of the drug.  
 
When AZT was tested in combination with 3TC, HIV-1M184V displayed a 
slight replicative advantage over HIV-1WT during cell-to-cell spread. 
Both viruses were however effectively suppressed by the triple 
combination of 3TC+AZT+EFV. HIV-1M184V is 120-fold less susceptible to 
inhibition by 3TC in the drug susceptibility assay; the combined effect 
of 3TC+AZT was not sufficient to allow inhibition of cell-to-cell spread of 
this virus to the same degree as HIV-1WT   even considering its increased 
susceptibility to AZT. This may suggest that the ability of a given 
combination to inhibit viral replication in the context of drug resistance 
may be a balance between the potency of individual drugs in the 
combination against cell-to-cell infection, the strength of the synergistic 
interactions between drugs in the combination and the magnitude of 
the drug resistance phenotype of the virus in question. Cell-to-cell 
spread of both viruses was effectively blocked by the triple 
combination of 3TC+AZT+EFV. In vivo hyper susceptibility to NNRTIs, 
specifically EFV has been associated with the M184V mutation 
(Shulman et al., 2001)and may contribute to the enhanced potency 
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observed with the triple combination against both the wild type and 
drug-resistant virus.  
 
Although the selection of drug resistance mutations to any drug in a 
cART regimen is an undesirable feature, usually leading to the drug in 
question being replaced, the M184V mutation is one of the rare 
mutations for which this rule may not always apply. In addition to 
increasing the sensitivity of the mutated virus to other NRTIs notably 
thymidine analogues, M184V leads to a reduction in the viral 
replication capacity (Diallo et al., 2003) and also raises the barrier for 
the selection of resistance mutations to other NRTIs (Naeger et al., 2001, 
Wolf et al., 2003). For this reason some clinicians favour maintaining 
patients on 3TC regimens even when this mutation is present. This 
strategy, although not part of the current WHO treatment guidelines, is 
supported by evidence from clinical studies showing that the ability of 
3TC regimens to suppress viral replication is maintained in the presence 
of this mutation (Campbell et al., 2005, Castagna et al., 2006, Dunn et 
al., 2011). Such conservative strategies have the potential to be very 
useful in settings where scarce resources limit the pool of antiretroviral 
drugs to choose from when composing a salvage treatment regimen 
for patients with drug resistance. The findings that even when 
spreading in a cell-to-cell mechanism, HIV-1M184V remains susceptible to 
drug combinations containing 3TC offers an additional possible 
explanation as to why the presence of this mutation does not render a 
3TC containing regimen useless for the treatment of HIV infected 
patients. 
Exploring the Impact of Antiretroviral Drugs on the Cell-to-Cell Spread of HIV-1 
 
Chapter Six – Conclusions and future directions 
220 
6 Conclusions and future directions 
6.1 Conclusions 
Three decades since the start of the HIV-1 pandemic, the pathogenesis 
of the disease is still not fully understood. Access to effective 
antiretroviral therapy has led to a rapid decline in disease-associated 
mortality and new infections. However, with the development of drug 
resistance coupled with the cost and toxicity of long-term antiretroviral 
therapy it seems evident that alternative strategies are needed in the 
fight against HIV-1 infection. In recent years the focus of HIV-1 research 
has shifted towards strategies aimed at eradicating the virus reservoir, 
alongside long-standing efforts to develop an effective vaccine to 
prevent new infections. These strategies are however far from being 
realised and antiretroviral drugs remain the best weapon to treat and 
potentially protect from HIV-1 infection. As the role of HIV-1 cell-to-cell 
spread across a virological synapse becomes more clearly defined, its 
putative importance in viral pathogenesis makes it an important 
element to consider in the context of antiviral therapy, ongoing viral 
replication in treated patients and the maintenance of the viral 
reservoir. In this thesis, I set out to explore and clearly define the impact 
of antiretroviral drugs on the unique mode of HIV-1 dissemination 
across a virological synapse. After identifying the best in vitro 
experimental approach to use to answer this question, I went on to 
assess the effects of PIs, INIs and RTIs alone and in clinically relevant 
combinations on HIV-1 cell-to-cell infection. My results provide insight 
into how antiretroviral drugs may affect HIV-1 cell-to-cell infection and 
allow us to speculate on what this could mean for their clinical use. 
 
In my thesis I have assessed and validated an in vitro assay system for 
studying the impact of antiretroviral drugs on HIV-1 cell-to-cell infection. 
The findings presented help to resolve some of the methodological 
controversies that existed in the field prior to the start of this project. The 
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quantitative T cell line assay that directly measures the early steps of 
HIV-1 infection provides a suitable unambiguous approach for studying 
the impact of antiretroviral drugs on cell-to-cell spread of HIV-1. On the 
other hand a Tat-driven reporter gene expression assay though useful 
for screening is less accurate for studying the effects of some drug 
inhibitors on HIV-1 cell-to-cell infection. Applying the qPCR-based 
quantitative T cell line assay, I have explored for the first time the 
impact of PIs, and INIs on their ability to inhibit HIV-1 T cell-to-T cell 
infection as well as reassessed RTIs that were previously studied by 
other groups but with conflicting results (Sigal et al., 2011, Permanyer et 
al., 2012b). I have also for the first time assessed the impact of PI-based 
and RTI-based combination therapies on cell-to-cell spread of both 
wild type and drug-resistant HIV-1. The finding that PIs, INIs and RTIs 
have variable effects on their ability to inhibit HIV-1 cell-to-cell infection 
raises interesting questions on the implications for both prophylactic 
and therapeutic uses of these antiretroviral drugs. 
 
Based on their work with RTIs Sigal et al.  suggested that HIV-1 cell-to-
cell infection could be a mechanism for antiviral escape in treated 
patients (Sigal et al., 2011). Their results are difficult to reconcile with the 
well-described effectiveness of antiretroviral therapy in suppressing viral 
replication in patients (Arts and Hazuda, 2012). This has generated 
considerable debate in the field on the true implications of cell-to-cell 
spread for treatment and driving ongoing replication to maintain viral 
reservoirs. My results show that different antiretroviral drug classes 
exhibit variable potencies against cell-to-cell spread of HIV-1. However 
when these drugs are used in combination they are effective against 
both cell-to-cell and cell-free HIV-1 infections. I also clearly 
demonstrate that drug-resistant variants of the virus gain an 
advantage when spreading by a cell-to-cell mechanism in the 
presence of cART. The potential for escape by a cell-to-cell 
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mechanism of spread is likely to be greater than with a cell-free 
mechanism of spread considering the higher multiplicity of infection 
and efficiency of the former. My results therefore suggest that cell-to-
cell spread could play a role as a mechanism of escape during 
monotherapy or inadequate treatment regimens, thus driving the 
selection and replication of drug-resistant variants. Antiretroviral 
therapy is required life-long and the side effects associated with 
treatment have serious implications for effective adherence in patient 
populations. This is particularly relevant in resource-constrained settings 
where uninterrupted supply of cART is not always guaranteed. Under 
such conditions, cell-to-cell spread of the virus could play a significant 
role in fostering drug resistance and therapeutic failure.  
 
The impact of cell-to-cell spread on ongoing replication and the 
maintenance of reservoirs with effective cART is less clear-cut. Using 
highly sensitive single copy assays, trace levels of viraemia can still be 
detected in effectively treated, fully adherent patients (Palmer et al., 
2008). Whether this trace viraemia represents ongoing viral replication 
with cART or release of virus particles from the latent reservoir (Chun et 
al., 1997), is a subject of intense debate. In vivo HIV-1 cell-to-cell spread 
most likely occurs predominantly in lymphoid tissues where there is an 
abundance of CD4+ T cells and effective antiviral drug penetration 
may be sub-optimal (Fletcher et al., 2014). Also in other anatomic 
sanctuary sites with reduced drug penetration(Cu-Uvin et al., 2010, 
Trono et al., 2010, Deleage et al., 2011, Fletcher et al., 2014); niches 
with cells in close proximity and the absence of sheer flow are likely to 
favour cell-to-cell spread. It is plausible to suggest that some degree of 
ongoing replication mediated by cell-to-cell spread is possible in these 
sites where drug penetration may be suboptimal, even during 
seemingly “fully suppressive” cART. Some studies have failed to detect 
evidence of viral evolution in patients receiving fully suppressive cART 
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arguing against ongoing viral replication in treated patients (Kieffer et 
al., 2004, Bailey et al., 2006, Evering et al., 2012, Josefsson et al., 2013). It 
is however important to note that due to the difficulty in sampling 
sanctuary sites where cell-to-cell spread is most likely to occur, these 
studies have mostly relied on the detection of HIV-1 in blood samples 
and thus may not be a reflection of what happens in other 
compartments. A few studies have shown viral evolution during cART, 
however in these studies concomitant drug measurements were 
absent making it impossible to exclude poor adherence as the driving 
force behind the observed viral evolution (Frenkel et al., 2003, Tobin et 
al., 2005). Treatment intensification studies with Raltegravir have been 
shown to reduce immune activation, inflammation and induce a 
transient increase in 2 LTR circle copies detected (Buzon et al., 2010, 
Llibre et al., 2012, Hatano et al., 2013). 2 LTR circles are episomal forms 
of viral DNA, which do not replicate and are generated during new 
infections suggesting that their detection in some Raltegravir 
intensification studies may indicate viral replication during therapy. It is 
nevertheless difficult to reconcile these results with findings from other 
intensification studies that fail to find evidence of ongoing replication 
(Dinoso et al., 2009, Yukl et al., 2010, Gandhi et al., 2010). It is interesting 
to note that in the Raltegravir intensification studies showing increased 
detection of 2 LTR circles, this effect was mainly observed in patients 
receiving PIs (Buzon et al., 2010, Llibre et al., 2012, Hatano et al., 2013). 
This could possibly be a reflection of the unique pharmacokinetic and 
pharmacodynamic properties of PIs, as opposed to a sign of ongoing 
replication during cART (Rabi et al., 2013, Laskey and Siliciano, 2014).  
At the moment it is impossible to say with certainty whether or not 
ongoing viral replication occurs during effective cART as there is 
substantial evidence both in support of and against this phenomenon. 
With the advent of intravital imaging techniques and humanised mice 
models, allowing the visualisation of cell-to-cell spread in vivo (Sewald 
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et al., 2012, Murooka et al., 2012), it would be interesting to revisit this 
question using these new techniques and sampling multiple sanctuary 
sites, to hopefully put the controversy to rest. 
 
Besides their use for treating HIV-1 infection, antiretroviral drugs have 
gained a lot of traction as prophylactic approaches  (PreP and PEP), to 
prevent HIV-1 infection pre-exposure and post-exposure. Prophylactic 
antiretroviral therapy targets very early infection with the aim of 
clearing infections before the formation of drug insensitive latent 
reservoirs. PreP is now a strategy that is recommended for well-defined 
risk groups as a way of preventing the spread of HIV-1 infections (WHO, 
2013, DHHS, 2014). The effectiveness of this strategy has been assessed 
in several clinical trials with encouraging but variable results. The 
CAPRISA 004 and VOICE trials tested the application of Tenofovir gel by 
women before sexual intercourse (Abdool Karim et al., 2010, Hankins 
and Dybul, 2013), while five studies tested oral Tenofovir in combination 
with Emtricitabine or as monotherapy for PreP (Baeten et al., 2012, 
Grant et al., 2010, Thigpen et al., 2012, Van Damme et al., 2012). The 
CAPRISA 004 trial showed a 39% reduction in HIV-1 transmission (Abdool 
Karim et al., 2010) but the VOICE trial was discontinued due to futility. 
Three of the five trials of oral PreP showed the effectiveness of this 
intervention ranging from 44-73% protection (Baeten et al., 2012, Grant 
et al., 2010, Thigpen et al., 2012) but two trials failed to show a 
demonstrable protective effect (Van Damme et al., 2012). It is worth 
noting that besides the CAPRISA 004 study, the other three trials that 
did show effectiveness of the intervention were of the oral combination 
of Tenofovir and Emtricitabine, two NRTIs. Although the explanations for 
why some trials failed to show a protective effect of the intervention 
are likely multifactorial including adherence, the type of sexual 
exposure, and choice of study populations. It is nonetheless attractive 
to speculate that biological factors such as the mechanism of 
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transmission and drug insensitivity could also contribute to infection 
breakthrough even with PreP, explaining some of the variability 
observed in these studies. 
 
 If cell-to-cell transmission is a significant mechanism of virus spread 
during early transmission events, this may cause a reduced sensitivity to 
some of the drugs, which have been assessed for PreP. This would 
increase the potential for infection to spread from the site of entry and 
establish distant foci of productive infection. There is considerable 
evidence from in vitro and primate based studies in support of cell-to-
cell transmission during initial exposure to HIV-1 (Kingsley et al., 2009, 
Weiler et al., 2008, John et al., 2001, Salle et al., 2010, Rousseau et al., 
2004). The studies on PreP to date have shown that this intervention is 
not 100% effective in preventing transmission of HIV-1. RTIs such as TFV, 
which is a key component of PreP, have up to 1000-fold reduced 
potencies against HIV-1 cell-to-cell infection (Sigal et al., 2011, Titanji et 
al., 2013, Duncan et.al, 2013, Agosto et al., 2014). We can therefore 
suggest that even a small decrease in susceptibility to antiretroviral 
PreP may lead to an increase in the number of people infected while 
receiving PreP. It would consequently be important to include 
interventions that effectively target cell-to-cell spread when assessing 
future microbicidal and oral PreP options. My data show that PIs and 
INIs are highly effective against cell-to-cell spread of HIV-1. These drug 
classes have not been assessed for their usefulness in PreP interventions 
and may be worth considering with the caveat that other factors such 
as drug penetration of mucosal tissue, pill burden and cost would need 
to be considered as well. 
 
We can also speculate on what the variable effects of antiretroviral 
drugs on HIV-1 cell-to-cell infection means for post-exposure 
prophylaxis (PEP). The window during which HIV-1 infection can be 
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cleared following exposure has been defined using non-human 
primate infection models as 24h (for intravenous injection)(Tsai et al., 
1998) and 48h (for vaginal challenge)(Otten et al., 2000). A recent 
study has shown that the latent virus reservoir is likely seeded much 
earlier in the course of infection than previously thought (within 72h) 
(Whitney et al., 2014). It is reasonable to suggest based on existing 
evidence that the reservoir requires an acute phase of infection and 
viral replication in order to seed sufficient numbers of cells (Chun et al., 
1998). Hence although the viral reservoir may be present within 72h it is 
likely not to be fully formed. This is supported by the fact that early 
treatment of HIV-1 infection within a month of exposure reduces the 
viral set point during established infection (Steingrover et al., 2008, 
Ananworanich et al., 2012, Wyl et al., 2011, Hocqueloux et al., 2013, 
Saez-Cirion et al., 2013, Fidler et al., 2013). In the study by Whitney et al. 
macaques exposed to SIV were initiated on suppressive cART 3, 7, 10 
and 14 days after infection and viral rebound was observed in all 
animals following treatment interruption (Whitney et al., 2014). It is 
valuable to work out whether the formation of early reservoirs 
established in the presence of cART involves drug insensitive cycles of 
infection possibly mediated by HIV-1 cell-to-cell spread. This question is 
made more compelling in light of rebound viraemia in the “Mississippi 
baby” who was treated with suppressive cART within thirty hours of life 
(NIH, 2014). The existence of such drug-insensitive cycles of infection 
remains to be proven. However if they do exist, this could provide the 
missing link between a curable infection and an established infection 
with a drug insensitive reservoir. 
 
As the AIDS epidemic has evolved through the decades, the growing 
realisation that antiretroviral drugs offer only a temporary solution to 
controlling the infection has shifted the focus more towards the search 
for a cure. One of the more popular cure strategies involves the use of 
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histone deacetylase inhibitors to reactivate the virus in latent reservoirs 
with the hope that these activated cells would be eliminated by the 
immune system, the cytotoxic effects of the virus and concomitant 
administration of antiretroviral drugs to prevent actively infected cells 
from infecting new cells (Siliciano et al., 2007, Sagot-Lerolle et al., 2008, 
Lehrman et al., 2005, Archin et al., 2012). It would be important to bear 
in mind the reduced sensitivity of HIV-1 cell-to-cell infection to inhibition 
by some antiretroviral drugs in the optimisation and testing of such cure 
strategies. 
 
6.2 Future Directions 
For this thesis a laboratory-adapted molecular clone of HIV-1 (NL4.3) 
was used to study cell-to-cell spread of the virus between T cells.  
Laboratory-adapted strains of HIV-1 can infect and replicate better in 
cultured T cell lines compared to most primary clinical isolates. It would 
be informative to expand this study by assessing the impact of 
antiretroviral drugs on cell-to-cell spread of different HIV-1 strains and 
clinical isolates. Although to date several studies have demonstrated 
that cART is equally efficient against HIV-1 infection with different 
clades of group M virus (Alexander et al., 2002, Pillay et al., 2002, 
Bannister et al., 2006, Bouchaud et al., 2011, Gatell, 2011, Scherrer et 
al., 2011), differences have been identified in the frequency and  
pathways to the selection of drug resistance viruses (Gao et al., 2004, 
Pieniazek et al., 2000). For instance one report suggests that some 
subtype D viruses may possess a natural resistance to non-nucleoside 
reverse transcriptase inhibitors, based on a single nucleotide 
substitution (Gao et al., 2004) and non-subtype B viruses appear to 
more frequently select for minor drug resistance mutations in protease 
(Pieniazek et al., 2000). My results show that drug-resistant variants of 
HIV-1 gain a replicative advantage when spreading from cell-to-cell in 
the context of cART. It would therefore be interesting to consider the 
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efficiency of cART on cell-to-cell spread of different HIV-1 clades 
especially in the context of drug resistance. This could be further 
extended to include non-group M viruses, which though responsible for 
only a small proportion of HIV-1 infections, may possess natural 
polymorphisms that make them intrinsically resistant or less susceptible 
to some components of cART.  
 
I have focused my study on T cell-to-T cell spread of HIV-1, however 
other cell types notably macrophages and dendritic cells also mediate 
HIV-1 cell-to-cell spread. Duncan et al. assessed the impact of RTIs and 
INIs on macrophage-to-T cell spread of HIV-1. They found that while RTIs 
were less effective against this mode of spread in an MOI dependent 
manner, INIs were effective against this mode of infection (Duncan 
et.al, 2013). Macrophages are long-lived cells, and their ability to 
traverse the blood brain barrier enables the spread of HIV-1 infection 
into sanctuary sites in the central nervous system (Sharova et al., 2005, 
Gartner et al., 1986). It would be attractive to expand the work I have 
done with drug combinations and drug-resistant viruses to 
macrophage-to-T cell spread of HIV-1 in order to complete the picture.  
 
Dendritic cells do not become productively infected with HIV-1, 
however they mediate infection of T cells by capturing HIV-1 and re-
presenting virus particles to T cells in a process known as trans-infection 
(Pope et al., 1994, Geijtenbeek et al., 2000, McDonald, 2010). This 
mode of spread between DC and T cells is thought to play a role in the 
initial phases of infection following the transmission event, allowing the 
virus to rapidly seed lymphoid tissues. To date only one study has 
assessed the impact of antiretroviral drugs on DC-to-T cell spread of 
HIV-1 (Muratori et al., 2009). Muratori et al. assessed the impact of PIs 
on cell-to-cell spread between DCs and T cell and found PIs to be 
effective inhibitors of this mechanism of spread.  It will be informative to 
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explore the impact of other antiretroviral drug classes notably RTIs and 
INIs on DC-to-T cell trans-infection.  
 
The results obtained with RTIs confirm the previous suggestion that high 
MOI can drive viral escape during cell-to-cell infection. It is difficult to 
evaluate whether the high MOI required for RTI escape can be 
achieved in vivo. This is however feasible in sanctuary sites such as 
lymphoid tissues where cell-to-cell infection predominates and antiviral 
diffusion can be reduced (Fletcher et al., 2014).  With the advent of 
intravital imaging techniques that can visualise cell-to-cell spread in 
vivo (Murooka et al., 2012, Sewald et al., 2012), it would be to 
interesting to apply these tools to study the effect of antiretroviral drugs 
on synaptic spread of HIV-1 in vivo. This would provide a better 
understanding of what likely happens in HIV-1 infected patients who 
receive cART. 
 
Protease inhibitors are one of the main foci of the work presented in this 
thesis. They stand out from the RTIs by being equally potent against 
both cell-to-cell and cell-free modes of HIV-1 infection (Titanji et al., 
2013). The unique pharmacology of this antiretroviral drug class 
continues to be unraveled (Rabi et al., 2013, Laskey and Siliciano, 
2014). Recent findings show that PIs inhibit multiple steps in the virus 
replication cycle with the block to entry being the most significant 
(Rabi et al., 2013). This block to entry has been attributed to the 
interactions between the uncleaved Gag and the cytoplasmic tail of 
Env, which inhibit entry until Gag is cleaved by Protease (Rabi et al., 
2013).  Some env mutations appear to confer resistance to PIs by 
allowing entry when Gag is not fully cleaved (Rabi et al., 2013). While 
we have explored cell-to-cell spread of wild type HIV-1 and a PI 
resistant virus carrying mutations in protease and gag, it would be 
interesting to assess env mutants conferring resistance to PIs in the 
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same manner. One of the enduring questions associated with PI-based 
treatments is failure in the absence of any discernable drug resistance 
mutations.  Exploring the interplay between env mutations associated 
with PI failure and the mode of virus dissemination may provide some 
insight into why some patients fail on PI-based therapy without 
apparent protease or gag mutations. 
 
A brief study of Raltegravir in this thesis has demonstrated its 
effectiveness against cell-to-cell spread of HIV-1 between T cells for the 
first time. It will be useful to extend this study to clarify its relative 
efficacy against cell-to-cell compared cell-free spread of HIV-1, which 
has not been assessed. Also I have not explored the impact of INI-
based combinations on cell-to-cell spread of HIV-1 in my work. INIs are 
not yet widely used in first-line and second-line treatment regimens but 
INI-containing salvage regimens are emerging as highly potent options 
for treatment-experienced patients. Understanding their combined 
effects with other drugs against the different modes of virus 
dissemination will provide useful information on this drug class, which is 
a fairly recent addition to the arsenal of antiretroviral agents. 
 
It now seems unequivocal that cell-to-cell spread of HIV-1 occurs in 
vivo and likely plays a role in viral pathogenesis. In view of our findings 
and bearing in mind the limitations of in vitro studies, the variable 
effects of antiretroviral drugs on cell-to-cell spread of HIV-1 would need 
to be considered for future prophylactic, therapeutic and eradication 
strategies in the fight against HIV-1 infection. The results presented in 
this thesis show that both PI and RTI-based combination therapies are 
potent against HIV-1 cell-free infection and highly efficient cell-to-cell 
infection. The variable potency of PIs and RTIs as single agents against 
cell-to-cell infection can therefore not be taken as an indication that 
this mode of virus dissemination is not relevant in vivo. Instead these 
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results suggest that both cell-to-cell and cell-free spread likely play a 
role in driving viral escape and treatment failure in the context of 
inadequate combination therapies. Predicting the outcomes of 
antiretroviral therapy in patients, though highly desirable, remains very 
difficult in current clinical practice. As new therapies are developed for 
the treatment of HIV, being able to assess the efficacy of novel 
combinations against all modes of virus dissemination will serve as a 
valuable tool for predicting their efficacy, prior to clinical testing. 
Employing a simple in vitro assay like the one used for this study 
provides a straightforward way of doing this. 
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